

1 some comments about it, but certainly we are  
2 interested in hearing basically what you have to say.

3                   But ultimately when there is sufficient  
4 interest in the pharmaceutical industry, we need to  
5 bring these questions to public discussion. We must  
6 also admit the following: that there is growing  
7 interest in gaining information about the usefulness  
8 of drugs in resistant indications. Doing this  
9 requires the commitment of resources on the part of  
10 the pharmaceutical industry. If there are no  
11 incentives whatsoever available at the end of the day  
12 for that type of commitment, then the likelihood of  
13 getting this information will be less than might  
14 otherwise be the case.

15                   DR. RELLER: Please.

16                   DR. DANNER: I think we're all agreed that  
17 the amount of data in actual resistant isolates is  
18 relatively small. So deciding whether the indication  
19 or changing the label makes sense is based on two  
20 things: one, that the overall resistance to Levaquin  
21 is very low; and the other, that Levaquin resistance  
22 and penicillin resistance are completely independent.

23                   And so because I'm fairly ignorant in  
24 statistics, I wanted to ask our statistician whether  
25 we saw enough data today to conclusively say that they

1                   are absolutely independent, and then ask the committee  
2                   if they're independent today.

3                   I mean I know they're independent  
4                   mechanisms, but that doesn't mean genetically in  
5                   clones of bacteria that they will necessarily be  
6                   independent or stay independent.

7                   So once this indication goes in, if they  
a                   don't stay independent is that a problem?

9                   DR. MURRAY: Resistances never stay  
10                  independent. They can be totally different  
11                  mechanisms, totally different everything. Once plasma  
12                  mediated one chromosomal like ciprofloxacin resistant  
13                  and MRSA, and they eventually come together.

14                  DR. DANNER: Right.

15                  DR. MURRAY: So in some instances, in this  
16                  case you could think well in an HIV population which  
17                  has high risk for penicillin resistant pneumococci  
18                  probably have a lot of fluoroquinolone resistance. So  
19                  you'd think they could come together independently if  
20                  for no other reason than a fluoroquinolone gets used  
21                  more often in the future because of that indication.

22                  DR. DANNER: Well, yeah. That's sort of  
23                  my point. I mean, in other words, if this goes into  
24                  the label and four years from now it's no longer  
25                  independent, i.e., that penicillin resistant organisms

1 also tend to be fluoroquinolone resistant and,  
2 therefore, fluoroquinolones and Levaquin specifically  
3 would not be a good drug to use if you know you had  
4 penicillin resistance, then it kind of makes the  
5 labeling incorrect over time.

6 DR. MURRAY: Yeah, but that's also true  
7 for every other antibiotic. I mean, resistance always  
8 develops so far. I mean you have to take it -- to me  
9 I think the caveat is we could say that about  
10 everything, every single drug that comes forth. I  
11 think most of us would agree there will eventually be  
12 resistance to everything.

13 But I'm sorry. You asked her the  
14 question. So I should shut up.

15 DR. DANNER: Yeah. Well, have we seen  
16 enough information with tests of independence to know  
17 that this is really independent?

18 DR. O'FALLON: No. You know, this is not  
19 very much information. I'm very aware of the fact  
20 that -- I mean it came through loud and clear -- that  
21 the company worked very, very hard to find these  
22 cases, and they were very, very rare, but they don't  
23 carry much information. That's the problem.

24 DR. MURRAY: He's asking about the  
25 resistances and there are huge numbers of isolates

1 that have been examined, thousands and thousands of  
2 isolates that Dr. Whitney told us about that have been  
3 examined. That's a huge database. That's separate  
4 from the resistance.

In the cases that you're talking about, I  
think you asked the question about the resistance per  
se.

8 DR. DANNER: Well, yeah, and the  
9 independence. So you could potentially look at, you  
10 know, any isolate, all the isolates you have and not  
11 necessarily just things that were in their studies  
12 and, say, do a statistical test. You would have to  
13 tell me which one, but say that there's absolutely no  
14 association between penicillin resistance and Levaquin  
15 resistance.

16 I mean, did we --

17 DR. O'FALLON: Okay.

18 DR. DANNER: Has that been done or looked  
19 at?

DR. O'FALLON: That part. Okay.

21 DR. DANNER: Because we do have very few  
22 cases, but if they are completely independent, then  
23 that would say, well, the small sample we have may be  
24 large enough to make an overall generalization because  
25 the resistances are completely independent.

I mean isn't that one of the things that  
was decided on when this was discussed in the previous  
meeting, that independence was important?

4 DR. GOLDBERGER: Actually, if the company  
5 has a slide available from their background package of  
6 Table 11.2, it may address this issue since there was  
7 a considerably greater amount of information, as Dr.  
8 Murray just alluded to.

In that case it looks like there are, if  
I'm reading this correctly, some 4,000 isolates  
altogether that were looked at in terms of penicillin  
susceptibility, and then levofloxacin susceptibility,  
and there appears on the surface to be no difference  
in the pattern of levofloxacin susceptibility across  
the board regardless of penicillin, but I don't know  
if the company has a slide to put that up.

17 It's page 9 of the Trust data, I believe.

18 DR. MURRAY: I guess, Bob, biologically  
19 I'm convinced genetically that they are separate.  
20 They never transfer together, but I also would predict  
21 that in the future you will have -- the two  
22 independent things will overlap at some point, and  
23 that's certainly been true with other resistances that  
24 can be completely independent genetically.

25 And the phraseology I use is usually

1 resistance begets resistance or birds of a feather  
2 flock together, and that does tend to occur for  
3 perhaps population treatment basis, but not  
4 mechanistically by biochemical mechanism or by genetic  
5 co-transfer, either one.

6 DR. SOPER: I guess I'm not so concerned  
7 about whether these end up coming together four years  
8 down hence because then there'll be a recognition that  
9 penicillin resistance is associated with levofloxacin  
10 resistance and the drug won't be used.

11 But as far as changing the labeling, I  
12 don't see a problem with what's proposed from that  
13 perspective. Maybe I've said what's already been said  
14 in another way.

15 DR. DANNER: Would the label then be  
16 changed again if they did associate with each other?

17 DR. GOLDBERGER: It certainly could be.  
18 I think that if you look, again -- I haven't had a  
19 chance to go through the questions, but it's all  
20 right. We can do it in a piecemeal fashion. It's  
21 just as good -- we asked in Question 2: do you have  
22 any recommendations regarding Phase 4 studies or data  
23 collection that the applicant could be requested to  
24 perform?

25 And data collection could, in fact, be an

1                   ongoing targeted surveillance program to insure that  
2                   we keep getting this type of information to look at  
3                   the patterns as to what is going on.

4                   On occasion, I mean, a lack of  
5                   surveillance information sometimes has been a problem.  
6                   One then has to negotiate with the company about this  
7                   issue in terms of potentially changing the label, but  
8                   that is possible to do, and there are, in fact, within  
9                   the agency some initiatives underway about trying to  
10                  do this more effectively on an ongoing basis.

11                  But one of the keys is to insure that  
12                  everybody's comfortable with the data that exists and  
13                  what data might be used.

14                  DR. DANNER: Well, I mean, just to  
15                  clarify, the issue of independence allows you -- if  
16                  they really are truly independent -- it allows you to  
17                  extrapolate a little bit from the penicillin resistant  
18                  isolates and say that, you know, Levaquin is very  
19                  effective against pneumococcus. You have a large  
20                  experience with that, and because Levaquin  
21                  effectiveness doesn't associated in any way with  
22                  penicillin resistance, it allows you to take this  
23                  small group and kind of feel more comfortable because  
24                  there's this much larger data set that should reflect  
25                  the same thing in penicillin resistance or penicillin

1 sensitivity.

2 DR. GOLDBERGER: Well, I think probably  
3 our view would be if we were to ask -- and, again,  
4 it's based in part on the recommendations you make  
5 here today -- if we were to ask for surveillance  
6 because of concerns as Dr. Murray raised that over  
7 time one is always concerned that resistances may  
8 become linked, and that may become more and more of a  
9 problem, we would ask for as well not just penicillin  
10 patterns, but we would also ask for them to determine  
11 the levofloxacin susceptibility of the isolates.

12 I think the only way to be comfortable  
13 that there is not a change in what happens over time  
14 is to measure this on an ongoing basis.

15 DR. BUSH: We have some slides that I can  
16 show that demonstrate this. We have the data from the  
17 Trust studies showing the apparent lack -- yes, right.

18 We have one set of data showing the  
19 apparent lack of -- okay. There it is. Again, we're  
20 looking at large numbers of isolates here. Overall  
21 there are over 16,000 isolates that have been  
22 examined, and we have shown that there at this time  
23 appears to be no linkage between penicillin  
24 susceptibility and levofloxacin susceptibility.

25 In addition, what we have data on are the

1       25 levofloxacin resistant isolates that were  
2 identified in the 1998-'99 respiratory season, and can  
3 you go to Slide 336? Because I understand that there  
4 appears to be a question about cross-resistance here.

5                   And if we look at those isolates that were  
6                   resistant in the last respiratory season, there were  
7                   25 isolates that were resistant to levofloxacin. Of  
8                   these, there was no apparent linkage to penicillin  
9                   resistance. In fact, if anything, we had more that  
10                  were susceptible in intermediate to penicillin.

11 Macrolide resistance was not linked.  
12 Trimethoprim sulfa was rather random throughout these  
13 25 isolates.

14 So at this time we aren't seeking linkage.  
15 I agree that at some point we probably will be seeing  
16 super bugs that have resistance to everything because  
17 this happens with every organism, and I think  
18 Streptococcus pneumoniae probably in the long run will  
19 not be immune to this.

20                   But at the present time we are not seeing  
21 cross-resistances. We are planning to continue to  
22 monitor. That is certainly a major concern of ours.  
23 It is something that we are committed to doing. We  
24 are planning to expand this not only in the United  
25 States, but also worldwide so that our monitoring will

NEAL R. GROSS  
COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 continue.

2                   Certainly we are veryinterestedin seeing  
3 whether we willbeginto see greater cross-resistance.

4                   DR. RELLER: Thank you, Dr. Bush.

5                   The reason for asking these questions is  
6 to clarify before voting on the questions, is to  
7 attempt to address the ripeness issue that Dr.  
8 Goldberger referred to, and not to skirt it, but at  
9 the same time to be very clear about the message that  
10 we're trying to send.

11                  And I'd like for people to recall the  
12 remarks made by Dr. Bell earlier. It seems to me that  
13 the strongest message that's come across throughout  
14 this, and it's been stated repeatedly: no linkage  
15 currently; different mechanisms of resistance.

16                  The failures in levofloxacin treated  
17 patients were all in patients with susceptible  
18 strains, penicillin susceptible strains. There appear  
19 to be no evidence that it makes any difference.

20                  So, I mean, one can't have it both ways.  
21 If there's no linkage, there's no connection, there  
22 are different mechanisms of resistance, you get  
23 failures in susceptible strains and you get successes  
24 in resistant strains, and the drugs that are currently  
25 used according to recommended guidelines as regards

1 beta lactems, namely, that there is little or no  
2 evidence that in community-acquired pneumonia caused  
3 by strains of intermediate susceptibility or even at  
4 two micrograms per mL there's any difference in  
5 efficacy, and although the numbers were minuscule, the  
6 data presented here from the comparative trials didn't  
7 change that.

8 That's what the medical letter recommends.  
9 That's what the NCCLS stated in their next edition,  
10 that those strains at .125 to one.

11 Now, if there be no connection, that's why  
12 I think it's so important to clarify this because if  
13 the Question 1 is the same as the package insert  
14 question, then, in fact, what the package insert is  
15 doing is linking, implying that somehow efficacy may  
16 be linked or not linked with penicillin intermediate  
17 or susceptible strains, and all of the evidence  
18 suggests it has nothing to do with it.

19 And the statement is made that we have to  
20 look in the future, that susceptible to levofloxacin  
21 and efficacy, which has been demonstrated, may not  
22 hold up in perpetuity.

23 So I don't think that the questions and  
24 the package insert necessarily go together. In fact,  
25 I think you could argue that they are quite different

1 ways of looking at this issue.

2 Dr. Goldberger, have I made the point  
3 clear so that we know what we're voting on?

4 DR. GOLDBERGER: Well, I think that, you  
5 know, I'm not sure I necessarily follow your logic.  
6 I think that realistically what we're basically asking  
7 is that the company would like to include the words  
8 "penicillin resistant Streptococcus pneumoniae" in the  
9 label. Arguably we could have said that there's no  
10 issue with doing this. They could do this  
11 automatically because people have talked about there  
12 is no linkage and, therefore, that's not an issue.

13 And you could have just said why can't you  
14 just put it in there as long as there's no linkage.  
15 Then the issue would be, first of all, assuring  
16 ourselves that the issue of linkage was correct now,  
17 and then some means of insuring that that would stay  
18 that way in the future.

19 From our perspective, however, and I think  
20 there was support a year ago at the committee, there  
21 were concerns, however, that even if a linkage itself  
22 does not exist, that patients who have infections due  
23 to penicillin resistant Strep. pneumoniae may in other  
24 ways be different than patients who have infections  
25 with penicillin susceptible Strep. pneumoniae. They

1 may have different underlying diseases. They may have  
2 been on multiple courses of antibiotics. They may  
3 have other things that may influence how, therefore,  
4 they need to be treated.

5 So it was our view that clinical data was  
6 an important component of this. The question is  
7 realistically how much clinical data. I mean, that's  
8 basically the way we looked at it.

9 In other words, to put this claim in the  
10 label, we would like to see some clinical data, but as  
11 far as linkage or not, I think that I'm not sure. I  
12 think it's important, but I don't follow your argument  
13 that the two things are contradictory. I just I just  
14 don't follow that.

15 DR. RELLER: Well, I think they're  
16 different questions, and I'll be very direct because  
17 we need to move on with the questions and then let Dr.  
18 Murray speak.

19 For example, Question 1, I could envision  
20 someone saying that -- or the data that it's effective  
21 in penicillin resistant pneumococci, meaning two  
22 micrograms or more, and you've got 14 cases, that  
23 people could say the data are not sufficient to make  
24 that statement.

25 One could say that bacteremic or not,

1       levofloxacin works for community acquired pneumonia  
2       where you know that there's a pneumococcus present  
3       without regard to anything other than susceptibility  
4       to levofloxacin, that people could vote yes on that.

5                  No in one and yes on the other, that is,  
6       by implication that it includes everything whether  
7       resistance or not because there's no relationship  
8       between resistance or intermediate.

9                  DR. GOLDBERGER: Well, in essence, that  
10      actually gets to the heart of what we're asking you.  
11      We are asking for you to look at the totality of the  
12      data that exists, including the issue of the  
13      preclinical data that has been presented, the PK/PD  
14      data, and the information that's been presented in  
15      penicillin susceptible pneumococcal infections, plus  
16      the information that has been presented on the  
17      linkage, and using the totality of the information  
18      state whether the amount of data is sufficient that  
19      that line be included in the label.

20                  So in essence, we are asking for you to  
21      consider all the pieces of information together and  
22      whether that is a sufficient package.

23                  DR. RELLER: Okay. Dr. Murray.

24                  DR. MURRAY: Actually one small technical  
25      question, and then I have some comments I'd like to

1 make.

2                   Were the penicillin susceptibilities  
3 redone in a central lab or were they done on site? So  
4 they're redone in a central lab so that we don't have  
5 to worry about the issue of them coming from a single  
6 site, not knowing how to do the susceptibilities?

7                   Okay. Then I think the problem, I think,  
8 that faced me-- thank you -- was there are two issues  
9 here. One is do we think it works, and the other  
10 issue is deep in our little hearts are we worried that  
11 if we say yes and it gets used even more than it is  
12 right now, that we're going to elicit more resistance.

13                  And we're not really being asked to  
14 address that second issue in the first question. I'm  
15 not sure if we should be or not.

16                  So the way I thought about it is --

17                  DR. GOLDBERGER: Could I just, before you  
18 continue --

19                  DR. MURRAY: Yeah.

20                  DR. GOLDBERGER: -- traditionally when we  
21 talk about the issue of safety and efficacy, the  
22 traditional issue about safety is safety specific  
23 toxicities in the patient population and question. It  
24 is at the discretion of the committee whether, for  
25 instance, you want to consider broader safety or

1                   public health issues. We did not specifically address  
2                   those in our question because this option exists for  
3                   you to discuss it, and in fact, as we expected, you  
4                   know, it has already come up.

5                   But you can if you wish address that on  
6                   balance.

7                   DR. MURRAY: Right, but I don't have to  
8                   keep in the back of my mind to answer Question 1. I  
9                   can save that for Question 2 that you've asked.

10                  But if you look at the sentence does it  
11                  work in pneumococcal disease, it looks spectacular  
12                  actually if you look at it versus comparator. It  
13                  works very well.

14                  Would it meet the ten percent rule? Not  
15                  quite, but it would meet the ten resistant isolates,  
16                  and it would come close to meeting the ten percent  
17                  rule probably or the ten percent idea for the  
18                  intermediates. It has all of the right animal model  
19                  pharmacokinetic data.

20                  The company has, I think, read exactly  
21                  what we wrote last year and went down and done  
22                  everything we said we would want to see before  
23                  approving something for a resistant organism. so I'll  
24                  have an easier issue addressing number one.

25                  I do, of course, in the back of my mind

NEAL R. GROSS  
COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 200053701

1       worry as somebody that studies resistance. I worry a  
2       lot about eliciting more resistance, and then thinking  
3       about Carl asked the question earlier, is this going  
4       to be like -- are the fluoroquinolones going to mimic  
5       penicillin against pneumococci or is resistance going  
6       to be more rapid in developing?

7           We've had 15 years -- I didn't even  
8       realize that -- of a fluoroquinolone out there in the  
9       market, ciprofloxacin, that's been used a good bit or  
10      naroxyn that's been used to a certain extent. We've  
11      had 15 years. There's 100 million prescriptions did  
12      I hear?

13           I'm sure resistance is going to develop,  
14       and I wish we could address it in some way, but  
15       there's already a huge amount of use out there, and it  
16       looks like it's going to be relatively slow in  
17       developing because it's not more of a problem in 1999  
18       than it is.

19           So I think I could address some of those  
20       issues separately, but I would likely when it comes to  
21       the vote have to separate those issues in my mind when  
22       making my final analysis of efficacy.

23           DR. RELLER: I think it's time for a vote.  
24       Yes or no, number one: are the data sufficient to  
25       demonstrate that levofloxacin is safe and effective

1 for the community-acquired pneumonia caused by  
2 penicillin resistant, two micrograms or more per mL,  
3 *Streptococcus pneumoniae*?

4 Dr. Murray?

5 DR. MURRAY: Yes. I think the data are  
6 sufficient.

7 DR. RELLER: Dr. O'Fallon?

8 DR. O'FALLON: I feel like I came into the  
9 middle of a game without know what the rules were,  
10 okay? So I really don't understand this well enough  
11 to make a vote. So I'm going to vote --

12 DR. RELLER: Pass?

13 DR. O'FALLON: -- pass.

14 DR. RELLER: Keith.

15 DR. RODVOLD: I agree. I think it is with  
16 one caveat though. As long as the dosages that  
17 currently are being proposed at 500 the MICs for  
18 levofloxacin is two or less, which is their sensitive  
19 break point.

20 If you move up to intermediate and above,  
21 those kinetics start to fall apart, and you might get  
22 questionable, and that means then the dose needs  
23 change. So currently, yes.

24 DR. RELLER: Dr. Christie?

25 DR. CHRISTIE-SAMUELS: I say yes with one

1           caveat for the labeling. Would the committee consider  
2           levofloxacin in the labeling for children with  
3           pneumococcal pneumonias and empyemas?

4           I believe this is still a safer and more  
5           effective alternative than the eventual need for a  
6           thoracotomy, drainage procedures, and pleural  
7           decortication for these ill children who have pen.  
8           resistant and pen. susceptible severe necrotizing  
9           pneumococcal pneumonias and pleural empyemas.

10           Thank you.

11           DR. RELLER: Dr. Soper.

12           DR. SOPER: Yes.

13           DR. RELLER: Danner?

14           DR. DANNER: Yes.

15           DR. PARSONNET: Yes.

16           DR. NORDEN: Yes.

17           DR. RELLER: Those are the voting members  
18           of the committee, and my vote is yes. MY  
19           qualifications will come later.

20           Okay. If the answer is yes, are there any  
21           caveats about its use that you would recommend to be  
22           included? Should any mention of PISP be made in the  
23           indications and usage section?

24           DR. NORDEN: Yes.

25           DR. RELLER: We'll go the other way

1 around. Carl.

2 DR. NORDEN: I have a couple of caveats.

3 First of all, I think if you're going to put this in  
4 the label it needs to be stated that penicillin  
5 resistance can only be determined by susceptibility  
6 testing, which will not be available at the time the  
7 patient is first seen, as long as we're going to say  
8 what penicillin resistance is.

9 The second caveat would be that I think it  
10 should say that other antibiotics are probably equally  
11 effective for penicillin intermediate resistant  
12 pneumococcus based on pharmacokinetic data and  
13 sensitivity data, or we should leave penicillin  
14 intermediate sensitivity out of the label completely  
15 because I don't think that's our clinical problem, not  
16 for pneumococcal pneumonia. For meningitis,  
17 absolutely, but not for pneumonia.

18 DR. GOLDBERGER: Dr. Reller, can I make  
19 just a comment about the PISP?

20 DR. RELLER: Yes.

21 DR. GOLDBERGER: And that is that the  
22 company has specifically requested it, and we felt it  
23 was, you know, therefore, appropriate to give  
24 committee members a chance to talk about this.

25 I think that our own perspective is,

1 frankly, that we do have some reservations about  
2 this, but we think it is appropriate to have, you  
3 know, an open discussion.

4                   In particular, if issues about resistance  
5 are to be included in the label, we think that -- and,  
6 you know, there's already been a little bit of comment  
7 just now about it -- we think that there ought to be  
8 some linkage to the fact that penicillin intermediate  
9 Strep. pneumoniae is, for instance, associated with a  
10 poorer outcome to penicillin because that is the  
11 presumption that many people reading the label would  
12 have.

13 So as you think about this, that would be  
14 one way to look at it. If we believed, for instance  
15 that it did make a difference, then I think, you know,  
16 it may very well be appropriate to make a statement.

If we think, however, that penicillin is still really the choice there, then our own perspective would be that that probably should not be in the label. However, you know, the company requested it, and we feel it's an important scientific issue that needs to have some discussion.

23                   But that's the genesis of the specific  
24 nature of that as part of Question 1.

25 DR. RELLER: We will go around to all of

NEAL R. GROSS  
COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

the committee members. We don't have a specific yes or no vote on Part 2(b). So we'll see what each person has to say.

And, Dr. Goldberger, can we formulate for your utility at the end of discussion, if it seems appropriate, on any specific measures to get a vote so that you get a sense of what people really think about, how strongly they feel about a particular specific issue?

DR. GOLDBERGER: Yes. (a) You are in charge, Dr. Reller.

DR. RELLER: Okay.

DR. GOLDBERGER: (b) It's often useful to have a sense of the strength of the committee's view on something.

DR. RELLER: Dr. Parsonnet.

DR. PARSONNET: I think PISP should not be in the recommendations. I think saying that it works for penicillin resistant strains already implies that it will work for penicillin intermediate strains, and including it, I think, would only serve to get people to use it more than they might otherwise, and use it in preference to antibiotics that have not yet had that as an indication.

And then I had a second question, which is

NEAL R. GROSS  
COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 200053701

1 just a question for the FDA, is how the advertisements  
2 by the company are regulated, whether we have any --  
3 those are two separate issues, whether when we do this  
4 approval we're sort of saying they can publicize this  
5 drug in any way or whether there are FDA requirements  
6 in addition above and beyond what these indications  
7 actually say.

8 DR. GOLDBERGER: First of all, there are  
9 certain options currently, and this is still under  
10 litigation about the ability to promote off label use  
11 regardless in fact of whether you have the indication.

12 Leaving that aside, however, for a second,  
13 the general rule is fair balance, that the statements  
14 in the labeling should not be taken out of context.  
15 If, for instance, one felt that caveats were important  
16 about how the drug should be used, what testing, et  
17 cetera, then the most effective way to insure that  
18 that material is included in the promotional material  
19 is to insure that it is also included in product  
20 labeling, and that, in essence, is the genesis of our  
21 question.

22 For instance, if you say it should be used  
23 only after testing, should be used in patients who are  
24 suspected to be at higher risk, although it would be  
25 nice to have some data about that, but whatever, that

1 information then we would expect would be in the  
2 promotional material along with the indication.

3 So it's important to give us a sense --  
4 YOU don't have to give us the exact wording,  
5 obviously, in the label -- of the concerns that you  
6 would have that ought to be included so that there is  
7 fair balance and that those physicians who read the  
8 label or the promotional material will have a more  
9 complete picture of the situation.

10 DR. RELLER: What we'll do, Dr. Bell,  
11 unless you have to leave, is go around the committee  
12 members and the hear other comments, which we would  
13 welcome, want to hear.

14 My view on this is that it is a mistake to  
15 include any alteration in the label that has to do  
16 with intermediate strains or even resistant strains.  
17 We didn't have any recommendations having to do with  
18 doing something differently for levofloxacin with  
19 regard to sulfamethoxazol, trimethoprim, erythromycin,  
20 clarithromycin, macrolide susceptibility, yes or no.  
21 With what we heard, the choice of levofloxacin and  
22 what is done with the guidelines for pneumonia do not  
23 have it based on whether or not the strain is --  
24 without regard to the susceptibility of the strain,  
25 and there are no clinical data that supports that it

1 makes any difference.

2 So that if it's not a factor, then it  
3 seems to me it should not be mentioned because of the  
4 possibility, indeed, likely probability by someone of  
5 promoting this when it's not germane to whether or not  
6 the drug works, and the continuation of the drug has  
7 to do with clinical response and whether or not it  
8 turns out if there be an isolate, whether it's  
9 susceptible by standardized testing.

10 Dr. Danner.

11 DR. DANNER: Leave out PISP for the  
12 reasons stated.

13 DR. RELLER: Soper.

14 DR. SOPER: I look at this as just adding  
15 another microorganism like E. coli or moraxel  
16 (phonetic) or whatever because of the ripeness dogma,  
17 and that I agree with Barth that it probably really  
18 isn't necessary, but because of the issue of marketing  
19 and its linkage to what's in the package insert that  
20 this becomes an important issue.

21 And, therefore, I would just support  
22 putting it in exactly the way that it was presented to  
23 us.

24 DR. RELLER: Dr. Christie.

25 DR. CHRISTIE-SAMUELS: No, PISP shouldnot

NEAL R. GROSS  
COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, DC. 20005-3701

1           be included in the label. I think there is already  
2           enough confusion trying to sort out PISP from PRSP  
3           without adding yet another category for family  
4           practitioners.

5           I wonder if maybe we should just say all  
6           pneumococcal strains.

7           DR. RELLER: Dr. Rodvold.

8           DR. RODVOLD: I agree that I would leave  
9           it out, but I'd leave it out for all of the reasons  
10          above, but also another reason is that I'd be  
11          concerned with another company coming along wanting to  
12          only go up to PIS and not to go all the way to  
13          resistance, and so now you'd leave companies with  
14          penicillin sensitive, penicillin intermediate, but not  
15          penicillin resistant, and others with penicillin  
16          resistant and penicillin sensitive.

17          So I would leave it out, and you've got to  
18          go all the way to the top of the bar.

19          The other caveats in this question is that  
20          I think someplace in the labeling or in the back of  
21          the insert with studies and things is that at this  
22          time with the data that's available, that you've got  
23          to spell out or tell them that the comparative arms  
24          were equivalent, and that's got to get across so that  
25          the prescriber realizes that this was no better in

1 this and that the comparative numbers were the same,  
2 you know, 100 percent efficacy in there.

8                   And my other comments previously about the  
9 MIC for levo. needs to be also spelled out because  
10 it's important at this time.

11 DR. RELLER: Dr. O'Fallon.

12 Dr. Murray.

13 DR. MURRAY: I thought it was fairly easy  
14 to answer the question. This is the real hard part,  
15 and I do worry a lot about over marketing, and if  
16 there was some way to get a caveat in there about  
17 other antibiotics still effective in a number of  
18 instances or concerns about overuse and emergence of  
19 resistance, I would welcome the company to try to work  
20 on something that would make us happy because I think  
21 the company hears what our concerns are.

22 I think the phraseology of effective  
23 against CAP caused by pneumococci regardless of  
24 penicillin susceptibility might be a nice one, even  
25 strains not susceptible to penicillin, which is just

NEAL R. GROSS  
COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, DC. 20005-3701

1 getting even more vague since that includes both  
2 categories.

3                   But I do worry about how it's phrased and  
4                   the potential for promoting even more use.

5 DR. RELLER: Dr. Bell.

6 || Thank you.

7 DR. BELL: Thank you so much. I just  
8 wanted to advocate for the judicious use of  
9 fluoroquinolones. It's not just a matter of worrying  
10 about pneumococci developing resistance. It's nice to  
11 hear that in Japan this hasn't apparently happened,  
12 but there are the other respiratory pathogens or  
13 gastrointestinal flora. Levaquin has an indication  
14 for urinary tract infection, for example, and you  
15 know, I don't know what the prevalence of E. coli  
16 resistance is now, but it's an issue for cipro., and  
17 so I mean, fluoroquinolones are very valuable drugs,  
18 and we just want to make sure they're used judiciously  
19 also.

I want to -- I didn't know until just now  
that the indication being proposed was not only for  
penicillin resistant, but also penicillin intermediate  
resistance, and to me, speaking personally, including  
an indication for penicillin intermediate resistance  
is really the opposite of the way we ought to be

NEAL R. GROSS  
COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 200053701

1 going.

2 I mean, why would a drug receive an  
3 indication for penicillin intermediate resistant  
4 pneumonia when even penicillin works for that  
5 condition? I mean, I just find that in terms of the  
6 confusion being sewn it would go from bad to hopeless.

7 DR. RELLER: I think, Dr. Goldberger, you  
8 have a sense on 1 (b).

9 DR. BURTON: Graham Burton. I just  
10 wondered if I could reassure the advisory committee  
11 that were this indication to be granted with greater  
12 or lesser wording as your deliberations carry on, and  
13 in conjunction with our colleagues at the FDA, that we  
14 are determined to promote or market this product  
15 sensibly and correctly. I'd just like to make that  
16 statement to you.

17 You've already heard that we're going to  
18 continue with the Trust studies looking at the  
19 emergence of resistance in the community, and should  
20 any information or flickers of concern arise there, we  
21 will bring that data to the attention of our  
22 colleagues at the FDA and proceed from there.

23 We want to do this scientifically and  
24 correctly.

25 In terms of use of antibiotics by the

prescribing community, yes, we are integral even now as we speak with educating and being a participant alongside the professional societies, alongside the institutions, and we would not propose to do anything there that would be at all unscientific or dare I suggest unscrupulous? You have our word on that.

Thank you.

DR. RELLER: In other package inserts where it affects safety and efficacy, there are specific susceptible or resistant issues that are mentioned, like with Streptococci and beta lactems not to be used for excluding methicillin resistant strains. To bring this to a full head and to be very explicit, I think we've danced around the issue. I would like to suggest that we have a committee expression, yes or no, of the exclusion of any qualifier having to do with Streptococcus pneumoniae and community acquired pneumonia.

19 So community acquired pneumonia having to  
20 do with -- this is a comment from the committee. It's  
21 only advisory to the FDA -- is what the committee's  
22 sense is having to do with the simple statement of  
23 community acquired pneumonia owing to Streptococcus  
24 pneumoniae, period.

25 Dr. Norden.

NEAL R. GROSS  
COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 DR. NORDEN: That **was** what I suggested at  
2 the beginning, and Dr. Goldberger answered, I think,  
3 appropriately regarding ripeness and so on.

4 I would prefer not to change the label  
5 because I think the potential for damage or misuse or  
6 misinterpretation is great no matter what caveats we  
7 put in and because I think the present label is  
8 sufficient.

9 So that's my comment.

10 DR. RELLER: Dr. Parsonnet.

11 DR. PARSONNET: I would favor actually  
12 including some reference to pneumococcal resistance in  
13 the label, and I would favor doing it maybe somewhere  
14 along the lines of what Dr. Murray said, making it a  
15 little bit less directly, something along the lines  
16 that you said, but I think there are a lot of  
17 physicians out there who may be seeing resistant  
18 isolates and might like that sort of guidance in the  
19 label.

20 DR. RELLER: I think the label should  
21 refer to *Streptococcus pneumoniae* susceptible to  
22 levofloxacin are the target organisms when one has an  
23 organism, and the empirical treatment for appropriate  
24 according to guidelines is another issue altogether.

25 Dr. Danner.

1 DR. DANNER: I guess I don't object to  
2 adding the penicillin resistant to the label. I think  
3 Carl's right. It's sort of cleaner and it covers the  
4 universe of issues, the labeling, as it is, but on the  
5 other hand, I guess I don't know of any compelling  
6 reason that would say that, you know, this shouldn't  
7 be done, and there's certainly a lot of antibiotics  
8 coming along that are being developed specifically for  
9 resistant type organisms.

10 So maybe developing labeling for that kind  
11 of indication is something that needs to be done for  
12 these future things coming along.

13 DR. RELLER: Dr. Soper.

14 DR. SOPER: I agree that I don't think the  
15 label needs to be changed unless the company is  
16 handcuffed in marketing because of no label change.  
17 In other words, I would say why change the label, but  
18 the company should be allowed in their advertising to  
19 say that their antibiotic is effective for the  
20 treatment of this microorganism, much along the lines  
21 that Barth outlined.

22 So if we don't change the labeling, does  
23 that mean the company can't market along those lines  
24 or are we saying we're giving this company and all  
25 companies to follow the opportunity to market any way

1                   they see fit?

2                   DR. GOLDBERGER: I mean, leaving aside the  
3 pending litigation which I would not try to comment  
4 on, not the least of which because I really don't  
5 understand it completely, the issue is that if the  
6 company is to promote in the normal fashion and state,  
7 for instance that penicillin, you know, resistance --  
8 that it is effective against penicillin resistance  
9 isolates or, to use Dr. Murray's language, regardless  
10 of penicillin susceptibility, we believe that that  
11 information should be in the product label if they are  
12 going to, in fact, promote that.

13                  To promote that type of information  
14 without its being in the product label sets a variety  
15 of precedents which I think in the long run would not  
16 be a positive thing.

17                  DR. SOPER: Okay. So if that's the case,  
18 then I would support changing the label.

19                  DR. RELLER: Dr. Christie.

20                  DR. CHRISTIE-SAMUELS: I guess I'd have to  
21 maintain my integrity and stick with the former  
22 comment that we should probably just say all  
23 *Streptococcus pneumoniae*, implying susceptible,  
24 resistant, intermediate, recognizing, of course, that  
25 there will always be the risk that the prescribing

1           community might overdo it.

2           DR. RELLER: Keith.

3           DR. RODVOLD: I think that they should  
4           change the labeling. I think that, you know, we've  
5           had several meetings about this, and they've followed  
6           what we've suggested to do and stepped up to the plate  
7           at this point, and it will affect them from what you  
8           said in the advertisement and being able to promote  
9           it.

10           So I think you do have to at this point  
11          move ahead if you believe in the data which we just  
12          voted on in the first part.

13           DR. RELLER: Dr. O'Fallon, any comment?

14           DR. O'FALLON: Well, on the basis of the  
15          first one and the vote to the first one, which was  
16          unanimous, I believe, and hearing the comments here I  
17          don't see how anyone can deny that, them to make the  
18          change.

19           DR. RELLER: Dr. Murray.

20           DR. MURRAY: Yeah, I like the either  
21          regardless of penicillin susceptibility or including  
22          penicillin nonsusceptible strains.

23           DR. RELLER: Question No. 2, do you have  
24          any recommendations regarding Phase 4 studies or data  
25          collection that the applicant should be requested to

1 perform?

2 Anything that we haven't covered, Julie?

3 DR. PARSONNET: I favor a lot of what's  
4 been mentioned before, which is continued surveillance  
5 over time to see what happens to the Levaquin's  
6 activity and to see whether it does start to correlate  
7 with penicillin sensitivity at the same time.

8 And I think there has to be some  
9 understanding that the label might change if those  
10 aspects of the therapy change.

11 DR. RELLER: Bob, anything you want to say  
12 about two?

13 DR. DANNER: I guess this may be part of  
14 two and part of three, but I guess I would repeat some  
15 of the earlier comments that it would be a very  
16 correct thing for the company to try to do studies of  
17 Levaquin in children, particularly with severe  
18 pneumococcus disease since there's a higher incidence  
19 of resistance, and studies in that population would be  
20 very helpful in terms of knowing how to use the drugs  
21 in those settings.

22 DR. RELLER: Dr. Christie, anything  
23 further to say on two?

24 DR. CHRISTIE-SAMUELS: I would have to  
25 advocate for children again. I believe studies should

1           be performed in health children who are hospitalized  
2           with community acquired pneumococcal pneumonia  
3           evidenced by a positive blood culture or positive  
4           pleural fluid, regardless of whether the organism is  
5           drug resistant or drug susceptible to whatever drug.

6           Thank you.

7           DR. RELLER: Dr. Murray.

8           DR. MURRAY: Not really, and I wouldn't  
9           want to say anything bad about children, but just to  
10          remind the commonly quoted phrase that the best thing  
11          that ever happened to preserve the life span of the  
12          fluoroquinolones was those beagle puppies, and the  
13          fact that the drug has not been out there in wide use  
14          in the pediatric day care center population, but I  
15          certainly think it needs to be and has to be studied  
16          in severe disease in children.

17           DR. RELLER: Question 3, do you have any  
18          recommendations for future clinical trials? Such  
19          recommendations might address, but not limited to  
20          issues of the supportive value of isolates from other  
21          body sites, usefulness of data from penicillin  
22          intermediate isolates.

23           We'll go in the reverse. Dr. Murray, any  
24          comment on three?

25           Dr. O'Fallon?

1 Rodvold?

2 Christie?

3 DR. CHRISTIE-SAMUELS : Clinical trials in  
4 children again.

5 Thank you.

6 DR. RELLER: Dr. Soper.

7 Danner.

8 Dr. Goldberger, Dr. Kweder, any closing  
9 remarks?

10 Yes, Dr. Christie.

11 DR. CHRISTIE-SAMUELS: Just one more.  
12 When we're looking at children, if we could somehow  
13 find out if the drug is concentrated in the pleural  
14 fluid, that would be good, too.

15 DR. RELLER: So in summary, I think we  
16 have a strong sense that this drug works for community  
17 acquired pneumonia without regard to susceptibility or  
18 resistance for pneumococci, and how best to handle  
19 that fortunately rests with the FDA.

20 Yes, Dr. Kweder.

21 DR. KWEDER: I just have one final  
22 comment. I want to thank you all for your  
23 deliberations. I think that this is something. The  
24 fact that we have had I think this probably brings us  
25 to three, maybe four advisory committee meetings where

1           this general area of discussion has been held, sort of  
2        serves to illustrate what a difficult topic or area  
3        this is to get your arms around from both scientific  
4        and a regulatory perspective.

5           Some of the things that you've touched on  
6        today fall into a general construct that we're  
7        grappling with at the agency that goes even beyond  
8        antibiotic resistance, which is a construct of risk  
9        management, and if we think about antibiotic  
10      resistance, both the treatment of patients with  
11      resistance organisms and the further burden of  
12      preventing the development of additional resistance,  
13      those all come under the broad heading of drug safety  
14      both for individual patients and the public health and  
15      risk management.

16           A lot of risk management not only involves  
17      risk assessment, what's the risk of future resistance,  
18      some of the things you've talked about today, but also  
19      how do we educate the public health professionals and  
20      consumers about how to manage that risk and prevent it  
21      from becoming greater.

22           Some of that from our standpoint comes in  
23      how we -- the language we choose for labels, where we  
24      choose to include things in labels and not, and so  
25      we've heard you today, and we really thank you for

1 your comments. I think sometimes you feel like  
2 they're just out there with few constraints around  
3 them, but they are very meaningful to us in  
4 application to what we need to do now with review of  
5 this NDA. So thanks.

6 And there will be more of that tomorrow.

7 DR. RELLER: We'll reconvene at eight  
8 o'clock in the morning.

9 (Whereupon, at 5:22 p.m., the meeting was  
10 adjourned, to reconvene at 8:30 a.m., Thursday,  
11 October 21, 1999.)

12

13

14

15

16

17

18

19

20

21

22

23

24

25

CERTIFICATE

This is to certify that the foregoing transcript in the  
matter of: 67<sup>TH</sup> MEETING

Before: ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE

Date: OCTOBER 20, 1999

Place: SILVER SPRING, MARYLAND

represents the full and complete proceedings of the  
aforementioned matter, as reported and reduced to  
typewriting.

irene gray

## **INDEX**

## Look-See Concordance Report

UNIQUE WORDS: 3, 809  
 TOTAL OCCURANCES: 24, 388  
 NOISE WORDS: 385  
 TOTAL WORDS IN FILE:  
 62,912

## SINGLE FILE CONCORDANCE

CASE SENSITIVE  
 NOISE WORD LIST(S):  
**NOISE.NOI**

INCLUDES ALL TEXT  
 OCCURRENCES

IGNORES PURE NUMBERS

WORD RANGES @ BOTTOM  
 OF PAGE

**- 1 -**

10:03 [1] 67:25  
 12:05 [1] 163:17  
 12A30 [1] 165:5  
 16-fold [1] 211:23  
 1970s [1] 221:2  
 1980s [2] 174:20; 212:12  
 1990s [5] 174:19, 21; 212:14;  
 221:16, 77  
 :00 [2] 163:18; 164:2

**- 2 -**

23F [1] 188:15  
 270-odd [1] 225:7

**- 3 -**

30-fold [1] 243:17  
 30s [1] 230:2  
 3:28 [1] 269:19  
 3:45 [2] 269:13, 76  
 3:48 [1] 269:20

**- 5 -**

5: 22 [1] 338:9

**- 6 -**

6-beta [1] 91:24  
 60s [2] 223:22; 233:5  
 65-plus [1] 185:4  
 67th [1] 5:4

**- 7 -**

70s [1] 223:22

**- 8 -**

80s [1] 221:9  
 8:13 [1] 5:2  
 3:30 [1] 338:10

**- 9 -**

90s [1] 233:8  
 97-98 [1] 215:5

**9:42 [1] 67:24**

**- A -**

a.m. [4] 5:2; 67:24, 25; 338:10  
**AAC**[5] 207:12; 208:7;  
 210:25; 216:3; 217:3  
**abbreviate** [1] 270:15  
**abbreviation**[1] 270:12  
**ABCs** [9] 174:25; 175:7;  
 177:10; 178:12; 179:13, 18;  
 184:2; 186:13  
**ability** [10] 49:4; 115:21;  
 152:8; 154:2, 8, 23; 227:24;  
 228:20; 291:20; 322:10  
**able** [34] 28:23; 52:24; 92:7;  
 99:23,25; 106:15; 108:25;  
 111:8, 77, 12; 121:14, 24;  
 128:7; 141:14, 75; 145:23;  
 148:9; 154:9; 156:9; 157:11,  
 23; 158:5; 162:11; 191:25;  
 192:1; 251:11; 264:17; 267:22;  
 272:12; 275:8; 294:7,77;  
 298:1; 333:8  
**abscess** [1] 250:5  
**abscesses** [2] 248:25; 249:14  
**absence** [6] 51:12, 19; 52:10,  
 1' 6; 117:18; 292:14  
**absolute** [3] 102:10; 113:2;  
 262:10  
**absolutely** [a] 58:24; 96:18;  
 109:24; 112:1; 143:20; 301:1;  
 303:13; 319:17  
**abysmal** [1] 223:6  
**academic** [1] 9:18  
**accelerate**[1] 262:14  
**accept** [5] 66:16; 101:21;  
 111:18; 113:8; 114:12  
**acceptable** [6] 23:24; 43:15;  
 44:1, 22; 46:12; 170:23  
**accepted** [2] 23:17; 247:5  
**access**[3] 18:14; 42:1; 87:13  
**accord** [2] 13:11; 147:16  
**accordance** [2] 7:19; 164:24  
**according** [6] 183:22; 184:16;  
 214:22; 251:1; 309:25; 330:24  
**accruing** [1] 233:9  
**accumulated** [1] 259:11  
**accumulation** [1] 258:19  
**accurately** [2] 79:15  
**achievable** [1] 90:25  
**achieve** [1] 158:5  
**achieved** [1] 158:9  
**achieves** [2] 230:13, 74  
**acid** [1] 210:21  
**acknowledge** [1] 165:24  
**acquired** [46] 42:14; 133:14;  
 197:11,78; 198:3,25; 200:13,  
 15; 201:2; 202:2; 231:12;  
 232:6,74; 253:14; 257:19;  
 260:8,24; 266:22; 270:8,72,  
 27; 271:3, 77, 12, 13, 75,77/  
 272:25; 273:9,12; 274:16,22,  
 25; 275:3,13; 276:18,79;  
 286:23;  
 287:1; 295:4; 313:1; 329:18,  
 19, 23; 335:2; 336:17  
**acronyms** [1] 270:11  
**Act** [1] 42:10  
**Acting** [1] 168:6  
**acting** [2] 79:2; 164:5

**action** [2] 202:14; 293:7  
**active**[1 o] 15:15; 19:1; 23:10;  
 174:24; 175:8; 199:20; 203:7;  
 220:10; 247:12; 283:19  
**activities** [2] 8:14; 168:16  
**activity** [18] 23:14; 197:17;  
 198:18; 202:18; 203:13;  
 204:17, 19; 205:7, 15, 76, 18;  
 206:16; 223:1, 9; 242:1; 296:2;  
 334:6  
**actual** [1] 300:17  
**actuality**[1] 135:8  
**ad** [1] 290:23  
**add** [10] 70:23; 74:25; 77:20;  
 80:24; 125:18; 202:1; 248:3;  
 271:2; 273:4; 293:13  
**add-on** [1] 99:6  
**added** [5] 76:22, 25; 98:22;  
 121:1; 264:19  
**adding** [7] 46:1; 78:15; 241:7;  
 294:2; 324:14; 325:3; 331:2  
**addition** [24] 9:12, 74; 16:7;  
 23:23; 68:14, 23; 81:3; 719:4;  
 154:6; 164:24; 165:7; 175:18;  
 176:17; 186:3, 5; 189:23;  
 198:19; 201:5; 231:4; 249:20;  
 271:4; 274:23; 307:25; 322:6  
**Additional**[1] 231:8  
**additional** [13] 21:2; 30:23;  
 76:24; 98:23; 177:6; 198:18;  
 206:17; 241:8; 262:21; 278:14;  
 284:12; 288:16; 337:12  
**additionally** [1] 38:24  
**address** [26] 8:5; 28:79; 33:2;  
 34:12; 59:4; 65:6; 111:23;  
 122:15; 129:16; 147:4, 10;  
 166: 7 6; 202: 15; 288:8; 289:4;  
 290:16; 293:9; 297:1; 304:6;  
 309:7; 314:14; 315:1, 5;  
 316:14, 19; 335:19  
**addressed** [6] 33:25; 95: 7 9;  
 170: 7; 2 15:22; 260:17; 265: 78  
**addresses** [2] 7:9; 164:9  
**addressing** [5] 202:13;  
 261:24; 262:1, 7; 315:24  
**adds**[1] 39:6  
**adequate** [3] 15:10; 42:8;  
 46:18  
**adequately** [1] 145:17  
**adjourned** [1] 338:10  
**adjunctive** [3] 19:12, 15;  
 34:13  
**adjusted** [1] 183:4  
**administered** [1] 218:19  
**Administration** [1] 196:9  
**admission** [1] 287:5  
**admit** [1] 300:6  
**admitted** [1] 124:4  
**adopted** [1] 31:17  
**adults** [11] 36:4; 71:15; 75:9;  
 96:16; 130:3; 187:10; 191:14;  
 192:6; 233:3; 249:13, 15  
**advance** [5] 19:10, 72, 77;  
 20:3; 34:8  
**advantage** [1] 169:15  
**advantageous** [1] 7 70: 74  
**adverse** [6] 240: 77, 79, 23;  
 241:11, 24; 243:21  
**adversely** [1] 116:16  
**advertise** [1] 296:4  
**advertisement** [1] 333:8

**advertisements** [1] 322: 7  
**advertising** [2] 299:10;  
 31:18  
**dvice** [2] 172:9; 173:2  
**divisory** [1] 5:5  
**divisory** [14] 12:4, 25; 48:24;  
 66:23; 171:24; 172:3; 196:8;  
 88:8, 10; 291:16, 78; 328:10;  
 29:21; 336:25  
**dvocate** [5] 83:17; 96:15;  
 32:25; 327:8; 334:25  
**eruginosa** [4] 12:12; 101:23;  
 23:3, 7  
**febrile** [5] 37:14; 52:8; 57:9;  
 7:8; 159:6  
**ffairs**[1] 196:11  
**ffect** [4] 34:2; 115:21;  
 16:24; 333:7  
**ffected**[1] 212:3  
**ffects**[3] 33:23; 180:1; 329:9  
**ffiliation** [1] 5:77  
**ffinities** [2] 206:14, 79  
**ffirmed**[1] 294:22  
**frica** [1] 221:2  
**ftemoon** [17] 164:3, 5;  
 66:22; 173:20; 774: 18;  
 96:7, 76, 78; 197:1; 199:10;  
 02:8; 247:2; 269:23; 270:2;  
 94:8  
**fterwards**[1] 150:7  
**ge** [12] 180:5; 183:4; 185:2,  
 , 7, 23; 187:6; 192:4; 233:13,  
 4; 237:22; 295:20  
**gency**[1] 165:5  
**gency** [8] 10:4; 15:12; 19:10;  
 0:10; 165:18; 171:20; 306:9;  
 137:7  
**igenda** [6] 5:6; 7:13, 24;  
 64:13; 166:11; 168:8  
**gent** [12] 83:8; 97:20; 103:6;  
 176:3; 145:23; 146:2, 9;  
 148:23; 158:3; 186:19; 203:14;  
 265:4  
**gents** [13] 19:7; 67:7; 140:5;  
 146:5; 177:3, 22; 186:23;  
 187:21; 188:3; 199:12, 25;  
 210:10; 266:1  
**ages** [3] 35:15; 233:15; 238:8  
**aggregate** [2] 79:19, 22  
**rgressive** [2] 248:24; 258:8  
**ngree** [50] 25:20; 28:14;  
 37:25; 38:5; 48:4; 49:11; 58:1,  
 24; 60:23; 72:23; 76:9; 81:21;  
 92:1; 86:25; 91:11, 27; 92:22;  
 96:13, 78; 100:10; 102:19;  
 103:1, 78; 109:24; 110:10;  
 111:2; 117:2, 8; 118:15; 119:9;  
 121:5; 124:8, 9, 75; 128:9;  
 129:23;  
 144:22; 156:7; 193:14, 22;  
 260:11; 262:18; 263:6; 265:17;  
 302:11; 308:15; 317:15;  
 324:17; 325:8; 331:14  
**agreed** [3] 105:6; 107:4;  
 300:16  
**agreement** [1] 109:18  
**agrees** [1] 143:18  
**AIDS** [1] 191:21  
**al** [4] 184:23; 204:15; 217:3;  
 224:20  
**Albany** [1] 201:9

|  |   |  |   |
|--|---|--|---|
| allergic [2] 18:22; 246:3<br>allocated [1] 34:14<br>allow [5] 13:25; 18:3; 173:5;<br>281:5, 6<br>allowed [2] 40:14; 331:18<br>allowing [1] 42:12<br>allows [4] 299:9; 306:15, 76,<br>22<br>alluded [1] 304:8<br>alone [11] 16:10; 18:19;<br>27:13; 28:11; 30:18; 65:11;<br>106:5; 109:22; 158:10; 251:5;<br>295:20<br>alongside [2] 329:3<br>alpha [1] 43:18<br>alt [1] 45:17<br>alter [1] 210:19<br>alteration [5] 16:17; 30:4;<br>31:6; 59:11; 323:15<br>altered [5] 16:19; 79:20; 80:3;<br>233:20; 250: 75<br>alternative [lo] 77:24; 81:6;<br>98:3; 170:6; 246:27; 259:6;<br>266:10; 268:15, 77; 318:5<br>Alternatively [1] 16:21<br>altogether [2] 304:1; 330:24<br>alveolar[5] 226:7, 8; 227:20,<br>25; 249:20<br>ambiguities [2] 64:20; 715:4<br>America [2] 221:13; 247:9<br>American [2] 243:14, 78<br>amount [14] 138:12; 142:25;<br>772: 7; 173:9; 74:20; 222:4,<br>25; 291:25; 292:7; 297:5;<br>300:17; 304:7; 313:18; 316:15<br>amoxicillin [2] 176:5; 296:20<br>ampicillin [4] 228:8, 77, 23;<br>229:3<br>ample [1] 196:4<br>analyses[2] 24:3; 210:17<br>analysis[26] 20:5; 22:7;<br>26:17; 50:2; 61:8, 24; 92:21;<br>104:9; 105:3, 6, 8; 117:21;<br>123:14, 77; 124:5; 129:6;<br>183:17; 185:21; 272:2; 275:10;<br>279:10; 289:22, 23; 316:22<br>analytic [1] 14:12<br>analyze [1] 50:5<br>analyzed [5] 13:24; 22:21, 22;<br>211:1; 279:23<br>anatomic [1] 16:6<br>Anderson [1] 47:7<br>anecdotal [2] 55:10; 249:7<br>animal [9] 202:18; 203:9;<br>278: 7; 225:3; 238:22; 253:2;<br>255: 7; 268:2; 375: 78<br>announcement [2] 7:8; 164:8<br>annually [I] 12:24<br>answer[25] 24: 10; 67:6;<br>69:21; 73:3; 83:7, 77; 122:4;<br>129:11; 181:20; 201:7, 27;<br>229:73; 257:1; 258:9; 259:4,<br>74; 262: 78; 267: 15; 269:3;<br>288:9,75, 77; 315:8; 318:20;<br>326: 74<br>answered [5] 55:18; 74:20;<br>267:22; 330:2<br>answering [1] 82:19<br>antecedent [1] 242:10<br>anti-fungal[1] 28:5<br>Anti-infective [6] 5:4; 7:4; | 8:15; 11:5, 76; 13:12<br>anti-infective [3] 7 15:20;<br>199:12; 291:4<br>antibacterial [1] 231:25<br>antibiogram [17] 18:1; 68:24;<br>82:6; 89:6; 90:15, 17, 78; 91:5,<br>6, 14, 76, 27; 92:12; 98:10, 74;<br>109:9<br>antibiograms [3] 81:16;<br>90:20; 93:20<br>Antibiotic [1] 151:4<br>antibiotic [22] 9:1; 28:24;<br>69:19; 108:13, 79; 115:20;<br>140:23; 142:10; 148:18; 151:6;<br>169:24; 789: 14; 193:23; 195:2;<br>203:13, 79; 255:20, 23; 302:7;<br>331:19; 337:8, 9<br>antibiotics [24] 40:11, 25;<br>91:22; 117:6; 141:20; 143:4;<br>146:12; 147:6; 152:18; 153:7;<br>154:24; 246: 76, 2 7; 263:3;<br>283: 78, 22, 24; 295: 10; 312:2;<br>319:10; 321:23; 326:17;<br>328:25; 33 1:7<br>antibiotigrams [1] 88:7<br>antimicrobial[23] 5:7; 7 1:8;<br>13:14; 21:2; 39:6; 99:15;<br>71:6; 2, 140:5; 145:22; 146:2, 8;<br>157:16; 158:10; 168:15;<br>174:10; 178:9; 193:4; 199:25;<br>247:20; 266:24; 280:2; 283: 79;<br>295:14<br>antimicrobials[4] 16:8;<br>157:1 1; 158:5; 295:24<br>antiseptic [I] 7 17:6<br>antithesis [1] 58:15<br>anxiety [3] 258:7, 25; 259:15<br>anybody[4] 70: 77; 72:14;<br>128:25; 163:10<br>anymore [2] 7 13:10; 173:21<br>anyplace [1] 66:15<br>anyway [3] 64:23; 66:9; 92:24<br>anywhere [2] 33:24; 264: 16<br>APACHE [2] 24:4; 31:19<br>apart [3] 82:23; 135:12;<br>317:21<br>apologize [1] 250:9<br>apparent [7] 109:4, 70;<br>117:16; 221:10; 307:17, 79;<br>308:8<br>apparently [2] 48:15; 327:11<br>appeal [ 1] 262:22<br>appear [2] 206:25; 309:18<br>appearance[4] 7: 7 7; 164:11,<br>79; 165:16<br>appeared [6] 57:21; 160:20;<br>205:6, 8, 74, 79<br>appears [12] 182:24; 188:16;<br>204:9, 72; 27 1:17; 229:5, 77,<br>73; 244:3; 304:13; 307:23;<br>308:4<br>Appelbaum [3] 203:15, 24;<br>209:23<br>apples [1] 124:6<br>applicable [1] 54:17<br>applicant [4] 271:4; 288:25;<br>305:23; 333:25<br>application [6] 169:23;<br>196:20; 197:4; 231:1; 248:2;<br>338:4<br>applied[6] 19:19; 20:3; 34:9; | 84:7, 8; 169:21<br>applies [2] 153:25; 247:8<br>apply [3] 35:9; 73:22; 231:23<br>appreciably [1] 227:17<br>appreciate [4] 9:22; 10:17;<br>34:10; 68:11<br>appreciated [2] 68:5<br>appreciation [1] 10:3<br>approach [9] 54:8; 229:14;<br>17; 271:9, 24; 272:2; 279:10,<br>12, 22<br>approached [1] 298:21<br>appropriate [25] 23:15, 79;<br>40:6, 7 1; 68:20; 69: 73, 24;<br>71:13, 24; 74:18, 21; 75:24;<br>96:24; 134:24; 248: 13; 266: 1;<br>272:15; 275:9; 298:9, 73;<br>319:23; 320:2, 76; 321:6;<br>330:23<br>appropriately [3] 69:23;<br>150:4; 330:3<br>approval [ 11] 40:2; 42:18;<br>151:21; 169:2, 24; 197:4, 9,<br>22, 24; 286:22; 322:4<br>approve [2] 52:14; 254:19<br>approved [7] 23:16; 75:4;<br>169:3; 254:8; 270:20, 25;<br>295: 73<br>approving [1] 315:23<br>approximately [14] 205:9;<br>216:4, 11; 219:11; 230:11;<br>273:6; 274:1, 7; 275:22;<br>276:12; 277:17; 283:3, 15;<br>287:2<br>area[12] 8:20; 47:2; 77:10;<br>175:13; 178:18; 183:4; 190:14;<br>225:8, 17; 265:16; 337:1, 2<br>areas [7] 9:6, 68:9; 175:11;<br>178:12, 73; 222:21; 270:16<br>aren't[5] 72:17; 81:8; 153:3;<br>268:13; 308:14<br>Arguably [1] 311:9<br>argue [5] 105:8; 106:12;<br>150:1; 297:17; 310:25<br>argument [5] 45:13; 106:8;<br>132:5; 229:9; 312:12<br>arguments [1] 106:2<br>aright [1] 269:22<br>arise [I] 328:20<br>arising [1] 77:18<br>arm [10] 125:1; 272:15; 273:5;<br>275: 7 7, 23; 277: 78; 282:9;<br>283: 74; 285: 79, 23<br>arms[3] 274:6; 325:23; 337:3<br>Armstrong [I] 57:16<br>arose [1] 24:24<br>arrive [1] 128:7 | arterial [2] 15:2; 78:1<br>article[2] 7 15:24; 216:10<br>articles [3] 60:24; 89:17;<br>103:23<br>ascribe [1] 101:16<br>ascribing [I] 101:7<br>aside [2] 322: 72; 332:2<br>asking [16] 69:14; 76:15;<br>82:24; 156:12; 192:19; 267:15;<br>288:7; 292:9; 293:22, 24;<br>302:24; 309:5; 311:6; 313:10,<br>11, 20<br>ASM [I] 101:12<br>aspartic [1] 210:21<br>aspects [3] 68: 17; 200:2;<br>334:10<br>aspirated [1] 97:3<br>assess[3] 67:9, 77; 156:22<br>assessed [6] 13:23; 14:12;<br>69:8; 94:1 7, 19; 109:23<br>assessing [2] 69:4; 131:2<br>assessment [3] 20:22;<br>158:20; 337: 7 7<br>assessments [I] 20:8<br>assist [1] 171:11<br>Assistant [1] 201:18<br>associate [1] 305:16<br>associated[14] 9:3; 13:3, 5;<br>21:8; 133:15; 191:23; 194:8;<br>196:27; 200: 15; 229:5; 249:2;<br>305:9; 306:21; 320:9<br>association [2] 187:6; 303:14<br>assume [2] 123:23; 257:23<br>Assuming [I] 43:6<br>assuming [3] 44:19; 112:18;<br>257:24<br>assuring [1] 311:15<br>asymptomatic [4] 32:1, 6;<br>130:19; 161:10<br>athenoalanine [I] 210:18<br>Atlanta [2] 167:23; 168:14<br>attempt [5] 62:12; 140:23;<br>145:7; 262:20; 309:7<br>attempting [2] 32:20; 65:6<br>attempts [I] 27 1:3<br>attendant [1] 222:6<br>attention [3] 46:19; 177:25;<br>328:21<br>attributable [I] 13:3<br>attributes [I] 203:12<br>attributing [1] 72:20<br>atypical [1] 170:10<br>AUC [23] 208:21; 209:9;<br>219:3, 7, 10, 72, 76, 77, 20,<br>24; 220: 15; 224:24; 225:4;<br>228:9; 229: 11, 75, 20, 24;<br>230:1, 9, 76; 238:25<br>AUCs [I] 229:5<br>audience [1] 163:4<br>audits [1] 175:14<br>Aureus [1] 56:12<br>Austrian [I] 182:15<br>author [1] 7 16:4<br>automated [1] 92:15<br>automatically [1] 311:11<br>availability [2] 47:20; 115:7<br>available [17] 28:14; 30:12;<br>42:8; 50:22; 83:6; 88:13, 22;<br>91:9; 7 14:14; 265:25; 294:16;<br>298:7; 299:7; 300: |
|--|---|--|---|

## Basic Systems\_Applications

**average** [7] 104:25; 224:23; 227:3; 256:8, 9; 262:2, 8  
**avoid** [3] 19:18; 112:25; 298:24  
   ware [8] 8:1; 82:17; 162:7; 166:12; 193:10; 224:7; 249:25; 302:19  
**axillary** [2] 74:6, 7  
**azithromycin** [2] 234:21; 251:22

**- B -**

**background** [5] 11:15; 197:3; 248:21; 270:19; 304:5  
**backwards** [1] 265:10  
**bacteremias** [7] 52:23; 55:13; 20, 27; 117:14; 125:6; 131:24  
**bacteremic** [24] 16:5; 18:15; 133:22; 135:7; 141:19; 172:23; 225:20; 237:3, 4, 9, 75; 238:6; 240:1; 244:18; 247:19; 249:4; 252:22; 253:25; 259:8; 283:13; 284:6, 8; 312:25  
**bacteria** [9] 126:17; 144:12; 14; 153:1, 4, 8; 226:3; 229:10; 301:5  
**bacterial** [2] 7 74:25; 208: 76  
**bacteriocidal** [2] 19:7; 203:14  
**badly** [1] 295:24  
**BAL** [1] 226:14  
**balance** [6] 42:4; 246:16; 260:12; 315:6; 322:13; 323:7  
**balloon** [3] 246:14; 259:3; 260:9  
   **banner** [1] 100:23  
   **oar** [6] 71:25; 72:8; 84:19; 85:24; 102:20; 325: 78  
**Barbara** [5] 5: 18; 58:5; 92:17; 125:15; 290:10  
**barrier** [2] 224:4, 6  
**Barry** [4] 61:7, 24; 104:8; 105:2  
**bars** [1] 180:9  
**Barth** [15] 5:15, 76; 72:24; 78:22; 79:6; 103:19; 110:10; 116:5; 119:16; 161:3; 164:3; 267:11; 290:12; 324:17; 331:21  
**Based** [4] 7:13; 41:9; 160:5; 164:13  
**based** [42] 30:12; 41:6; 44:7; 49:3; 50:5; 56:23; 57:24; 65:16; 88:14; 101:15; 135:17; 136:13, 74; 138:18; 175:4, 8; 179:10, 23; 181:17; 197:13; 79; 198:7; 213:4; 216:18; 234: 14; 235: 73, 22; 237: 7 7; 253:2; 256:15; 257:1; 268:2; 273:3, 27; 275:24; 285:3; 296:1, 21; 300:19; 307:4; 319:12; 323:23  
**baseline** [8] 36:15; 233:21; 242:24; 250: 1 8; 274: 1, 3; 283:5, 8  
   **asic** [2] 129:12; 246:18  
**basically** [10] 48:24; 57:5; 157:7; 236:23; 293:1 7, 22, 23, 300:2; 37:1:6; 312:8  
**basics** [1] 84:20  
**basis** [11] 19:4; 29:18; 86:8;

109:22; 121:25; 128:1; 230:23; 305:3; 306:10; 307:14; 333:14  
**batch** [1] 92:18  
**Bates** [2] 51:18; 89:17  
**bathing** [1] 226:6  
**BATTINELLI** [3] 167:20; 261:23, 265:8  
**Elattinelli** [3] 167:20; 261:22; 262:16  
**Elayer** [1] 165:10  
**beagle** [1] 335:12  
**bear** [1] 197:1  
**bbearing** [4] 198:9; 200:12; 239:23, 24  
**tbeauty** [1] 84:5  
**becomes** [6] 73:21; 113:12; 134:18; 172:21; 239:3; 324:20  
**becoming** [5] 35:25; 107:14; 152:23; 212:16; 337:21  
**beg** [1] 251:19  
**begets** [1] 305:1  
**begins** [1] 229:19  
**begs** [1] 111:17  
**behaving** [1] 221:7  
**behavior** [3] 193:3, 77, 20  
**behind** [3] 8:12; 76:6; 156:17  
**believe** [22] 97:17; 100:15; 19; 104:9, 75; 106:6; 112:20; 161:7; 165:22; 169:9; 173:2; 199:13; 200:12; 250:23; 260:23; 292:5; 304:17; 318:4; 332:10; 333:11, 16; 334:25  
**believed** [1] 320:14  
**believes** [1] 165:23  
**BELL** [2] 168:12; 327:7  
**lBell** [12] 168:11, 73; 171:14; 76; 261:24; 262:19; 265:17; 266:21; 268:23; 309: 72; 323: 10, 327:5  
**bench** [1] 85:4  
**benefit** [6] 134:13; 222:6, 10; 240:7, 73; 251:6  
**benefits** [1] 43:13  
**benzoconium** [3] 116:13, 15, 22  
**besides** [1] 76:24  
**beta** [29] 195:16, 77; 200:18; 204:2; 206:12, 75, 79; 212:25; 224:8, 9, 7 7; 240:25; 241:2; 244:4, 73; 246:9; 247:21; 251:3, 5; 252:5; 258:2; 264:1 7, 266:23; 267:10; 295:1; 310:1; 329: 7 7  
**Beth** [1] 201:18  
**bias** [4] 19:18; 20:5; 34:7, 73  
**biasing** [1] 118:10  
**bigger** [1] 104:19  
**biggest** [1] 178:15  
**Bill** [12] 6:13; 69:17; 95:10; 100:3; 101:25; 7 71:2, 4; 150:23; 158:22; 159:14; 163:13; 268:1  
**biluminal** [1] 62:22  
**binding** [5] 32:24; 204:6; 206:11, 74, 79  
**bioassay** [1] 105:22  
**bioavailability** [1] 226:22  
**bioavailable** [1] 222:8  
**bioburden** [2] 104:19; 105:18  
**biochemical** [4] 88:1 7, 20; 98:9; 305:4

**biofilm** [Q] 62:13, 77; 66:3; 140:4, 6; 149:24; 157:13; 158:1, 77  
**biofilms** [1] 139:23  
**biologically** [1] 304:18  
**biology** [1] 256:16  
**biopsy** [2] 143:22; 225:23  
**Biostatistics** [3] 39:17, 75; 167:2  
**biotyping** [1] 98:9  
**bird** [1] 258:15  
**birds** [1] 305:1  
**bit** [37] 8:12; 9:21; 33:9; 35:23; 36:5; 54:4; 70: 1 7; 74:4; 75:14; 114:5; 120:21; 138:15; 172:20; 187:3, 74, 22; 188:1; 196:7 3, 27 7:25; 220:2 7; 221:14; 227:4; 228:6; 229:2; 233:11; 237:22; 238:7; 241:16; 17, 254:4; 270:18; 272:5; 277:3; 306: 7 7; 316:9 320:6; 330: 15  
**black** [1] 180:11  
**bleed** [2] 242:13, 74  
**blind** [3] 15:19; 277:7; 278:19  
**blinded** [1] 231:5  
**block** [1] 223:20  
**blood-brain** [2] 224:4, 5  
**Blotte** [2] 50:13, 24  
**blush** [1] 222:10  
**board** [4] 242:3; 274:2, 5; 304:15  
**E3ob** [1] 6:10; 72:25; 77:23; 78:2; 100:23; 142:1; 144:15; 167:11; 168:1; 304:18; 334:11  
**body** [4] 200:1 7; 289:6; 292:21; 335:21  
**bolus** [1] 7 16:20  
**bonded** [4] 116:11, 72, 75, 27  
**Ilone** [1] 143:22  
**lBoston** [1] 167:21  
**bothers** [2] 156:18; 296:19  
**bound** [1] 290:23  
**bow** [1] 89:1  
**lbreak** [14] 67:21; 86:5; 158:11; 163:11; 169:19; 205:24; 206:4; 27 9:7 9; 229:25; 267:3; 269:12, 75, 77; 317:19  
**breakpoint** [1] 238: 76  
**breath** [1] 79:13  
**breaths** [1] 250:19  
**brief** [1] 8:13  
**briefly** [2] 155:5; 202:17  
**brilliant** [1] 223:25  
**bringing** [3] 37:1; 170:25; 255:24  
**brings** [2] 107:1 7; 336:24  
**Bristol-Myers** [1] 165:11  
**broad** [2] 67:8; 337:13  
**broader** [2] 298:18; 314:25  
**broken** [1] 236:18  
**broncho** [1] 226:6  
**bronchoscope** [2] 256:5, 6  
**bronchoscopy** [2] 226:14, 77  
**Brown** [2] 56:3; 200:24  
**Bruggemann** [1] 249:18  
**Brun-Buisson** [1] 17:15  
**bugs** [5] 86:19; 92:18; 156:25; 157:8; 308:16  
**building** [1] 165:6  
**built** [1] 135:18

**bullets** [1] 271:19  
**bunch** [1] 130:1  
**burden** [7] 45:18, 19; 46:1; 154:20; 755: 7; 222: 72; 337: 7 7  
**buried** [1] 139:23  
**IBURTON** [6] 196:7; 246:24; 251:9; 260:13, 78; 328:9  
**IBurton** [8] 195:25; 196:6, 70; 246:23; 248:7, 72; 250:24; 328:9  
**IBUSH** [3] 202:8; 256:23; 307:15  
**Bush** [7] 196:1; 199:11; 200:1; 202:7; 228:5; 256:14; 309:4  
**busy** [1] 44:11

**- C -**

**C-A-P** [1] 270:12  
**cake** [1] 102:9  
**calculate** [1] 290:7  
**calculation** [1] 41:7  
**calculations** [1] 127:16  
**call** [10] 85:7; 95:5; 118:13; 119:2; 140:15; 146:5; 153:19; 164:6; 788: 70; 229:8  
**calling** [1] 185:12  
**Campbell** [3] 231:17, 79  
**Campus** [1] 5:21  
**Canada** [1] 184:25  
**Canadian** [1] 215:24  
**Cancer** [2] 47:7; 167:2  
**Candida** [11] 48:14; 56:8, 9, 12; 123:7, 77; 125:19; 132:12; 147:23; 149:5; 194:10  
**candida** [1] 28:3  
**CAP** [13] 270:11; 271:22; 272:20; 276:25; 278:9, 7 7; 284:19; 285:24; 287:16, 27; 288: 74; 293: 79; 326:23  
**capability** [1] 92:20  
**capsules** [1] 227:23  
**captured** [1] 148:15  
**cardiac** [1] 15:4  
**cardiogram** [1] 129:7  
**cardiographic** [1] 35:19  
**Care** [5] 6:10; 29:22; 87:11; 167:11; 188:11  
**care** [18] 23: 78; 72:5; 73: 7 6; 126:16; 128:24; 129:5, 72, 73; 136:8; 143:12; 188:10; 189:5, 72; 253:1; 258:17; 261:1, 8; 335:14  
**careful** [3] 91:22; 101:10; 144:25  
**carefully** [1] 27:4  
**Carl** [11] 6:17; 10:10, 72; 142:15; 165:1; 166:2; 167:17; 260:22; 316:3; 319:1; 331:3  
**Carolina** [4] 6:9; 167:10; 201:13; 255:15  
**carriage** [10] 189:1, 75, 76, 78, 79, 22; 190:10, 72  
**carried** [1] 249:6  
**carries** [2] 39:20; 262:21  
**carry** [3] 222:24; 302:23; 328:12  
**carrying** [1] 190:11  
**case** [37] 23: 77; 24:23; 41:4; 43:19; 44:3, 16; 46:14; 86:21; 125:1; 146:3; 161:3; 169:3;

|  |   |  |
|--|---|--|
| 131: 76; 304:9;<br>332:17<br><b>Casterton</b> [1] 49:6<br><b>catarrhalis</b> [1] 263:22<br><b>catch</b> [1] 63:21<br><b>categories</b> [lo] 36:5; 274:14;<br>275:1 7, 25; 276:5, 73; 280:4;<br>284:3; 288: 7; 327:2<br><b>categorization</b> [1] 251:2<br><b>categorize</b> [1] 115:13<br><b>categorized</b> [2] 250:24; 283:8<br><b>category</b> [9] 56:10; 245:15;<br>265:5; 268: 10; 274:4; 275: 7, 5,<br>77; 325:3<br><b>cath</b> [5] 58:8; 83:1; 115:3;<br>124:12, 7 3<br><b>Catheter</b> [1] 14:15<br><b>caused</b> [9] 50:12; 82:21;<br>133:16; 149:4; 152:24; 169:12;<br>370:2; 377:7; 326:23<br><b>cautiousness</b> [1] 740: 10<br><b>caveat</b> [7] 254:20; 272: 70;<br>302:9; 317:16; 318:1; 319:9;<br>326:16<br><b>caveats</b> [9] 231:23; 288:18;<br>298:13; 299:17; 318:21; 319:2;<br>322:75; 325:1 9; 330:6<br><b>cc</b> [1] 225:13<br><b>CD-4</b> [1] 232:4<br><b>CDC</b> [10] 167:23; 168:15, 78;<br>170:21; 174:6, 24; 182:10;<br>248:17; 261:24; 295:8<br><b>cefataxime</b> [1] 267:7<br><b>ceftaxime</b> [1] 177:17<br><b>cefotaxime</b> [8] 176:6, 75;<br>178:2; 183: 78, 22; 184:20;<br>191:4<br><b>ceftriaxone</b> [1] 188:20<br><b>ceftriaxone</b> [12] 234:23;<br>251:7, 77, 23, 25; 252:1;<br>259: 7; 263:25; 267:7; 294:21;<br>296:5, 2 0<br><b>cefuroxime</b> [1] 176:5<br><b>cefuroxine</b> [1] 188:18<br><b>Celia</b> [4] 6:5; 167:6; 192:12;<br>248:14<br><b>cell</b> [2] 16:19; 204:5<br><b>cells</b> [1] 142:20<br><b>Center</b> [6] 5:17; 6:19; 47:7;<br>164:4, 76; 201:19<br><b>center</b> [5] 87:13; 258:17;<br>284:13, 15; 335:14<br><b>Centers</b> [1] 168:13<br><b>centers</b> [1] 91:2<br><b>central</b> [16] 14:21, 23, 25;<br>65:5, 66:5; 71:8; 89:25; 92: 79,<br>25; 99:13; 109:10; 145:3;<br>152:11; 208:8; 314:3, 4<br><b>Century</b> [2] 179:13, 20<br><b>cephalosporin</b> [7] 223:24;<br>224:2; 266:4; 273:3, 5, 27;<br>275:24<br><b>cephalosporins</b> [9] 169:11,<br>74; 770:4; 224:3, 5; 241:3;<br>246:2, 8<br><b>Cephalothin</b> [1] 224:6 | cephalothin [2] 223:23; 224:1<br><b>cetera</b> [10] 54:7; 114:17, 24;<br>149:7, 24; 172:24; 263:4;<br>295: 17; 299:24; 322:1 7<br><b>CFU</b> [5] 17:14, 76, 78; 25:22;<br>219:4<br><b>CFUs</b> [3] 218:7; 228:21; 229:3<br><b>chair</b> [3] 10:16, 22; 255:14<br><b>Chairman</b> [3] 167:21; 196:7;<br>246:24<br><b>chairman</b> [1] 164:5<br><b>championed</b> [1] 61:6<br><b>chance</b> [13] 25:14; 43:16, 27,<br>23, 24; 44:25; 67: 7; 72: 79;<br>131:25; 161:12; 281:12;<br>305:19; 319:24<br><b>change</b> [29] 9:20; 19:17; 22:1;<br>23:5; 70:25; 153:14; 173:15;<br>193:17; 209:17; 210:20; 211:6;<br>213:25; 214:15; 290:24; 294:1;<br>296:23; 298:6; 307:13; 310:7;<br>317:23; 326:6; 330:4; 337: 76,<br>17, 22; 333:4, 78; 334:9, 10<br><b>changed</b> [5] 29:24; 120:20;<br>216:20; 305:16; 331:15<br><b>changes</b> [6] 19:24; 20:1, 4;<br>36:15; 71:24; 210:12<br><b>changing</b> [6] 193:5, 79;<br>300: 79; 305: 7 7; 306:7; 332: 78<br><b>character</b> [1] 212:20<br><b>characteristic</b> [1] 282:25<br><b>characteristics</b> [7] 65:21;<br>87:2; 272:5; 273:16, 25;<br>281:18; 282:12<br><b>characterization</b> [1] 18:4<br><b>characterized</b> [1] 19:4<br><b>charge</b> [1] 321:11<br><b>Charles</b> [3] 201:12; 208:5;<br>255: 75<br><b>Charleston</b> [1] 6:9<br><b>chemotherapy</b> [3] 138:20;<br>141:9; 143:6<br><b>Chen</b> [3] 184:23; 185:20;<br>215:23<br><b>CHESNEY</b> [9] 5:23; 34:16, 79,<br>25; 35:7; 37:25; 70:18; 71:2;<br>74:2<br><b>Chesney</b> [8] 5:23; 34: 75;<br>37:24; 70:17; 73:7; 74:1;<br>294: 7; 296: 7<br><b>Chicago</b> [2] 6:4; 167:5<br><b>CHIKAMI</b> [14] 7:3; 8:11;<br>10:10, 74, 27; 28:17; 68:3;<br>94:1, 4, 72; 122:15; 135:15;<br>138:1; 163:2<br><b>Chikami</b> [4] 7:3; 8:9; 12:24;<br>28:16<br><b>Child</b> [2] 6:6; 167:7<br><b>Children</b> [1] 248:22<br><b>children</b> [29] 35:9, 75; 71:3,<br>15, 20; 116:11; 180:3, 5;<br>185:5; 191:2; 232:5; 248:16,<br>18; 249: 1, 4; 250:8; 253: 11;<br>295:17, 79, 20; 318:2, 7;<br>334: 17, 25; 335: 7, 9, 7 6;<br>336:4, 7 2<br><b>chill</b> [1] 138:22<br><b>chills</b> [1] 51:20<br><b>chlamydia</b> [2] 245:21; 268:18<br><b>chloramphenicol</b> [2] 92:2, 6<br><b>chlorophenocol</b> [1] 188:19 | chlorythromycin [1] 251:24<br><b>choice</b> [5] 19:9; 266:4, 7;<br>320: 78; 323:2 7<br><b>choices</b> [1] 76:16<br><b>choose</b> [7] 15:17; 170:8;<br>177:22; 265:24; 337:23, 24<br><b>chooses</b> [1] 240:7<br><b>choreography</b> [1] 269:14<br><b>chose</b> [1] 241:14<br><b>chosen</b> [3] 241:23; 243:13, 27<br><b>Christie</b> [8] 6:5; 167:6;<br>37 7:24; 324:24; 332: 7 9;<br>334:22; 336:2, 10<br><b>CHRISTIE-SAMUELS</b> [13]<br>6:5; 77:2; 167:6; 192:13, 24;<br>248: 1 5; 250: 7 7; 37 7:25;<br>324:25; 332:20; 334:24; 336:3,<br>77<br><b>chromosomal</b> [2] 206:25;<br>301:12<br><b>Cincinnati</b> [1] 248:22<br><b>Cindy</b> [3] 167:23; 191:18;<br>192:3<br><b>cipro</b> [2] 209:5; 327:16<br><b>Ciprofloxacin</b> [2] 217:16;<br>228: 7<br><b>ciprofloxacin</b> [32] 166:7;<br>185:14; 204:25; 205:5, 72, 73,<br>77; 207:14; 208:13, 79, 27, 22,<br>25; 209:4; 210.5, 7; 211:21;<br>216:15, 78; 220:8; 226:15, 20,<br>25; 227:3, 6, 78; 228: 73;<br>257:6; 295:21; 301:12; 316:9<br><b>circumstances</b> [3] 266:8;<br>292: 75; 299:20<br><b>circumvent</b> [1] 262:20<br><b>cited</b> [1] 48:16<br><b>City</b> [2] 188:6, 25<br><b>claim</b> [3] 201:24; 271:2; 312:9<br><b>clarification</b> [3] 58:23; 7 18:2;<br>296:10<br><b>clarify</b> [6] 109:16; 138:1;<br>293:6; 306: 75; 309:6; 3 70: 72<br><b>clarithromycin</b> [2] 234:22;<br>323:20<br><b>Class</b> [1] 250:22<br><b>class</b> [2] 224:12; 295:10<br><b>classes</b> [2] 776:20; 2 |
|--|---|--|

|  |  |  |
|--|--|--|
| <p><b>Colleges</b> [2] 6:2; 167:3<br/> <b>colonies</b> [11] 56:20; 57:7, 8;<br/> 63:2, 3; 84:16, 21; 85:6; 87:1;<br/> 106:4; 107:17<br/> <b>Colonization</b> [1] 157:18<br/> <b>colonization</b> [7] 55:23, 24;<br/> 138:12; 140:15; 156:10;<br/> 157:22; 248:20<br/> <b>colonized</b> [8] 49:7; 139:1;<br/> 145:16; 152:23, 24; 153:1, 4;<br/> 155:4<br/> <b>colonizers</b> [2] 18:2, 5<br/> <b>colony</b> [8] 27:6; 29:12; 31:11;<br/> 84:23; 114:3; 118:23; 153:8<br/> <b>column</b> [1r] 178:1; 273:22;<br/> 278:6, 16, 17, 18, 23; 282:20,<br/> 22; 283:16; 286:18<br/> <b>columns</b> [3] 177:13; 180:25;<br/> 278:21<br/> <b>coma</b> [3] 242:10, 11, 14<br/> <b>combination</b> [1] 267:7<br/> <b>combine</b> [1] 154:5<br/> <b>combined</b> [3] 46:6; 282:13,<br/> 75<br/> <b>combining</b> [1] 45:18<br/> <b>comers</b> [2] 274:21, 24<br/> <b>comfortable</b> [8] 64:12; 101:6;<br/> 107:3, 12; 110:13; 306:12, 23;<br/> 307:12<br/> <b>coming</b> [18] 53:19; 64:24;<br/> 82: 13, 23; 83:3, 12, 25;<br/> 102:12; 110:19; 147:15;<br/> 222: 15; 242: 11; 292:17; 305:7;<br/> 314:5; 325:11; 331:8, 12<br/> <b>comment</b> [30] 8:7; 9:16;<br/> 35: 17; 58:6; 66:24; 67:4;<br/> 68:10; 69:15; 75:7; 76:1;<br/> 88:25; 124:17; 126:19; 166:18;<br/> 171:9; 252:17; 255:14; 260:14;<br/> 16; 269:6; 284:10; 319:19;<br/> 320:6; 329:20; 330:9; 332:3,<br/> 22; 333:13; 335:24; 336:22<br/> <b>comments</b> [38] 9:13, 19;<br/> 67: 19; 68: 11; 70: 16; 74: 14;<br/> 76: 18; 77:24; 82: 15; 93: 14;<br/> 94:8; 119:18; 125:17; 129:20;<br/> 137:20; 163:6, 7, 9; 168:9;<br/> 171:15; 172:22; 265:17;<br/> 266:20, 21; 269:9; 270:16;<br/> 293:2; 294:10, 11, 12; 296:6;<br/> 300:1; 313:25; 323:12;<br/> 326:8; 333:16; 334:15; 338:1<br/> <b>commercially</b> [2] 88:13, 21<br/> <b>commitment</b> [2] 300:9, 12<br/> <b>commitments</b> [1] 294:8<br/> <b>committed</b> [1] 308:23<br/> <b>Committee</b> [1] 5:5<br/> <b>common</b> [9] 18:1; 158:18;<br/> 180:3; 198:25; 213:23; 239:4;<br/> 24 1:13; 246:1; 295:25<br/> <b>commonly</b> [1] 335:10<br/> <b>Commonwealth</b> [1] 5:21<br/> <b>Community</b> [1] 198:25<br/> <b>community-acquired</b> [7]<br/> 170:8, 20; 196:21; 293:14;<br/> 296:11; 310:2; 317:1<br/> <b>community-acquires</b> [1]<br/> 180:16<br/> <b>companies</b> [7] 76:15; 124:25;<br/> 126: 12; 128:11; 170:25;<br/> 325:13; 331:25 </p> | <p><b>Company</b> [2] 171:25; 173:2<br/> <b>company</b> [29] 59:19; 122:7;<br/> 134:10; 153:14; 172:8, 12;<br/> 223: 18, 298: 1, 20; 299:2;<br/> 302:21; 304:4, 16; 306:6;<br/> 311:7; 315:20; 319:22; 320:20;<br/> 322:2; 325:11; 326:4, 79, 27;<br/> 331:15, 18, 23, 24; 332:6;<br/> 334:16<br/> <b>comparable</b> [3] 105:7; 239:8;<br/> 296:5<br/> <b>comparative</b> [20] 67:7;<br/> 133:12; 231:2, 5, 14; 241:5;<br/> 242:2, 8; 251:5; 272:t 1; 273:2;<br/> 274:6, 12; 275:18; 276:t 1;<br/> 277:6, 11; 310:6; 325:23;<br/> 326: 1<br/> <b>comparator</b> [44] 18:23; 19:9;<br/> 23: 13, 16, 20; 43:6, 44:20;<br/> 73:4:t; 154:20, 25; 155:12, 13;<br/> 234:8; 241:11, 17, 78; 242:8;<br/> 251:15; 272:8, 13, 15; 273:21;<br/> 275:23; 277:18; 279:3; 281:19;<br/> 282:6, 7, 9; 284:2, 4; 285:18,<br/> 19, 21, 23; 286:1, 3; 287:3,<br/> 8, 10; 315:12<br/> <b>comparators</b> [9] 19:9;<br/> 205:13; 240:24, 25; 244:4;<br/> 277:15, 16; 278:t 7; 287:25<br/> <b>compare</b> [6] 43:1, 3; 180:25;<br/> 183: 7; 189:20; 234: 1<br/> <b>compared</b> [18] 83:10; 135:13;<br/> 181:24; 182:7; 183:15, 20;<br/> 204:2, 18; 205:4, 7; 208: 73;<br/> 210:8; 214:9; 218:8; 220:8;<br/> 228:23; 256:19; 273:3<br/> <b>comparing</b> [3] 45:20; 46:1;<br/> 199:24<br/> <b>comparison</b> [3] 208:12;<br/> 213:24; 241:6<br/> <b>comparisons</b> [1] 272:16<br/> <b>compartment</b> [1] 208:8<br/> <b>compartmentalize</b> [1] 223:25<br/> <b>compelled</b> [1] 63:25<br/> <b>compelling</b> [6] 65:9; 89:6;<br/> 105:13; 123:18; 130:15; 331:5<br/> <b>competing</b> [1] 165:11<br/> <b>Complete</b> [1] 21:16<br/> <b>complete</b> [4] 111:2; 175:15;<br/> 186:25; 323:9<br/> <b>completely</b> [14] 87:21; 124:7;<br/> 127:18, 19; 138:13; 144:4;<br/> 222:8; 262: 18; 300:22; 303:22,<br/> 25; 304:24; 319:14; 332:5<br/> <b>completion</b> [5] 148:24;<br/> 149: 15; 279: 18, 20; 280:2<br/> <b>complex</b> [5] 127:9; 128:21;<br/> 129:5; 142:21; 262:17<br/> <b>complexities</b> [1] 129:9<br/> <b>complexity</b> [2] 126:20; 135:23<br/> <b>complicated</b> [1] 160:12<br/> <b>complications</b> [1] 87:16<br/> <b>component</b> [2] 97:12; 312:6<br/> <b>components</b> [4] 31:5, 19, 21;<br/> 97:13<br/> <b>composite</b> [3] 21:14; 22:12;<br/> 45:18<br/> <b>compound</b> [1] 44:18<br/> <b>comprehensive</b> [1] 248:9<br/> <b>conceive</b> [1] 36:19<br/> <b>concentrate</b> [2] 53:15; 243:18 </p> | <p><b>concentrated</b> [1] 336:13<br/> <b>concentrating</b> [1] 202:9<br/> <b>concentration</b> [1] 249:18<br/> <b>concept</b> [2] 42:9, 72<br/> <b>concern</b> [8] 30:21; 33: 10;<br/> 56:25; 64:3; 139:13; 249:7;<br/> 308:22; 328:20<br/> <b>concerned</b> [15] 30:17; 86:6,<br/> 12; 94:21; 95:10; 116:10;<br/> 141:3; 145:25; 184:13; 248:15;<br/> 267:2; 296:1; 305:6; 307:7;<br/> 325: 7 1<br/> <b>concerning</b> [7] 164:23;<br/> 165:20; 166:3; 187:2, 22;<br/> 188:1, 2 3<br/> <b>concerns</b> [11] 12:6; 38:17;<br/> 95:6; 268:23; 291:19; 294:15;<br/> 307:6; 311:2 1; 323:5; 326: 18,<br/> 21<br/> <b>conclude</b> [2] 230:12; 244:9<br/> <b>concludes</b> [1] 288:3<br/> <b>conclusion</b> [5] 45:6; 150:12,<br/> 24; 219:25; 220:3<br/> <b>conclusions</b> [1] 128:7<br/> <b>conclusively</b> [1] 300:25<br/> <b>concordance</b> [4] 17:23;<br/> 61:20; 68:25; 81:17<br/> <b>Concordant</b> [3] 17:12, 17, 20<br/> <b>concordant</b> [3] 17:4; 89:5;<br/> 97:1<br/> <b>concurrent</b> [3] 12: 17; 55:25;<br/> 57:10<br/> <b>condition</b> [2] 72:21; 328:5<br/> <b>conditions</b> [6] 15:12; 62:1, 2;<br/> 192:1; 207:25; 209:7<br/> <b>conducted</b> [1o] 175:14;<br/> 213:17; 216:22; 226:10;<br/> 230:23, 25; 231:5, 6, 8, 13<br/> <b>confidence</b> [5] 97:18; 266:12;<br/> 290:2, 4, 7<br/> <b>confident</b> [2] 110:22; 239:7<br/> <b>confirmed</b> [1] 195:10<br/> <b>conflict</b> [6] 7:7, 9; 164:7, 9,<br/> 79; 165:16<br/> <b>confusion</b> [11] 169:6, 16, 25;<br/> 171:7, 13; 262:1, 20; 264:7;<br/> 265:9; 325:2; 328:6<br/> <b>congestive</b> [1] 160:13<br/> <b>congratulate</b> [2] 39:16; 46:25<br/> &lt;b</p> |
|--|--|--|

Basic Systems Applications  
**derived** [10] 41:14; 201:11;  
 222: 10; 226: 18; 233:5; 277:3;  
 279:5; 279:7; 281:1; 284:1 7

**10/20/99: Anti-Infective Drugs Advisory Committee:**

112:4, 5, 76; 279:15; 289:23;  
 24 differential [1] 50:14; 53:13;  
 104 AF. 4A6:24; 112:8 10:

244:16; 24:248:19; 249:6, 73;  
 254:1; 255:1, 6; 261:16; 265:6;  
 274:1, 2; 281:7, 12; 283:4, 8,  
 10; 284:6, 7; 315:11; 334:18;

**draw** [10] 89:12; 100:15, 19;  
 116:14; 118:20; 121:6, 7;  
 139:2; 143:8; 144:12  
**drawing** [9] 52:15; 81:9; 96:5;  
 104:18; 106:22; 116:3, 20;

**67th Meeting**

Basic Systems Applications

**10/20/99: Anti-Infective Drugs Advisory Committee: 67th Meeting**

Concordance by Look-See(91)

**convinced** [4] 85: 13, 21;  
 247:11; 304:19  
**Cooper** [2] 6:18; 167:18  
**cooperate** [1] 227:23  
**cooperation** [1] 199:5  
**coordinate** [1] 168:15  
**copy** [1] 165:3  
**core** [1] 174:25  
**corner** [1] 256:5  
**Corporation** [1] 165:10  
**CORRADO** [7] 220: 19;  
 249:22; 250:13; 251:10;  
 252:10, 17; 255:13  
**Corrado** [4] 196:1; 200:1;  
 220:16; 251:9  
**correctly** [4] 131:16; 304:10;  
 328:15, 24  
**correctness** [1] 197:2  
**correlate** [4] 57:21; 109:6;  
 185: 18; 334:6  
**correlation** [2] 90:21; 91:8  
**corresponding** [3] 43:7;  
 44:12; 251:2  
**cost** [1] 222:12  
**costs** [1] 44:12  
**cotrimoxazole** [4] 175:23;  
 176:15; 177:19; 178:5  
**cough** [1] 245:8  
**count** [7] 16:19; 27:6; 36:6, 9,  
 12; 118:23  
**counted** [1] 79:15  
**countries** [2] 41:13; 216:24  
**country** [8] 12:24; 29:14;  
 58: 11; 193:20; 221:25; 235:3;  
 246: 11; 249:8  
**counts** [3] 84:23; 153:8; 232:4  
**couple** [15] 29:8; 56:5; 60:8;  
 68:9; 74:2; 103:12; 105:10;  
 174:12, 15; 256:2; 261:17;  
 282:19; 284:3; 289:15; 319:2  
**course** [22] 41:24; 44:6; 45:2;  
 54:3; 101:22; 122:17, 22;  
 135:18; 136:2; 138:20; 143:1,  
 5; 148:21; 149:10; 151:5;  
 189:9; 195:12; 199:13; 292:7;  
 297:23; 315:25; 332:24  
**courses** [5] 198:14, 15;  
 295:19; 312:2  
**cover** [1] 255:11  
**coverage** [1] 170:9  
**covered** [3] 116:2; 270:16;  
 334:2  
**covers** [1] 331:3  
*C o X* [7] 167:24; 270:2;  
 289: 17; 290:5, 7, 16, 20  
*C o X* [4] 167:24; 269:25; 270:1,  
 2  
**CPA** [1] 272:20  
**CPNP** [1] 46:5  
**Craig** [12] 6:13; 10:15, 22;  
 94:1; 103:3; 131:13; 164:21;  
 218:10, 21; 229:7; 268:5;  
 269:2  
**create** [2] 71:2; 165:16  
**creatinine** [1] 225:12  
**credible** [1 1 223:1

**Critical** [4] 6:10; 29:22; 87:11;  
 167:11  
**critical** [4] 29:1; 38:25; 72:5;  
 112:1  
**critically** [1] 80:14  
**criticized** [1] 226:3  
**cross** [2] 224:3, 5  
**cross-linkage** [1] 235:3  
**cross-resistance** [10] 177:6,  
 9; 186:10; 187:23; 195:17;  
 263:2; 286:7; 292:5; 308:4;  
 309:3  
**cross-resistances** [1] 308:21  
**crucial** [1] 79:24  
**cuff** [1] 78:16  
**culprit** [1] 66: 18  
**cultured** [5] 36:21, 22; 57:5;  
 112:3; 124: 12  
**culturing** [1] 60: 12  
**cumulative** [1] 234:4  
**cure** [31] 21:4, 14, 19; 31:24;  
 41:17; 51:5, 12; 53:18; 129:17,  
 24; 130:14, 25; 132:18; 133:2;  
 138:24; 141:16, 17; 159:10;  
 237: 12; 274:18; 275:8; 279:16;  
 280:9, 12; 281:9; 285:4;  
 289:21, 22; 290:3  
**curiosity** [2] 54:11; 289:12  
**Current** [1] 40:3  
**current** [7] 8:6; 157:10;  
 166: 17; 202: 1; 205:22; 270:25;  
 271:4  
**Currently** [2] 12:21; 235:5  
**currently** [13] 43:2; 46:4;  
 111:8; 143:3; 175:2; 299:3, 7;  
 309: 15, 24; 317: 17, 23; 322:9;  
 326:7  
**curve** [2] 225:9, 17  
**cut** [3] 102:24; 259:2; 295: 1  
**cutoff** [1] 17:14, 16, 18;  
 25:22; 26:23; 48:5; 49: 12;  
 56:18; 57:13, 18; 107:5  
**cutoffs** [4] 56:15, 16; 181:16;  
 184:16  
**cutting** [1] 125:11  
**CVC** [8] 48:8; 50:19; 55:22;  
 109:2; 140:6, 12; 141:1; 146:7  
**cycle** [1] 141:8  
**Cynthia** [2] 174:5, 7

**- D -**

**Daichi** [1] 197:8  
**daily** [2] 129:5; 132:21  
**damage** [1] 330:5  
**danced** [1] 329:14  
**dangerous** [5] 25:20; 101:17,  
 21; 112:25; 113:1  
**Daniel** [1] 183:1  
**DANNER** [37] 6:10; 71:12;  
 73:3; 78:5, 24; 80:10; 81:8;  
 87:11; 138:9; 139:8, 16; 141:4,  
 17; 142:15; 144:8, 19; 145:5,  
 11; 146:10; 147:1; 152:9;  
 153:22; 154:14; 167:11;  
 300:16; 301:14, 22; 302:15;

167:11; 318:13; 324:10;  
 330:25; 336:7  
**dare** [1] 329:5  
**Data** [1] 204:14  
**database** [8] 236:16; 241:7, 9;  
 252:21, 22, 23; 253:21; 303:3  
**date** [4] 199:22; 226:5; 267: 1;  
 290:24  
**Dave** [1] 167:20  
**David** [16] 6:8; 7:1; 10:25;  
 11:4; 24:14; 27:8; 28:20;  
 29: 10; 37:5; 39:8; 68:2, 3;  
 69:9; 128:9; 167:9; 168:13  
**Dawn** [1] 213:14  
**day** [23] 33:21; 64:25; 109:23;  
 113:20; 163:19; 182:13, 20,  
 23; 183:2; 189:9; 226:15, 16;  
 235:15; 239:20; 244:15;  
 258:17; 263:16; 265:7; 280:16;  
 299: 12; 300: 11; 335: 14  
**days** [40] 21:5; 33:21; 51:11,  
 12; 54:10, 11; 55:15; 58:13;  
 84:22; 1 13:19; 122:11; 125:7,  
 12; 128:25; 132:18; 134:24;  
 135:2, 7; 136:7; 148:16, 21,  
 22; 149:14; 159:18, 19; 160:2;  
 161:24; 198:16; 200:3; 226:17;  
 235:19; 261:17; 280:10, 13,  
 14;  
 281:3, 9  
**Deaconess** [1] 201:19  
**deal** [3] 8:20; 115:16; 221:7  
**dealing** [6] 54:3; 55:8; 88:18;  
 110:15; 128:11; 290:8  
**dealt** [1] 94:4  
**Death** [1] 22:4  
**death** [5] 123:8, 9, 12; 183:10;  
 227:23  
**deaths** [4] 182:12; 183:1, 23;  
 188:11  
**debate** [1] 84:25  
**debilitated** [2] 222:17; 225:11  
**decade** [2] 185:23; 257:2  
**decades** [1] 264:9  
**December** [2] 197:5; 270:20  
**descent** [1] 25:10  
**decide** [5] 66:14; 128:5;  
 143:17; 292:20; 299:13  
**decided** [3] 21:3; 159:6;  
 304:2  
**deciding** [1] 300:18  
**decision** [4] 44:6; 93:3;  
 268:24; 292: 17  
**decolonization** [1] 144:2  
**decolonize** [10] 140:3;  
 142:10; 145:23; 146:5; 151:22;  
 152:5; 153:5; 157:11, 23;  
 158:4  
**decolonized** [3] 139:20;  
 144:4; 146: 17  
**decolonizing** [2] 139:19;  
 152:1  
**decompression** [1] 34:24  
**decontaminate** [1] 141:14  
**decottication** [1] 318:7  
**decrease** [1] 145:3; 180:21

**decreasing** [1] 222:11  
**deem** [1] 298:8  
**deep** [2] 139:23; 314:10  
**default** [1] 246:1  
**deffervesce** [1] 137:7  
**define** [12] 12:1; 14:15; 40:18;  
 49:22; 61: 19; 86:5; 92:4;  
 94:17; 104:4; 142:1; 255:5;  
 299:23  
**defined** [24] 12:16; 14:16;  
 16:6; 21:14; 39:1; 47:21; 55:5,  
 10; 86:7; 98:tt; 175:9;  
 183:21; 184:3, 15; 211:19;  
 249:16; 250:14; 280:4; 281:8;  
 284:24; 285:2, 25; 286:2  
**defining** [6] 16:12; 34:19;  
 69:6; 80:13; 93:25; 205:22  
**definite** [12] 48:11, 27; 50:1,  
 3, 5; 117:22, 23; 118:5; 12;  
 126:25; 262:10; 265:16  
**definitely** [3] 93:6; 125:24;  
 212:16  
**definition** [12] 12:7; 13:20,  
 21; 14:7; 57:23; 66:7; 68:17;  
 96:10; 107:4; 136:20; 185:12,  
 13  
**definitions** [4] 21:13; 47:15;  
 95:2; 96:2  
**definitive** [2] 53:16; 245:10  
**defotaxime** [1] 184:14  
**degree** [5] 127:20; 226:8;  
 241:1; 244:5; 291:15  
**delete** [1] 73:10  
**deletes** [1] 73:11  
**deliberations** [2] 328:12;  
 336:23  
**delighted** [2] 168:18; 170:24  
**delineate** [3] 60:14; 64:18;  
 98:25  
**delineated** [3] 39:1; 148:22;  
 266:25  
**delineation** [1] 147:18  
**delta** [28] 23:24; 40:6, 11, 13,  
 15, 76, 17; 41:5; 42:24, 25;  
 13:1, 4, 8, 13, 16, 21, 23; 44:4,  
 5, 14; 45:3, 7, 8, 13, 15, 16;  
 16:8, 11  
**demand** [1] 31:25  
**demands** [1] 258:8  
**demographic** [2] 175:20;  
 180:2  
**demographics** [1] 233:12  
**demonstrable** [2] 23:14, 20  
**demonstrate** [5] 68:24; 81:16;  
 288:12; 307:16; 316:25  
**demonstrated** [3] 172:15;  
 247:22; 310:21  
**demonstration** [1] 24:23  
**Dennis** [2] 29:19; 56:15  
**denominators** [1] 289:25  
**deny** [1] 333:17  
**Department** [9] 5:24; 6:6, 11;  
 39:15; 87:12; 167:7, 12;  
 188:25; 189:4  
**depend** [2] 93:3; 168:21  
**depending** [7] 12:11; 15:15,

|   |   |  |
|---|---|--|
| edition [1] 310:9<br>educate [1] 337:19<br>educating [2] 261:21; 329:2<br>Education [1] 167:21<br>education [2] 265:19; 268:25<br>educational [2] 264:9; 298:17<br>Edward [3] 167:24; 269:25;<br>270:2<br>effect [1 o] 16:8; 23:21, 22;<br>26:7; 29:1; 116:20; 135:8;<br>203:20; 219:6, 7<br>effective [29] 18:17; 28:24;<br>37:14; 45:9; 83:14; 156:23;<br>157:8; 170:19; 177:23; 178:6;<br>182:24; 191:5; 220:2; 244:15;<br>247:16; 288: 13:29:18;<br>296:16, 20; 306:19; 312:20;<br>316:25; 318:5; 319:11; 322:17;<br>326:17, 22; 331:19; 332:8<br>effectively [1] 306:10<br>effectiveness [6] 15:13, 76;<br>123:3; 156:22; 172:15; 306:21<br>efficacious [3] 83:8; 203:9;<br>218:11<br>efflux [8] 207:3; 211:14, 78,<br>19, 20, 22; 212:1, 2<br>effort [3] 173:8; 232:20; 253:8<br>efforts [1] 264:9<br>effusions [1] 250: 1<br>eight [16] 37:19; 162:10;<br>175:3; 189:18, 25; 207:23, 25;<br>209:6; 214:18; 251:22; 268:6;<br>277:5; 282:4; 284: 72; 285: 73;<br>338: 7<br>Eighteen [2] 242:21; 252:10<br>eightfold [1] 27 1:24<br>EKG [1] 242:20<br>EKGs [2] 242:23<br>elaboration [1] 224:9<br>elderly [6] 70:1, 73; 132:8;<br>142:23; 180:7; 245:8<br>electromicroscopy [1] 49:5<br>electron [2] 66:3; 99: 7 7<br>electrophoresis [13] 7 7:25;<br>69:3; 81:18; 83:24; 90:21, 25;<br>91:9, 12; 93:8, 19; 98:7, 17;<br>115:10<br>elevated [3] 33:12; 183:23;<br>211:22<br>ELF [1] 230:15<br>Eli [1] 165:10<br>elicit [1] 314:12<br>eliciting [1] 316:2<br>eligible [1] 280:20<br>eliminate [1] 156:10<br>eliminated [1] 95:8<br>ELIOPOULIS [2] 262:16;<br>265:15<br>Eliopoulos [2] 201:17; 262:6<br>embarked [1] 199:6<br>embodied [1] 293:7<br>emerge [1] 256:18<br>emergence [4] 40:24; 174:22;<br>326:18; 328:19<br>emergency [1] 256:4<br>emission [4] 271:18; 275:14,<br>21; 276:10<br>emphasis [8] 15:23; 22:8;<br>66:4; 74:18; 80:24; 98:18;<br>115:12; 150:3<br>emphasize [7] 25:7; 32:22; | 719:21; 170:21; 214:4; 245:4;<br>295:9<br>empiric [4] 15:20; 170:7, 79;<br>264:19<br>empirical [3] 266:24; 268:24;<br>330:23<br>empirically [ 1] 264:2<br>employee [1] 7:21<br>empyema [1] 250:5<br>empyemas [4] 248:25;<br>249:15; 318:3, 9<br>en [1] 252:21<br>enable [1] 112:17<br>enabled [1] 196:3<br>encode [1] 206:13<br>encompass [1] 268:22<br>encompassed [1] 296:18<br>encompasses [1] 296:14<br>encountered [1] 233:25<br>encourage [1] 124:25<br>encouraged [ 1] 126:12<br>encourages [ 1] 326:3<br>encouraging [1] 9:5<br>End [1] 21:1<br>end [22] 24:6; 35:22; 94:25;<br>109:22; 118:5; 119:2; 125:5;<br>137:16; 148:19; 151:17;<br>153:19; 159:5, 77; 160:25;<br>197:22; 226:10; 245:9; 292:23;<br>299:12; 300:11; 305:7; 321:5<br>endocarditis [7] 18:11; 32:8,<br>75, 21; 35:20; 51:7; 118:18<br>endothelial [1] 227:5<br>endovascular [6] 16:5; 18:10;<br>32:7; 136:3, 9, 20<br>endpoint [19] 21:14; 22:11;<br>123:10; 142:4, 13; 143:16;<br>152:2; 153:25; 154:1, 70;<br>156:5, 6, 70; 157:6, 7; 158:3,<br>6, 7<br>endpoints [1] 22:14<br>endstage [1] 242:12<br>engender [1] 224:13<br>England [2] 215:23; 216:10<br>enhance [2] 76:25; 246:8<br>enrich [1] 201:6<br>enroll [4] 15:21; 41:11;<br>253:17; 291:20<br>enrollable [1] 109:21<br>enrolled [12] 16:13, 27; 41:7;<br>43:9; 44:13; 109:25; 232:13;<br>233: 7 7; 253:8; 273:6, 12<br>enrolling [1] 109:20<br>enrollment [6] 19:21; 41:9;<br>44:14; 81:2; 115:9; 283:20<br>ENT [1] 295:16<br>enter [1] 133:2<br>enteric [1] 141:5<br>enterobacter [2] 101:23;<br>144:24<br>enterobacteriaceae [ 1] 145:5<br>enterococci [1] 246:12<br>entities [2] 90:6; 153:12<br>entitled [1] 216:16<br>entity [9] 11:12; 14:15; 18:9;<br>22:25; 23:11; 28:13; 73:16;<br>117:8, 1 2<br>entry [23] 16:24; 17:20; 18:15,<br>78; 20:9, 27; 21:16, 23; 22:24,<br>25; 25: 12; 33: 74; 34:7; 72:9;<br>75:21; 95:13; 124:4; 125:22; | 149:18; 151:11; 159:7; 242:12;<br>283: 14<br>environment [1] 157:12<br>envision [1] 312:19<br>enzymes [1] 204:5<br>epi [31] 54:2, 8, 16; 55:20;<br>57:1, 72, 18, 24; 59:24;<br>85:12, 75, 23; 87:20; 88:19;<br>90:6, 8, 10, 15; 109:9; 117:15;<br>118:15; 119:8; 124:23; 125:6,<br>77; 131:23, 24; 144:17, 19;<br>162:4<br>epidemiologically [ ] 246:20<br>epidemiologist [1] 246:5<br>Epidemiology [1] 55:17<br>epidemiology [3] 174:9, 77;<br>178:8<br>epidermidis [13] 48:14;<br>50:12; 51:9, 16, 24; 52:22;<br>55:13; 56:12; 66:17; 70:22;<br>91:13; 140:8; 141:1<br>epis [1] 124:18<br>episode [1] 142:7<br>episodes [1] 243:3<br>equal [11] 97:11; 125:12;<br>134:11; 183:14; 190:15; 205:9,<br>79; 206:1, 3, 5<br>equally [5] 199:20; 203:7;<br>220:10; 247:11; 319:10<br>equivalence [4] 15:17; 23:18;<br>38:21; 43:17<br>equivalent [3] 44:19; 155:14;<br>325:24<br>evidenced [1] 335:3<br>evolved [1] 58:20<br>ex [1] 27:14<br>exacerbated [1] 169:16<br>exact [4] 161:14; 172:22;<br>227: 11; 323:4<br>exactly [8] 29:25; 33:5;<br>728: 7 7; 7 72:3; 252: 72; 258:9;<br>315:20; 324:22<br>exam [1] 56:23<br>examination [2] 198:5; 219:2<br>examined [7] 89:25; 207:13;<br>209:25; 218:14; 303:1, 3;<br>307:22<br>example [22] 12:17; 18:15;<br>34:23; 36:6; 43:1; 51:23; 54:2;<br>61:2; 63:24; 70:2; 77:9; 89:8;<br>91:4; 102:23; 113:17; 136:4,<br>18; 177:15; 179:12; 251:7;<br>312:19; 327:14<br>Examples [1] 42:14<br>exceed [1] 230:20<br>exceeding [1] 230:17<br>exceedingly [9] 101:10;<br>111:9; 112:8; 113:13; 161:13;<br>229: 7 7; 267:6; 268:20, 27<br>excellent [2] 92:18; 228:17<br>except [2] 18:21; 31:19<br>exception [ 1] 216:24<br>exceptions [2] 90:3; 164:20<br>excerpted [1] 270:23<br>excessive [1] 7 19:6<br>exclude [18] 8:1; 16:9; 32:20;<br>25; 36:8; 53:4; 59:22; 60:3;<br>75:17; 81:4; 101:10; 115:1;<br>117:5; 118:9; 127:25; 166:13;<br>232: 11:245:22<br>excluded [12] 41:16; 58:25;<br>59:5; 74:24; 164:22; 192:8; |
|---|---|--|

|   |  |  |
|---|--|--|
| <p>231:25; 232:4, 5, 6, 25; 248:16<br/> <b>excluding</b> [4] 18:8; 255:20;<br/>     256: 10; 329:12<br/> <b>exclusion</b>[11] 8:2; 14:11;<br/>     23:3; 27:13; 35:18; 53:3;<br/>     100:3; 114:17; 166:14; 254:9;<br/>     329:16<br/> <b>exclusions</b> [1] 258:1<br/> <b>Excuse</b> [1] 59:15<br/> <b>excuse</b> [1] 112:9<br/> <b>exemplified</b> [1] 217:13<br/> <b>exercise</b> [1] 105:9<br/> <b>exist</b> [6] 72:7; 116:23; 271:15;<br/>     255:9; 297: 14; 311:22<br/> <b>existing</b> [1] 98:4<br/> <b>exists</b> [3] 306:12; 313:12;<br/>     315:2<br/> <b>exit</b> [1] 100:14<br/> <b>expand</b> [3] 79:6; 201:24;<br/>     308:24<br/> <b>expanded</b> [1] 241:7<br/> <b>expands</b> [1] 35:10<br/> <b>expect</b> [7] 146:2; 155:24;<br/>     157:5; 158:2; 163:7; 206:9;<br/>     323: 7<br/> <b>expected</b> [1] 315:3<br/> <b>expecting</b> [1] 7 18:18<br/> <b>experience</b>[15] 35: 10, 7 7;<br/>     41:6, 10; 87:17; 104:7; 120:5;<br/>     138:8; 145:9; 201:20; 236:13;<br/>     247:23; 252:9, 257: 7; 306:20<br/> <b>experiments</b> [3] 205:12;<br/>     207:22; 209:20<br/> <b>expertise</b> [1] 9:23<br/> <b>--experts</b> [5] 169:9; 170:15;<br/>     200:21, 22; 201:5<br/> <b>explain</b> [2] 253:7, 23<br/> <b>explicit</b> [1] 329:14<br/> <b>exploratory</b> [1] 20:5<br/> <b>expressed</b> [1] 12:5<br/> <b>expression</b> [1] 329: 76<br/> <b>extend</b> [3] 75:14; 171:23;<br/>     173:7<br/> <b>extended</b> [1] 246:9<br/> <b>extension</b> [1] 13:25<br/> <b>Extensive</b> [1] 246:7<br/> <b>extensive</b> [1] 98:10<br/> <b>extensively</b>[1] 256:25<br/> <b>extent</b> [1] 316:10<br/> <b>external</b> [3] 49:7; 62:11, 15<br/> <b>extra</b> [3] 74:18; 102:1; 198:19<br/> <b>extract</b> [1] 49:4<br/> <b>extraluminal</b> [1] 61:15<br/> <b>extrapolate</b> [1] 306: 1 7<br/> <b>extreme</b> [1] 260:6<br/> <b>extremely</b> [13] 27:23; 47: 12;<br/>     23; 51:18, 25; 109:17; 123:5;<br/>     15; 127:9, 73; 140:2; 195:6<br/> <b>exudate</b> [8] 16:24; 17:21;<br/>     20:20; 36:17; 58:1, 2; 125:22;<br/>     126:8<br/> <b>eyebrows</b> [1] 221:1<br/> <b>eyes</b> [1] 220:25       </p> <hr/> <p style="text-align: center;"><b>- F -</b></p> <p><b>face</b> [3] 79:12; 223:19; 257:18<br/> <b>faced</b> [2] 245:6; 314:8<br/> <b>facilities</b> [1] 189:12<br/> <b>Facility</b> [1] 188:11<br/> <b>facility</b> [2] 188:10; 189:5</p> | <p><b>facing</b> [1] 245:4<br/> <b>factor</b> [4] 27:14; 123:8; 195:6;<br/>     324:2<br/> <b>factors</b> [8] 24:3; 147:18;<br/>     179:25; 180:2; 194:7; 195:2;<br/>     231:18; 232:24<br/> <b>faded</b> [1] 191:20<br/> <b>fail</b> [5] 154:10; 155:8; 156:14,<br/>     15; 267:25<br/> <b>failed</b> [4] 21:21; 194:20, 22;<br/>     195:18<br/> <b>failing</b> [1] 232:2<br/> <b>failure</b> [34] 19:23; 20:25; 23:6;<br/>     37:8, 20; 38:6; 45:19, 22; 53:1,<br/>     2; 58:25; 74:25; 75: 1/132:9;<br/>     135:5; 139:7, 27; 140:15;<br/>     141:11; 146:6, 8; 147:3;<br/>     153:20; 154:12; 155:2; 160:4,<br/>     13, 25; 161:18; 184:19;<br/>     238:20; 259:7; 280:20<br/> <b>failures</b> [16] 184:1, 6, 9, 73,<br/>     78; 191:8; 223:6; 238: 14, 76,<br/>     21; 280:18, 19; 294:20; 295:1;<br/>     309:16, 23<br/> <b>fair</b> [6] 70:15; 74:4; 133:20;<br/>     296:4; 322: 73; 323:7<br/> <b>fairly</b>[10] 33:13; 67:8; 76:7;<br/>     79:3; 7 15:7; 132:22; 177:2;<br/>     182:3; 300:23; 326:13<br/> <b>fairness</b> [2] 8:5; 166:16<br/> <b>fall</b> [6] 78:1, 4; 79:17; 268:10;<br/>     317:21; 337:6<br/> <b>falls</b> [1] 127:24<br/> <b>false</b> [1] 116:17<br/> <b>familiar</b> [2] 192:22; 267:13<br/> <b>family</b> [3] 261:12; 295:16;<br/>     325:3<br/> <b>Farr</b> [4] 61:7, 24; 104:8; 105:2<br/> <b>fashion</b> [2] 305:20; 332:6<br/> <b>fast</b> [2] 40:25; 79:13<br/> <b>faster</b> [1] 112:19<br/> <b>favor</b> [5] 138:10; 140:20;<br/>     330:11, 13; 334:3<br/> <b>favorable</b> [1] 263:8<br/> <b>FDA</b> [37] 6:12, 24; 7:1, 5, 25;<br/>     8:9; 10:25; 39: 76; 42:9; 44:24;<br/>     56:4; 122:6; 128:4; 165:23;<br/>     166:11; 167:13, 25; 168:2;<br/>     171:20; 196:18; 197:5; 198:8;<br/>     199:5; 269:11, 13, 15, 24;<br/>     270:5; 272:2; 279: 10; 290: 72;<br/>     322:1, 5; 328:13, 22; 329:21;<br/>     336:19<br/> <b>feasibility</b> [1] 42:4<br/> <b>feasible</b> [2] 127:2, 6<br/> <b>feather</b> [1] 305:1<br/> <b>features</b> [1] 200:10<br/> <b>febrile</b>[11] 52:3, 5, 18, 24;<br/>     54:24; 70:3, 14; 72:15; 100:13;<br/>     118:19; 138:11<br/> <b>February</b> [1] 179:17<br/> <b>Federal</b> [2] 9:15; 163:5<br/> <b>feel</b> [25] 37:7; 63:25; 70:19;<br/>     73:24; 74:16, 27; 75:4; 76:25;<br/>     96:24; 101:25; 107:3, 12;<br/>     7 10:6, 72; 122:24; 126: 10;<br/>     130:15; 162:17, 79; 299:16;<br/>     306:23; 317:8; 320:21; 321:8;<br/>     338: 7<br/> <b>feeling</b> [5] 30:7; 120:3;<br/>     129:25; 138:3; 159:9       </p> | <p><b>feels</b> [1] 74:17<br/> <b>Feikin</b> [9] 182:9, 71; 183:1, 6;<br/>     191:19; 192:3; 194:9, 13 ;<br/>     267:13<br/> <b>fell</b> [1] 289:22<br/> <b>felt</b> [6] 83:16; 119:19; 159:3;<br/>     292:19; 319:22; 322:15<br/> <b>fever</b> [39] 16:18; 30:4, 10, 23;<br/>     31:3; 33:12; 42:16; 51:12, 20;<br/>     52:25; 53: 79; 68: 78; 69 7 7;<br/>     70:8, 22; 71:13; 72:22; 73:20;<br/>     74:11, 18; 75:2, 5; 76:3, 76,<br/>     24; 78:13; 81:3; 85:14; 108:5,<br/>     8; 124:10; 130:11; 132:4, 14;<br/>     151:12; 155:11; 160:16;<br/>     161:10,<br/>     23<br/> <b>feverous</b> [1] 58:13<br/> <b>fevers</b> [1] 146:14<br/> <b>fiber</b> [2] 228:11<br/> <b>field</b> [32] 17:25; 47:9, 69:3;<br/>     87: 7 7, 23; 82:8, 22; 83:6, 23;<br/>     84:9, 7 7; 85:3, 7 7, 17; 86: 15,<br/>     78; 87:2, 17, 22, 24; 92:20;<br/>     93:7; 98:6, 76; 102:10, 19;<br/>     103:24; 7 13:17, 27, 22;<br/>     115:10; 201:20&lt;br</p> |
|---|--|--|

forward [3] 9:5, 9; 68:7  
 Found [1] 251:18  
 found [14] 61:2, 4; 93:12;  
 181:22; 182:2; 183:6; 185:3, 5,  
 22; 186:14; 189:1; 217:4;  
 228:7; 277: 78  
 Four [4] 226:19; 251:19;  
 281:24; 282:4  
 fourfold [2] 211:23, 24  
 fourth [2] 36:2; 209:16  
 Fqa [1] 27:1:19  
 frames [1] 112:17  
 framework [1] 276:23  
 France [1] 50:14  
 frankly [2] 30:17; 320:1  
 Fred[3] 6:24; 26:1; 36:24  
 free [1] 157:24  
 Freedom [1] 165:5  
 frequency [4] 207:17, 78;  
 240:20; 241:13  
 frequent [1] 30:8  
 frequently [a] 37:11; 75:2;  
 775:24; 223:22; 224:27;  
 243:16; 255:22; 257:6  
 freshly [1] 116:21  
 Friedland [1] 181:22  
 front [5] 129:8; 195:8; 256:17;  
 264:2; 272: 10  
 Fukuda [2] 207:11; 210:15  
 full[5] 164:25; 170:10; 241:9;  
 248:11; 329:13  
 fully [33] 105:6; 109:18;  
 169:8,10, 78; 197:25; 199:7;  
 209:11; 211:7, 9, 72; 212:14;  
 213:1, 8; 221:16; 222:15;  
 232:18; 233:2, 6, 9; 234:20;  
 235:10,24; 236:7, 20; 237:5,  
 7; 238:5; 239:21; 245: 75;  
 246: 15; 265: 17; 294:75  
 fundamental [2] 129:12;  
 255:8  
 funny [2] 56:19; 264:24  
 future [11] 47:13; 289:3;  
 301:21; 304:21; 310:20;  
 311:18; 326:6; 331:12; 335:18;  
 337:17

**- G -**

gain [4] 60:18; 67:15; 172:11;  
 297:10  
 gaining [2] 177:5; 300:7  
 game [1] 317:9  
 Ganz [1] 15:1  
 gap [1] 180:13  
 garner [1] 231:9  
 Gary [5] 7:3; 8:9; 10:23; 68:1;  
 762: 73  
 gas [2] 80:20, 22  
 gases [1] 80:15  
 gasses [1] 81:11  
 gastrointestinal [2] 171:5;  
 327:13  
 gathered [2] 137:19; 199:17  
 gave[7] 44:15; 101:5; 7 14:1;  
 189:6, 8; 211:9; 267:12  
 gears [2] 9:20; 181:12  
 gel [23] 17:25; 69:3; 81:17,  
 23; 82:8,22; 83:6,23; 84:9,  
 17; 85:3, 5; 86:15; 90:24; 91:8  
 12; 93:7, 19; 98:6, 16; 102:10,

19; 115:10  
 gels[1] 84:24  
 gender [2] 237:23; 238:9  
 gene [1] 92:5  
 generalist [3] 262:23; 264:8,  
 74  
 generalization [1] 303:24  
 generate [1] 205:3  
 generated [1] 196:5  
 generation [3] 246:2, 7; 266:3  
 genes [2] 206:13; 207:5  
 genesis [2] 320:23; 322:20  
 genetic [1] 305:4  
 genetically [3] 301:4; 304:19,  
 24  
 gentlemen [2] 196:9; 246:25  
 geographic [3] 178:10, 78;  
 190:23  
 George [2] 201:8, 77  
 Georgia [1] 178:14  
 germane [1] 324:5  
 gets [12] 27:17; 32:5; 66:13;  
 86:3; 115:15; 142:7; 155:6;  
 246:3; 268:12; 301:20; 313:10;  
 314:11  
 GI[2] 242:13, 74  
 give [31] 5:10; 8:9; 26:10;  
 28:5; 30:23; 43:21; 45:2;  
 50:12; 66:9; 70: 75; 93:23;  
 99:7; 117:12; 130:10; 162:24;  
 174:11; 211:12; 215:24;  
 240: 73; 243: 7 3; 244:20; 260: 7;  
 263:15; 272:14; 273:16;  
 285:18; 286:7; 319:23; 323:3,  
 4  
 Given [2] 117:8; 254:20  
 given [39] 13:18; 19:19; 30:1;  
 31:13; 32:23; 35:18; 38:2;  
 39:5; 64:20; 68: 77, 78; 69:5,  
 77, 24; 70:15; 87:20; 88:13;  
 94:15; 97:11; 98:13; 99:14;  
 115:4; 127:15; 133:13; 147:14;  
 148:23; 170:12; 182:22;  
 194:21; 195:16; 222:8; 226:15;  
 244: 74;  
 272:3; 291:6, 7, 12; 292:15  
 gives [4] 41:19; 238:24;  
 241:5; 279:5  
 giving[5] 14:6; 23:21; 71:13;  
 189:13; 331:24  
 glad [1] 111:22  
 gleaned [1] 198:10  
 global [1] 244:9  
 globally [1] 243:8  
 glycochalcates [1] 153:9  
 goal[3] 152:14; 153:4; 154:14  
 goals [3] 13:17; 148:9; 292:12  
 goes [11] 27:5; 33:20, 27;  
 76:4; 82:14; 112:7; 291:17;  
 297:22; 301:7, 23; 337:7  
 gold [a] 35:25; 72:1, 2; 81:24;  
 84:10; 221:3; 261:9; 263:15  
 GOLDBERGER [22] 168:3;  
 171:22; 194:13; 76, 24;  
 290:18; 291:2; 293:11; 296:25;  
 304:4; 305: 77; 307:2; 371:4;  
 313:9; 314:17, 20; 319:18; 27;  
 321:10, 73; 322:8; 332:2  
 Goldberger [11] 168:3;  
 171:18; 290:20; 293:9; 296:10;  
 309:8; 37 1:2; 321:4; 328:7;

330:2; 336:8  
 Gordon [9] 5:20; 49: 7 7;  
 75:14, 25; 111:3; 130:15;  
 133:1, 13; 164:21  
 gotten [1] 103:6  
 government [2] 7:21; 10:5  
 grade [1] 136:1  
 graft [1] 18:12  
 grafts [1] 15:5  
 Graham [5] 195:25; 196:6, 10;  
 246:23; 328:9  
 Gram [15] 36:18; 52:6; 56:19;  
 58:2; 93:20; 101:15; 125:23;  
 126:8; 141:5; 207:1; 229:10,  
 72, 15, 76, 20  
 grant [2] 297:15; 299:11  
 granted [5] 7:21; 11:17, 79;  
 764:25; 328: 77  
 granting [1] 299:9  
 grappling [1] 337:7  
 great[12] 25:16; 33:5; 35:8;  
 38:19; 108:21; 114:3; 120:17;  
 151:17; 170:16; 190:14;  
 223:23; 330:6  
 greater [34] 31:12; 33:10;  
 48:7; 77:25; 78:21; 104:16, 22;  
 106:7; 107:9; 183:13; 184:16;  
 186:6; 203:3, 4; 206:3, 5;  
 214:18; 216:6, 78; 219:16;  
 220:8, 15; 226:22; 229:21;  
 233:21; 235:5; 250:18; 251:22;  
 294:17, 78; 304:7; 309:3;  
 328:11; 337:21  
 greatly [1] 43:24  
 grounds [2] 101:17; 106:6  
 group [29] 13:12, 78; 24:7;  
 26:2; 39:4; 56:2; 64:23; 73:13,  
 78; 74:12; 75:1; 79:3; 80:13;  
 116:8; 163:1; 183:9; 72, 76,  
 20; 184:5; 242:2; 249:3,10;  
 266:6; 272:13; 280:17; 291:8;  
 294:21; 306:23  
 grouped [1] 177:10  
 groups [9] 38:13, 75; 59:18;  
 183:11; 185:4, 7; 227:13;  
 248: 79; 273:20  
 grow [2] 105:20; 114:19  
 growing [4] 98:20; 142:19;  
 297:5; 300:6  
 grown [1] 92:11  
 grows [2] 101:14; 112:19  
 growth [14] 17:5, 72, 77, 20,  
 24; 83:1; 97:2; 116:25;  
 208:16; 209:13,15, 76;  
 228:14, 20  
 guess [26] 24: 74; 35: 7 7; 36:2;  
 69:14; 76:22; 78:18; 80:10;  
 81:14; 89:1; 103:10, 20;  
 139:13; 151:9; 161:21; 257:16;  
 259:17; 296:9, 79, 23; 304: 78;  
 305:6; 331:1, 5; 332:20;  
 334:13, 74  
 guidance [36] 8:18; 9:7, 10;  
 10:17; 11:7, 73; 13:13, 22;  
 14:6, 77; 24:9; 26:7; 31:1;  
 32:17, 76, 24; 33:6; 39:18,27;  
 40:3, 7; 42:11; 47:1, 75; 51:2;  
 53:4; 55:6; 59:2; 68:12, 77;  
 77:7, 15; 108:21; 135:16, 24;  
 330:18  
 guideline [1] 95:22

guidelines [9] 47:11, 12;  
 71:14; 128:10; 147:18; 260:24;  
 309:25; 323:22; 330:24  
 Guidewire[1] 33:19  
 guidewire [2] 19:25; 20:4  
 Guinea [1] 220:24  
 gut [1] 120:10  
 guy [1] 223:25  
 guys[2] 123:25; 124:1  
 gyrA[6] 206:22; 210:13, 78;  
 211:3, 8  
 gyrase[lo]202:24; 204:8, 7 7,  
 18, 79,24; 205:8; 206:22;  
 210:13; 211:2  
 gyrB[3] 206:22; 210:13;  
 211:4

**- H -**

habits[1] 193:5  
 Half [1] 41:15  
 half[11] 8:22; 176:2; 191:6, 8;  
 203:22; 240:21; 241:13, 15;  
 260: 1; 269:23  
 half-life [1] 224:25  
 half-lives[1] 21:6  
 hallmarks[2] 178:8; 190:21  
 hammered[1] 264:8  
 hand[11] 63:13; 70:4; 72:24;  
 102:9; 109:20; 121:12; 156:4;  
 202:6; 299:9; 70; 331:5  
 handcuffed [1] 331:16  
 handful [2] 255:4, 5  
 handle[3] 121:21; 281:16;  
 336:18  
 happening [2] 92:23; 155:18  
 happens [7] 38:21; 108:5;  
 126:8; 200:25; 307:13; 308:17;  
 334:5  
 happy [3] 24:10; 107:5;  
 326:20  
 hard [8] 24:8; 127:13; 139:25;  
 252: 7 5; 255: 7 7; 256:9; 302:2:7;  
 326: 74  
 harder [1] 181:19  
 hardest [1] 128:8  
 hardware [2] 66:15; 69:2  
 Harvard [1] 201:19  
 hasn't [2] 265:22; 327:17  
 hastening [1] 168:25  
 hat [1] 246:6  
 haven't [7] 30:1; 127:12;  
 139:20; 279:2; 298:22; 305:18;  
 334:2  
 he'll [1] 201:3  
 head[2] 38:20; 329:13  
 head-to-head [1] 241:6  
 heading [2] 80:14; 337:13  
 heads [1] 74:19  
 Health [4] 6:6; 167:7; 188:25;  
 189:4  
 health [7] 168:17; 266:2;  
 315:1; 335:1; 337:14, 79  
 healthy [2] 224:22; 249:1  
 hear [12] 29:4; 36:3; 129:20;  
 196:14; 222:20; 268:4; 269:6,  
 7; 316:12; 323:12, 73; 327:11  
 heard[15] 94:22; 119:16, 78;  
 127:16; 199:15; 221:1, 75, 23;  
 228:4; 243:5; 270:14, 79;  
 323:21; 328: 77; 337:25

hearing [6] 157:4; 168:9; 262:8; 266:22; 300:2; 333: 16  
**hears** [1] 326:21  
**heart** [7] 31:12; 33:10, 73; 71:18; 79:8; 128:22; 313:10  
**hearts** [1] 314:10  
**heat** [1] 71:17  
**heavily** [3] 30:6; 155:4; 256:17  
**held** [3] 79: 7 7; 290:23; 337:7  
**help** [11] 61:19; 91:25; 92:4; 104:3; 168:22; 201:6, 7, 27; 248: 72; 260:4; 265:7  
**helpful** [17] 39:21; 47:12; 55:6; 65:19; 77:21; 80:12; 86:16, 24; 91:5, 72; 92:14; 126:13; 140:7, 18; 292:16; 298: 74; 334:20  
**helping** [1] 65:4  
**helps** [2] 104:4; 264:7  
**Hemodialysis** [1] 53:6  
**hemodialysis** [1] 59:8  
**Hemophilus** [1] 263:21  
**hence** [3] 107:24; 158:2; 305:8  
**heparin** [3] 116:11, 74, 21  
**hepatic** [5] 18:20; 53:5; 242:10, 11, 14  
**hesitancy** [1] 295:22  
**heterogeneous** [1] 39:4  
**Hi** [1] 191:18  
**Hickman** [1] 14:22  
**hide** 111 124:1  
**hierarchy** [5] 97:10, 77; 99:8; 103:8, 9  
**High** [1] 220:4  
**high** [26] 13:2; 41:19, 27; 52:25; 59:6; 79:8; 85:25; 101:19; 102:20; 118:23; 120:14; 136:1; 174:22; 176:2; 181:6; 183:14; 202:21; 217:9; 223:6; 230: 14; 235:2; 249:6; 257:3; 263:10; 299:22; 301:17  
**higher** [40] 25:13; 27:6; 57:18; 61:13, 14; 62:3; 72:1, 8, 22; 104:20; 110:19; 126:5; 131:16; 25; 135:5; 154:20; 155:3; 161:22; 180:6, 20; 181:2; 191:23; 211:9; 219:8; 225:8; 16, 77; 226:1, 21, 24; 227:9; 17; 228:3; 230:14; 233:9; 240:21; 253: 72; 257:25; 322:24; 334: 18  
**highest** [2] 62:9; 248:18  
**highlighted** [2] 44:23; 201:25  
**highly** [14] 48:18; 49:25; 50:20, 22; 107:10; 108:25; 178:6; 188:24; 191:10; 244:10; 247: 74, 16; 268: 74  
**hinges** [1] 174:3  
**hint** [1] 186:24  
**Hiramatsu** [2] 207:12; 210:15  
**historical** [1] 23:19  
**history** [3] 35:6; 220:21; 242:10  
**hits** [2] 118:4; 140:15  
**HIV** [2] 232:3; 301:16  
**Ho** [1] 217:3  
**hoc** [6] 90:1; 92:21; 127:25; 129:6; 259:18; 290:23  
**Hoechst** [1] 197:7

**hold** [4] 33:22; 102:20; 220:17; 310:22  
**hollow** [2] 228: 7 1  
**Holter** [2] 242:20, 27  
**home** [1] 129:13  
**homogeneous** [1] 72:4  
**homogenized** [ 1] 226:4  
**honest** [2] 171:7; 262:1  
**Hong** [2] 216:25; 217:2  
**honored** [1] 196:2  
**hook** [3] 144:10, 77, 73  
**hooked** [1] 138:21  
**hope** [7] 28:12; 81:20; 173:4, 23; 247:11; 251:11; 257:9  
**hoped** [2] 221:13; 232:19  
**hopefully** [2] 79:2; 264:4  
**hopeless** [1] 328:6  
**hoping** [1] 221:5  
**HOPKINS** [1] 168:1  
**Hopkins** [1] 168:1  
**Hoshino** [1] 204:15  
**Hospital** [5] 6:6, 78; 167:7, 78; 248:22  
**hospital** [20] 42:14; 76:4; 92:20; 98: 7 3; 128:25; 7 33; 74; 182:13, 20, 23; 183:2; 192:14, 15, 17, 22; 201:3; 215:13; 222: 15; 232:8; 244:25; 246:5  
**hospitalization** [2] 274:5; 282:25  
**hospitalizations** [2] 222:9, 7 1  
**hospitalized** [9] 129:13; 182:12; 192:7; 194:14; 232:7; 245:20; 253: 74; 274:8; 335: 7  
**hospitals** [10] 76:2; 192:15, 27; 274:1; 215:12, 75, 77; 246: 10, 7 7; 249:8  
**hour** [2] 219:17; 269:21  
**hours** [46] 18:17, 78; 20:22; 23:4; 50:18; 89:12; 108:4, 7, 72, 20; 124:22, 24; 125:2; 133:20; 7 55: 10; 203:22; 208:17; 209:3, 6, 7, 73, 74; 218:20; 219:4; 224:25; 226:19, 23, 25; 227:4, 77, 18; 228:12, 74, 15, 78, 20, 25; 232: 7; 242:24; 259:23; 280:21; 283:18, 22, 24  
**house** [1] 240:9  
**hub** [28] 17:17; 20:20; 24:25; 25:8, 73, 76, 79; 49:13, 74; 55:23; 60: 70, 1 3, 7 7; 62:24; 63:2, 72; 65:2; 82: 15; 83: 73; 99:9; 104:2, 16, 79; 105:11; 106:21; 110:22; 126:10; 740: 75  
**hubcap** [2] 24:16; 94:22  
**hubs** [3] 61:4; 65:4; 99:7  
**huge** [5] 73: 7 7; 239:4; 302:25; 303:3; 316:15  
**human** [4] 208:10; 219:14; 220: 78; 253:3  
**humans** [3] 203:10; 219:17; 220:2  
**hung** [1] 79:25  
**hurdle** [1] 43:17  
**hyperkalemia** [1] 7 76: 18  
**hypotension** [1] 16:20  
**hypothermia** [1] 16:18  
**hypothermic** [1] 73:21

- | -

**I've** [29] 22:8, 7 7; 76:14; 83:17; 116:10; 119:16, 78; 120:6; 130:21; 131:11; 132:13; 177:9; 178:10; 179:13, 15; 188:24; 212:7; 223:20; 231:22; 232:23; 236: 7 7; 241:23; 243:13, 21; 269:3; 276:15; 281:15; 305:13  
**i.e.** [1] 301:25  
**IC-50** [3] 204:16; 205:9, 74  
**IC-50s** [1] 204:17  
**ICAAC** [3] 50:16; 218:22; 220: 7  
**ICU** [1] 104:25  
**ICUs** [1] 80:14  
**ID** [2] 264:20; 266:6  
**idea** [6] 87:25; 98:1; 103:8; 266:9; 281:10; 315:17  
**ideal** [3] 84:10; 90:24; 158:3  
**identical** [6] 31:8; 68:24; 81:16; 88:16; 228:25  
**identification** [ 1] 88:22  
**identified** [16] 151:10; 159:7; 7 75:25; 176: 10; 198:23; 207:17; 210:3; 216:4; 247:7; 277:13, 22, 23; 281:22; 282:3; 286: 13; 308:2  
**identify** [4] 166:24; 175:12; 199:2; 278:7  
**identifying** [1] 88:12  
**IDSA** [1] 260:24  
**ignorant** [2] 220:24; 300:23  
**II** [1] 24:4  
**II.2** [1] 304:6  
**ill** [9] 80:14; 137:6; 225:8, 10; 237: 15; 239: 7 7; 245:6, 7; 318:7  
**Illinois** [2] 6:3; 167:4  
**illness** [6] 192:2; 195:12; 236:19; 237:1; 249:16; 250:12  
**illnesses** [ 1] 249:1  
**illustrate** [4] 80: 17; 177:8; 179:12; 337:2  
**illustrated** [1] 186:10  
**illustrates** [1] 188:2  
**imagine** [4] 36:10; 63:2; 130:18; 193:9  
**imbedded** [3] 62:13, 77; 140:4  
**immediately** [2] 137:7; 245:23  
**imminent** [1] 73:1  
**immune** [1] 308:19  
**immunized** [1] 189:7  
**immunocompromised** [1] 74: 72  
**Immunologic** [2] 171:19; 270:4  
**impact** [4] 7:17; 40:20; 42:25; 246:6  
**impacted** [1] 293:24  
**impacts** [1] 7 16:16  
**implanted** [1] 14:24  
**implicate** [11] 99:23; 100:8, 20; 101:3, 5; 110:8; 119:24; 120:2, 4; 121:16, 23  
**implicating** [7] 96:4; 120:14, 76; 121:4, 9; 126:5, 24  
**implication** [2] 24:2; 313:6  
**increasingly** [1] 198:24

|                                |                                  |                                 |                                  |
|--------------------------------|----------------------------------|---------------------------------|----------------------------------|
| incubation [1] 112:14          | 300:7; 73;                       | interesting [1] 211:23          | Israel [1] 201:19                |
| independence [5] 97:24;        | 302:16, 19, 23; 304:7; 306:2,    | interesting [5] 99:12; 158:6;   | issued [1] 42:17                 |
| 302:16; 303:9; 304:3; 306: 15  | 5; 313:14, 16, 17, 21; 323:1;    | 185:12; 200:10; 226:12          | issues [34] 7:16; 8:19; 9:25;    |
| Independent [1] 234:15         | 328:20; 332:11, 13               | Interestingly [1] 176:21        | 33: 7 7; 39:24; 40: 194:6; 95:7; |
| independent [25] 40:16;        | informative [1] 29:2             | interests [7] 7:14; 164:14, 76; | 122:22; 172:13; 173:16;          |
| 89: 19; 123:8; 203:20; 238:3,  | infuse [22] 14:19; 17:21;        | 165:9, 73, 77, 22               | 180:15; 186:13; 196:5; 248:11;   |
| 70; 239:13,16, 77; 252:19;     | 20:20; 49:76, 7 7; 56:20; 57:5,  | interlumenal [ 1] 55:23         | 261:20; 262:4; 269:7 7; 289:5;   |
| 300:22; 301:1, 2, 3, 6, 8, 10, | 8; 60: 70, 73, 7 7; 62:25; 63:3, | intermediates [1] 315:18        | 294: 7 5; 297:24; 298:4, 22;     |
| 25; 302: 7 7; 303:22, 25;      | 6, 11; 64:5, 7; 82:15; 83:13;    | Internal [1] 213:4              | 314:8; 315:1; 316:20, 27;        |
| 304:22, 24; 306:16             | 94:22; 106:23; 726: 7 7          | internal [1] 62:16              | 320:4; 322:3; 329:10; 331:4;     |
| independently [5] 97:22;       | infusates [2] 61:2; 65:4         | internally [1] 203:25           | 335:20                           |
| 98:2; 123:12; 224:15; 301:19   | infuse [1] 144:13                | interpret [2] 130:3; 267: 7 7   | item [1] 256:24                  |
| Indes [2] 6:7; 167:8           | infusing [1] 141:22              | interpretable [1] 148:18        | IV[15]8:16; 24:8; 138:21;        |
| indicate [3] 25:18; 203:13, 75 | infusion[4] 49:22; 56: 15;       | interpretation [2] 95:25;       | 152:11; 168:6; 204:11, 76, 79;   |
| indicated [5] 75:5; 159:4;     | 62:24; 143:4                     | 265:13                          | 205:6, 15, 78; 206:23; 235:16,   |
| 212:19; 258:15; 295:8          | inherent [ 1] 12:8               | interpretative [1] 205:22       | 78; 250:22                       |
| indicates [1] 202:19           | inhibit [ 1] 204:7               | interval [1] 290:4              | - J -                            |
| indicating [3] 170:2; 204: 79; | inhibiting [1] 204:4             | intervals [2] 290:3, 8          | JAMA [2] 51:20; 89:18            |
| 209:17                         | inhibition [4] 7 16:25; 204:8,   | intervention [5] 138:21;        | Jamaica [2] 6:7; 167:8           |
| indication [48] 11:16, 77, 79, | 77; 205:17                       | 189:5, 77, 23; 190:14           | Japan [8] 197:8; 217:14, 15,     |
| 22; 12:6; 13:10; 39:22; 40:3;  | initial [a] 25:14; 62:6; 126:17; | interventions [2] 59:9; 72:5    | 19,24; 247:10; 257:1; 327:11     |
| 44:2, 5; 52:16; 75:4; 79:24;   | 7 60: 7 5; 208:24; 209:7 7;      | intimately [ 1] 200:7           | Jersey [2] 6:18; 167:18          |
| 122:11; 127:9; 151:21; 153:15; | 216:12, 20                       | intracellular [2] 228:1; 230:15 | JID [1] 157:14                   |
| 170:22; 171:9; 172:6, 11;      | initially [3] 176: 73; 189:21;   | intraluminal [2] 61:15; 62:2    | Joan [2] 5:23; 73:24             |
| 187:10; 198:19; 248:4; 254:21; | 263:18                           | intraluminally [1] 116:2        | job [3] 64:24; 128:4; 290:21     |
| 255:10; 264:17; 273:9, 278:10, | initiated [1] 136:7              | Intravascular [ 1] 153:3        | Johnson [7] 6:21; 165:8;         |
| 7 1:289:4; 293:14; 294:2;      | initiating [1] 134:24            | intravascular [1] 119:12        | 171:25; 173:1, 8 ; 196:12        |
| 297:15;                        | initiation [1] 158:14            | intravenous [1] 194:17          | joined [2] 44:11; 56:2           |
| 299:8,14; 300:18; 301:7, 21;   | initiatives [1] 306:9            | intrinsic [2] 80:25; 223:9      | jointly [1] 40:18                |
| 321:24; 322:11; 323:2; 327:13, | inquire [ 1] 299:2               | introduce [1] 68:2              | Jorgensen [1] 210:24             |
| 21, 24; 328:3, 11; 331:11      | insensitivity [1] 113:25         | introduced [1] 20:6             | Journal [5] 61:8; 115:24;        |
| indications [10] 9:3; 12:15;   | insert [10] 122:12; 123:16;      | introducing [1] 47:6            | 157:14; 215:23; 216:10           |
| 166:4; 172:5; 270:21; 288:21;  | 224:19; 264:15; 269:1; 310:13,   | introduction [6] 8:10; 19:18,   | Jude [1] 74:9                    |
| 293:21; 300:8; 318:23; 322:6   | 14, 24; 324: 7 9; 325:2 7        | 25; 47:18; 171:21; 196:1        | judged [2] 233:18, 22            |
| indicator [1] 80:2             | inserted [2] 14:25; 116:21       | introductory [ 1] 266:21        | judicious [2] 193:23; 327:8      |
| individual [6] 92:20; 99:5;    | insertion [3] 57:17, 20; 58:3    | intubated [2] 233:20; 250:16    | judiciously [1] 327:18           |
| 105:9; 137:18; 178:22; 337:14  | inserts [1] 329:8                | Intuitively [1] 104: 73         | Judith [2] 5:25; 167:1           |
| individually [2] 78:24; 79:22  | inside [ 1] 144:5                | intuitively [1] 104:14          | Julie [7] 6:15; 10:6; 75:6;      |
| individuals [1] 39:10          | instance [18] 76:4; 91:25;       | invasive [1] 170:17             | 165:1; 167:14, 15; 334:2         |
| inducability [1] 92:9          | 122:7; 124:16; 133:7; 291:10;    | investigation [ 1] 198:3        | July[2]8:22; 42:1 7              |
| induce[1] 92: 11               | 292:4; 297:7; 298:5, 76, 17,     | investigator [1] 242:13         | June [1] 179:17                  |
| industry [9] 9:19; 13:14;      | 22; 314:25; 320:9,14; 322: 75,   | investigators [2] 52:13;        | justifiable [1] 30:22            |
| 124:20; 129:10; 168:19; 297:6; | 22; 332:7                        | 240: 79                         | justified [1] 45: 17             |
| 300:4, 10; 326:3               | instances [2] 301:15; 326:18     | inviting [1] 196:18             | - K -                            |
| indwelling [1] 139:17          | Institute [1] 796: 72            | involve [3] 7:23; 59:10;        | K-90-071 [3] 273:1, 79;          |
| inevaluable [ 1] 7 19:3        | institution [4] 104:7; 108:10;   | 166:10                          | 274:12                           |
| infected [a] 14:18; 21:7;      | 120:6; 196:15                    | involved [14] 10:1; 58:7; 91:2; | Kahn [1] 249:17                  |
| 33:19; 103:21; 105:21; 141:12, | institutions [3] 83:5; 178:22;   | 101:20; 126:23; 189:8; 190:9;   | Karen [4] 199:11; 202:7;         |
| 23; 152:12                     | 329:4                            | 197:6; 200:2, 7; 201:9,74;      | 220:19; 256:15                   |
| Infection [1] 55:11            | insure[7]20:5; 68:22; 7 75: 75;  | 213:14; 256:3                   | Keep [2] 40:20; 85:25            |
| Infectious [8] 5:19; 6:16, 17, | 306:1, 77; 322:17, 79            | involvement [5] 8:2, 6;         | keep [12] 38:9, 12, 25; 54:22;   |
| 23; 52:2; 157:15; 167:16, 77   | insuring [1] 311:17              | 165:25; 166:13, 77              | 108:23; 129:6; 145:14; 157:4;    |
| infectious [3] 45:22; 58:9;    | integral [1] 329: 7              | involves [2] 188:4; 337:16      | 298:3; 299:5; 306:2; 315:8       |
| 244:24                         | integrity [1] 332:21             | involving [2] 197:14; 244:17    | keeping [2] 103:24; 267:3        |
| infinitely [1] 37:18           | intend [1] 53:13                 | IRB [ ] 52:14                   | Keith [5] 6:2; 165:2; 167:3;     |
| inflammation [6] 48:17;        | intended [2] 33:7; 295:19        | irrelevant [2] 25:15; 92:21     | 37 7: 74; 333:2                  |
| 95:13; 100:14; 109:3; 117:16,  | intensive [2] 73:16; 108:1 7     | irrespective [1] 131:10         | Keys [2] 95: 18; 306: 1 7        |
| 79                             | intensiveness [ 1] 61: 72        | Iсаam [3] 46:23; 47:7; 107:7    | kids [3] 73:23; 133:2; 258:17    |
| inflammatory [1] 29:22         | intent [8] 22:21; 39:5; 50:2;    | Island [ 1] 244:25              | kill[4]157:24; 203:14, 76;       |
| influence [4] 179:4; 297:25;   | 59:3; 109:21; 7 17:20; 118:8, 9  | isogeneic [1] 211:17            | 204:4                            |
| 298:24; 312:3                  | interactions [1] 19:12           | isolate [23] 85:20; 7 76: 10;   | killing[5]204:1, 70, 72;         |
| influenza [1] 263:21           | interchangeably [1] 197:1        | 177:22; 7 78: 7; 186:2, 5;      | 205:7; 206: 10                   |
| Information [1] 165:5          | interest [21] 7:7, 9, 25; 8:5;   | 187:16; 189:25; 209:16, 77;     | Kills [1] 133:17                 |
| information [47] 60:17; 67:12, | 19:2; 28:12; 134:16; 149:1;      | 210:2; 229:7; 267:24; 268: 7 1; | Kinds [4] 88:19; 106:17;         |
| 76; 99:7; 101:16; 124:21;      | 164:7, 9, 79; 165:14, 18;        | 271:18; 275:14, 27; 276:10;     | 134:14; 145:4                    |
| 125:13; 131:6; 151:3; 172:6;   | 166:12, 76; 173:12; 243:22;      | 287:6, 27; 291:12; 303:10;      | kinetics [3] 203:14, 76;         |
| 173:5; 174:12; 175:20; 181:18; | 297:6; 300:4, 7                  | 324:8                           | 317:21                           |
| 793: 18, 25; 7 98:9; 222:20;   | interested[13] 16:7; 29:4;       | isolated [5] 175:10; 197:18;    | Kleb [1] 82:6                    |
| 228:5; 282: 18; 286:6; 291:24, | 30: 74; 36:3; 75:7; 100:22;      | 245:10; 277:13, 74              |                                  |
| 25; 292:8, 27; 293:6, 25;      | 149:22; 150:11, 12; 255:14;      | isolates [1] 175:16             |                                  |
| 297:13; 298:11, 74; 299:23;    | 299: 7; 300:2; 309:2             | isolation [1] 179:22            |                                  |

## Basic Systems Applications

**knock** [1] 153:7  
**knowing** [6] 83:5; 7 11:19;  
 134:17; 268:17; 314:6; 334:20  
**-knowledge** [1] 67:5  
**Kodak** [1] 116:17  
**Kong** [2] 216:25; 217:2  
**KWEDER** [2] 168:5; 336:21  
**Kweder** [4] 168:5; 293:9;  
 336:8, 20

## - L -

**lab** [8] 20:12; 85:4; 92:14, 19,  
 25; 105:21; 314:3, 4  
**label** [46] 122:23; 171:10;  
 270:24; 273:2; 277:7, 8, 20;  
 278:20; 293:24; 294:1; 296:11,  
 24; 297:23, 25; 298:6, 12;  
 300:79; 301:24; 305:15; 306:7;  
 311:9; 312:10; 313:19; 319:4,  
 14; 320:5, 11, 20; 322:10;  
 323:5, 8, 75; 325:1; 330:4, 7,  
 73, 79,  
 203:1:2, 15, 16, 17; 332:11,  
 14, 18; 334:9  
**labeled** [2] 42:2; 55:20  
**labeling** [24] 12:16; 197:16;  
 201:24; 202:1; 262:21; 264:14;  
 270:25; 271:5; 288:19; 293:12;  
 299:79, 20; 302:5, 305:7, 7;  
 378:7, 2; 322:14, 20; 325:20;  
 326:6; 331:4, 10, 22; 333:4  
**labels** [2] 337:23, 24  
**labor** [2] 61:11; 108:11  
**laboratories** [8] 67:7 1:1, 7;  
 72; 113:7; 115:7; 175:13, 77;  
 214:8  
**laboratory** [11] 20:13; 29:13;  
 89:25; 112:23; 175:14; 203:15;  
 24; 208:6; 209:24; 245:7, 7;  
 258:20  
**labs** [4] 64:7; 88:7; 92:5;  
 111:20  
**lack** [14] 12:6; 13:6, 78;  
 41:17; 52:14; 64:21; 67:4;  
 79:22; 85:3; 715:6; 232:20;  
 306:4; 307:17, 19  
**lactem** [10] 200:18; 224:8, 9;  
 251:3, 5; 252:5; 258:3; 266:2;  
 267:10; 295:7  
**lactemase** [1] 224:9  
**lactemases** [1] 246:9  
**lactems** [18] 91:24; 195:16,  
 78; 204:2; 206:7, 75, 20;  
 212:25; 224:11; 240:25; 241:2;  
 244:5, 73; 247:21; 264:17;  
 310:1; 329:11  
**Lacy** [2] 208:5; 228:5  
**ladies** [2] 196:9; 246:24  
**laid** [1] 276:4  
**Lancet** [1] 51:1  
**language** [2] 332:9; 337:23  
**large** [21] 30:19; 33:11; 41:11,  
 74, 22; 65:15; 73:13; 110:8;  
 7 3:3; 74:2; 79:7; 177:29;  
 14;  
 227:23; 230:4; 231:9; 234:2;  
 241:18; 242:3; 303:24; 306:19;  
 307:20  
**largely** [1] 172:4  
**larger** [5] 31:4, 77; 180:14;  
 225:9; 306:24

**largest** [2] 217:18; 233:1  
**last** [30] 13:5; 44:10; 47:10;  
 58:5, 6; 94:15; 113:3; 162:16;  
 163:9; 174:15; 176:12; 178:1;  
 184:21; 186:14; 188:6; 190:5;  
 215:9; 217:3; 226:19; 246:19;  
 249:24; 254:5; 258:22, 23;  
 278:21; 291:16; 292:18; 295:9;  
 308:6; 315:21  
**Lastly** [1] 295:24  
**lastly** [1] 223:14  
**Late** [1] 212:12  
**late** [10] 21:9, 20; 22:5, 77;  
 37:7, 21; 183:23; 221:2, 17;  
 223:22.  
**latest** [3] 174:7 1:184:22;  
 216:9  
**Laughter** [1] 290:19  
**Laughter** [5] 130:5; 162:15;  
 245:2; 266:18; 269:8  
**law** [2] 255:10; 297:1  
**lead** [3] 171:4; 220:16; 289:24  
**Leader** [1] 168:2  
**lesader** [1] 199:12  
**leadding** [1] 191:15  
**lpads** [2] 193:2; 199:13  
**lbarn** [1] 69:22  
**lbarned** [2] 240:08, 10  
**Leave** [1] 324:77  
**leave** [15] 47:17; 131:17;  
 141:10; 144:23; 154:15, 77;  
 155:4; 294:1; 299:25; 379:73;  
 323:17; 325:8, 9, 73, 17  
**Leaving** [1] 322:12  
**leaving** [7] 106:19; 123:11;  
 139:17; 161:24; 298:14; 332:2  
**Lee** [2] 51:19; 89:17  
**legionella** [3] 245:22; 263:23;  
 268:18  
**legitimately** [1] 252:20  
**Leigh** [1] 6:22  
**len** [2] 56:2; 81:19  
**lend** [1] 109:25  
**length** [1] 54:9  
**Leonard** [2] 114:1, 3  
**lesser** [4] 104:22; 241:1;  
 244:5; 328:12  
**letter** [1] 310:8  
**letting** [2] 43:21; 45:9  
**Levaquin** [23] 164:23; 165:20;  
 22; 222:4; 270:6, 25; 271:3;  
 272:20; 274:13; 276:17;  
 284:20; 286:23; 287:15;  
 300:20, 21; 302:2; 303:14;  
 306:18, 20; 327:13; 334:5, 77  
**level** [14] 32:17; 41:23; 45:5;  
 144:9; 174:21, 22; 176:2;  
 202:21; 220:4; 227:3; 258:7;  
 25; 263:20; 266:23  
**levels** [14] 210:1; 225:16;  
 226:1, 24; 227:6, 7, 9, 17;  
 228:3; 230:14, 75; 250:2;  
 262:25  
**lev** [1] 326:9  
**Levofloxacin** [8] 7 78:5;  
 197:4; 200:10; 205:16; 217:16;  
 220:10; 244:3, 10  
**liberal** [1] 33:14  
**lies** [1] 43:19  
**life** [4] 37:17; 128:20; 171:3;  
 335:7 7

**lumen** [4] 49:9; 63:4; 104:25;  
 107:16  
**jumping** [1] 289:15  
**lunch** [2] 163:11, 78  
**lung** [16] 166:7; 200:12;  
 218:7; 223:5; 225:18, 21, 22;  
 24; 226:2, 4; 227:15; 248:25;  
 249:20; 250:5; 261:16

## - M -

**M/1-92-07[3]** 273:10, 23;  
 276:6  
**M.D.** [2] 46:24; 47:7  
**macrolage** [1] 263:4  
**Macrolide** [1] 308:11  
**Inacrolide** (1 1) 195:16;  
 212:13, 14; 241:1; 246:2;  
 251:17; 259:8, 9; 261:10;  
 265:12; 323:20  
**macrolides** [11] 170:18;  
 195:18; 200:19; 213:1; 244:5;  
 14; 245:18; 247:22; 259:2, 7;  
 264:1  
**macrophage** [3] 226:9;  
 227:20, 25  
**macrophages** [2] 227:21;  
 249:20  
**main** [2] 43:24; 190:19  
**mainly** [2] 41:8; 44:10  
**maintain** [1] 332:21  
**major** [11] 15:23; 22:8;  
 203:11; 212:9; 215:13; 272:24;  
 273:8, 17; 278:10; 297:23;  
 308:22  
**majority** [7] 61:10; 80:18;  
 114:21; 170:16; 187:20;  
 225:19; 241:2  
**Maki** [10] 17:14; 25:24; 26:4;  
 24; 49:20; 60:19, 25; 62:6;  
 90:14; 99:1  
**rhale** [1] 224:22  
**manage** [1] 337:20  
**management** [9] 34:4; 47:1 1;  
 122:19, 22; 123:1; 146:1;  
 337:9, 75, 76  
**mandate** [1] 33:7  
**maneuvers** [1] 85:4  
**manifest** [4] 52:24; 162:8, 9,  
 11  
**manifestations** [7] 48:16;  
 51:13; 52:10; 132:3; 140:14;  
 162:2, 5  
**Marion** [1] 197:7  
**Mark** [3] 168:3; 171:18;  
 194:12  
**mark** [1] 64:19  
**marked** [2] 190:23, 24  
**market** [7] 70:5; 102:21;  
 168:20; 316:9; 328:14; 331:23,  
 25  
**marketed** [2] 295:13; 298:5  
**marketing** [10] 197:5; 198:12;  
 243:9, 15, 23; 244:6; 247:23;  
 324:18; 326:15; 331:16  
**MARSIK** [8] 6:24; 26:3, 10,  
 74, 16, 21; 27:5; 36:25  
**Marsik** [2] 6:24; 26:1  
**Maryland** [1] 157:20  
**mask** [1] 132:8  
**masse** [1] 252:21

|   |   |   |   |
|---|---|---|---|
| massive [1] 126:20  | men [1] 240:10  | 24; 22:9; 7 12:21, 24; 236:3, 5; 291:5, 8, 11   | 124:6; 127:8  |
| match [2] 31:17; 77:3   | meningitis [11] 42:16; 169:20; 181:15; 184:6, 77; 258:13; 263:10; 266:25; 294:24; 319:16  | microbiologist [1] 6:25   | mL [14] 56:20; 57:8; 185:15;  |
| material [7] 294: 16; 298:2, 17; 322: 18; 323:2, 8  | mentation [2] 233:20; 250:15  | microbiology [1o] 26:1; 29:13; 48:4; 61:11; 75:23; 79:23; 105:21; 109:12; 245:1 7; 286:24   | 206:1, 2, 3, 6; 219:19; 228:21; 229:3; 294:18, 19; 310:4; 317:2     |
| materials [1] 171:10  | mention [7] 48:23; 49:16; 266:4; 272:9; 280:23; 288:20; 318:22  | microblot [1] 213:23  | model [15] 183:3; 194:6, 9,   |
| matrix [1] 45:20  | mentioned [ 14] 12:25; 56:8; 66:3; 71:5; 112:22; 170:24; 191:19; 199:2; 210:11; 211:14; 254:25; 324:3; 329:11; 334:4  | microefficacy [1] 284:21  | 10; 208:4, 8, 10; 209:22; 218:21; 219:1, 72, 15, 22; 220:18; 315:18 |
| matter[1o] 67:23; 111:6; 143:10; 165:14; 181:16; 182:21; 221:12; 269:18; 327:9; 330:6           | mercifully [1] 244:23   | micrograms [14] 185:14; 206: 1, 2, 3, 6; 219:18; 224:24; 227:4, 77; 294:17, 18; 310:4; 312:22; 317:2  | modeling [1] 201:10   |
| Mayo [2] 5:25; 167:2  | Mercury [1] 240:12  | microorganism [2] 324:15; 331:20  | models[8] 194:6, 11; 202:18; 203:9; 218:1, 5; 220:13; 225:3         |
| meaning [5] 17:6; 146:24; 165:15; 176:23; 312:21  | MERMEL [41] 56:5, 14:5; 7, 2, 14; 58:5; 60:3, 6, 22; 63: 13; 65:7; 69:17, 20; 81:20; 84:4; 88:25; 102:8; 104:6; 105:15; 106:16; 107:1; 111:15; 114:4, 7; 115:23; 116:7; 117:2; 7 18: 7; 123:5; 125: 75; 128: 79; 130:13, 20; 131:7; 132:10, 13; 134:22;   | microphone [2] 47:4; 268:2  | moderate[2] 236:22; 250:22  |
| meaningful [7] 51:14; 63:7, 8; 7 40:18; 226:5; 338:3  | 135:25; 136:16; 137:3; 146:19; 161:20   | microscopy [2] 66:3; 99:1 7   | moderately[3] 231:12; 250:22; 256: 78                               |
| means [7] 88:8; 264:11; 267:4; 275:7; 293:13; 311:17; 317:22                                    | Mermel [16] 50:15; 56:1, 2; 60:9; 69:15; 81:19; 88:24; 90:14; 91:11; 102:7; 104:3; 111:14, 22; 115:20; 123:4; 125:14  | MICs [22] 170:15; 183:8, 13; 208:24; 209:3, 10; 21 1:6, 9, 22; 214:19; 216:6, 18; 237:25; 238:9; 239:9; 245:15; 251:25; 258:24; 263:8; 294: 7 7, 18; 317:17 | Modernization [1] 42:10   |
| meant [3] 28:23; 54:19; 68:8  | meropenem [1] 188:21  | mid[1] 233:5  | modification [2] 193:2; 293:12                                      |
| meantime [1] 137:19   | message [2] 309:9, 73   | mid-1980s [1] 212:11  | modified [2] 22:21; 95:8  |
| measurable [1] 207:18   | meta[7] 26:17; 61:7, 24; 104:9; 105:2, 6, 8   | mid-1990s [1] 221:17  | modify [ 1] 96:25   |
| measure [3] 103:21; 250:1; 307:14   | metastatic [9] 21:9, 20; 22:5, 77; 37:7, 21; 38:4; 135:2; 137:17  | mid-80 [2] 276:1; 287:3   | modifying [1] 299:18  |
| measured [2] 207:21, 25   | methiciliin [3] 133:16; 264:10; 329: 12   | mid-90 [1] 287:8  | molecular[6] 82:11; 83:18; 84:6, 19; 89:10; 103:15                  |
| measurement [2] 79:1 7, 18  | method [16] 60:19, 25; 61:19; 62:1, 6, 8, 10, 14, 78; 63:18, 79, 23; 64:2; 105:23; 213:22   | middle [2] 132:23; 317:9  | moment [2] 292:20; 297:16   |
| measurements [1] 116:16   | methodology [3] 18:3; 61:25; 104:10   | Mike [4] 200:2, 9; 244:22; 252:7  | monitor [3] 87:15; 242:20; 308:22                                   |
| measures [1] 321:6  | methods [15] 61:9, 74; 66:1; 67:10; 75:10; 84:15; 103:10; 104:23; 105:18; 106:23; 171:20; 715:8; 117:9,12; 722: 7   | mild [1] 236:22   | monitoring [1] 308:25   |
| measuring [1] 76:3  | MIC-50s [3] 214:12, 23; 215:4   | milligram [4] 226:14, 16; 235:14; 244:14  | monitors [1] 242:22   |
| mechanism [5] 9:16; 202:14; 206:1 7; 207:4; 305:4   | MIC-90 [1] 219:23   | milligrams [1] 239:20   | monotherapy [ 1] 252:4  |
| mechanisms [14] 91:24; 92:4; 199:23; 202:15, 25; 204:1, 4, 7, 8; 206:8; 301:4, 7 7; 309: 75, 22 | MIC-90s [4] 214:12, 75, 23; 215:4   | milliliter [1] 224:24   | monotonously [1] 98:12  |
| mechanistic [2] 222:1; 235:3  | mice [4] 218:14, 24, 25; 219:6  | million [8] 175:6; 198:14,16; 243:6, 7, 20; 244:6; 316:1 7  | month [2] 41:10; 136:9  |
| mechanistically [1] 305:4   | Michael [1] 200:1   | mimic [2] 29:21; 316:4  | months [1] 146:14   |
| MEDEIROS [6] 244:22; 245:3; 258:5; 259:22, 25; 260:11   | Micro [2] 61:8; 7 15:25   | mind [14] 35:21; 72:16; 90:7; 103:13; 108:23; 128:14; 198:9; 202:5; 262:2; 298:3; 299:5; 315:8, 25; 316:21  | mop [1] 152:16  |
| Medeiros [4] 200:23; 244:20; 257:17; 262:5  | microbes [1] 82:11  | minds [1] 290:24  | morality [1] 13:3   |
| media[4] 112:3, 4, 14; 294:24   | microbiologic [35] 14:10; 17:2; 22:12, 15, 24; 69:5, 7; 77:10; 93:24; 94:8, 70, 16, 18; 95:2, 5; 96:22; 107:23; 117:23; 135:20; 136:25; 161:1; 171:8; 179:15; 235:22; 236:1; 275:2, 4, 5, 6, 9, 19; 276:8; 287:17, 22; 299:21   | mindset [1] 40:12   | moraxel [1] 324:15  |
| mediated [2] 207:2; 301:12  | microbiological [1o] 63:19; 65:17; 84:15; 97:18; 99:9; 150:4; 197:19; 199:11; 202:10; 203:11  | mines [1] 221:3   | Moraxeila [1] 263:22  |
| Medical[15] 5:17, 79, 20; 6:8, 19, 27; 164:4; 167:9, 79, 24; 168:1; 201:12, 79; 269:25; 270:3   | microbiologically [1o] 15:21,   | minimal [2] 40:23; 131:6  | morbidity[3] 13:3; 249:6; 254:2                                     |
| medical [6] 7:1; 11:4; 44:7; 59:8; 153:2; 310:8   | microbiologist [1] 6:25   | minimize [3] 19:18; 246:17; 259: 15   | moribund [1] 18:20  |
| Medicine [8] 6:3, 11; 87:11; 167:4, 72, 22; 200:23; 201:18                                      | microbiology [1o] 26:1; 29:13; 37:6; 40:1; 41:1; 42:1; 43:1; 44:1; 45:1; 46:1; 47:1; 48:1; 49:1; 50:1; 51:1; 52:1; 53:1; 54:1; 55:1; 56:1; 57:1; 58:1; 59:1; 60:1; 61:1; 62:1; 63:1; 64:1; 65:1; 66:1; 67:1; 68:1; 69:1; 70:1; 71:1; 72:1; 73:1; 74:1; 75:1; 76:1; 77:1; 78:1; 79:1; 80:1; 81:1; 82:1; 83:1; 84:1; 85:1; 86:1; 87:1; 88:1; 89:1; 90:1; 91:1; 92:1; 93:1; 94:1; 95:1; 96:1; 97:1; 98:1; 99:1; 100:1; 101:1; 102:1; 103:1; 104:1; 105:1; 106:1; 107:1; 108:1; 109:1; 110:1; 111:1; 112:1; 113:1; 114:1; 115:1; 116:1; 117:1; 118:1; 119:1; 120:1; 121:1; 122:1; 123:1; 124:1; 125:1; 126:1; 127:1; 128:1; 129:1; 130:1; 131:1; 132:1; 133:1; 134:1; 135:1; 136:1; 137:1; 138:1; 139:1; 140:1; 141:1; 142:1; 143:1; 144:1; 145:1; 146:1; 147:1; 148:1; 149:1; 150:1; 151:1; 152:1; 153:1; 154:1; 155:1; 156:1; 157:1; 158:1; 159:1; 160:1; 161:1; 162:1; 163:1; 164:1; 165:1; 166:1; 167:1; 168:1; 169:1; 170:1; 171:1; 172:1; 173:1; 174:1; 175:1; 176:1; 177:1; 178:1; 179:1; 180:1; 181:1; 182:1; 183:1; 184:1; 185:1; 186:1; 187:1; 188:1; 189:1; 190:1; 191:1; 192:1; 193:1; 194:1; 195:1; 196:1; 197:1; 198:1; 199:1; 200:1; 201:1; 202:1; 203:1; 204:1; 205:1; 206:1; 207:1; 208:1; 209:1; 210:1; 211:1; 212:1; 213:1; 214:1; 215:1; 216:1; 217:1; 218:1; 219:1; 220:1; 221:1; 222:1; 223:1; 224:1; 225:1; 226:1; 227:1; 228:1; 229:1; 230:1; 231:1; 232:1; 233:1; 234:1; 235:1; 236:1; 237:1; 238:1; 239:1; 240:1; 241:1; 242:1; 243:1; 244:1; 245:1; 246:1; 247:1; 248:1; 249:1; 250:1; 251:1; 252:1; 253:1; 254:1; 255:1; 256:1; 257:1; 258:1; 259:1; 260:1; 261:1; 262:1; 263:1; 264:1; 265:1; 266:1; 267:1; 268:1; 269:1; 270:1; 271:1; 272:1; 273:1; 274:1; 275:1; 276:1; 277:1; 278:1; 279:1; 280:1; 281:1; 282:1; 283:1; 284:1; 285:1; 286:1; 287:1; 288:1; 289:1; 290:1; 291:1; 292:1; 293:1; 294:1; 295:1; 296:1; 297:1; 298:1; 299:1; 300:1; 301:1; 302:1; 303:1; 304:1; 305:1; 306:1; 307:1; 308:1; 309:1; 310:1; 311:1; 312:1; 313:1; 314:1; 315:1; 316:1; 317:1; 318:1; 319:1; 320:1; 321:1; 322:1; 323:1; 324:1; 325:1; 326:1; 327:1; 328:1; 329:1; 330:1; 331:1; 332:1; 333:1; 334:1; 335:1; 336:1; 337:1; 338:1; 339:1; 340:1; 341:1; 342:1; 343:1; 344:1; 345:1; 346:1; 347:1; 348:1; 349:1; 350:1; 351:1; 352:1; 353:1; 354:1; 355:1; 356:1; 357:1; 358:1; 359:1; 360:1; 361:1; 362:1; 363:1; 364:1; 365:1; 366:1; 367:1; 368:1; 369:1; 370:1; 371:1; 372:1; 373:1; 374:1; 375:1; 376:1; 377:1; 378:1; 379:1; 380:1; 381:1; 382:1; 383:1; 384:1; 385:1; 386:1; 387:1; 388:1; 389:1; 390:1; 391:1; 392:1; 393:1; 394:1; 395:1; 396:1; 397:1; 398:1; 399:1; 400:1; 401:1; 402:1; 403:1; 404:1; 405:1; 406:1; 407:1; 408:1; 409:1; 410:1; 411:1; 412:1; 413:1; 414:1; 415:1; 416:1; 417:1; 418:1; 419:1; 420:1; 421:1; 422:1; 423:1; 424:1; 425:1; 426:1; 427:1; 428:1; 429:1; 430:1; 431:1; 432:1; 433:1; 434:1; 435:1; 436:1; 437:1; 438:1; 439:1; 440:1; 441:1; 442:1; 443:1; 444:1; 445:1; 446:1; 447:1; 448:1; 449:1; 450:1; 451:1; 452:1; 453:1; 454:1; 455:1; 456:1; 457:1; 458:1; 459:1; 460:1; 461:1; 462:1; 463:1; 464:1; 465:1; 466:1; 467:1; 468:1; 469:1; 470:1; 471:1; 472:1; 473:1; 474:1; 475:1; 476:1; 477:1; 478:1; 479:1; 480:1; 481:1; 482:1; 483:1; 484:1; 485:1; 486:1; 487:1; 488:1; 489:1; 490:1; 491:1; 492:1; 493:1; 494:1; 495:1; 496:1; 497:1; 498:1; 499:1; 500:1; 501:1; 502:1; 503:1; 504:1; 505:1; 506:1; 507:1; 508:1; 509:1; 510:1; 511:1; 512:1; 513:1; 514:1; 515:1; 516:1; 517:1; 518:1; 519:1; 520:1; 521:1; 522:1; 523:1; 524:1; 525:1; 526:1; 527:1; 528:1; 529:1; 530:1; 531:1; 532:1; 533:1; 534:1; 535:1; 536:1; 537:1; 538:1; 539:1; 540:1; 541:1; 542:1; 543:1; 544:1; 545:1; 546:1; 547:1; 548:1; 549:1; 550:1; 551:1; 552:1; 553:1; 554:1; 555:1; 556:1; 557:1; 558:1; 559:1; 550:1; 551:1; 552:1; 553:1; 554:1; 555:1; 556:1; 557:1; 558:1; 559:1; 560:1; 561:1; 562:1; 563:1; 564:1; 565:1; 566:1; 567:1; 568:1; 569:1; 560:1; 561:1; 562:1; 563:1; 564:1; 565:1; 566:1; 567:1; 568:1; 569:1; 570:1; 571:1; 572:1; 573:1; 574:1; 575:1; 576:1; 577:1; 578:1; 579:1; 580:1; 581:1; 582:1; 583:1; 584:1; 585:1; 586:1; 587:1; 588:1; 589:1; 580:1; 581:1; 582:1; 583:1; 584:1; 585:1; 586:1; 587:1; 588:1; 589:1; 590:1; 591:1; 592:1; 593:1; 594:1; 595:1; 596:1; 597:1; 598:1; 599:1; 600:1; 601:1; 602:1; 603:1; 604:1; 605:1; 606:1; 607:1; 608:1; 609:1; 610:1; 611:1; 612:1; 613:1; 614:1; 615:1; 616:1; 617:1; 618:1; 619:1; 620:1; 621:1; 622:1; 623:1; 624:1; 625:1; 626:1; 627:1; 628:1; 629:1; 630:1; 631:1; 632:1; 633:1; 634:1; 635:1; 636:1; 637:1; 638:1; 639:1; 640:1; 641:1; 642:1; 643:1; 644:1; 645:1; 646:1; 647:1; 648:1; 649:1; 650:1; 651:1; 652:1; 653:1; 654:1; 655:1; 656:1; 657:1; 658:1; 659:1; 660:1; 661:1; 662:1; 663:1; 664:1; 665:1; 666:1; 667:1; 668:1; 669:1; 670:1; 671:1; 672:1; 673:1; 674:1; 675:1; 676:1; 677:1; 678:1; 679:1; 680:1; 681:1; 682:1; 683:1; 684:1; 685:1; 686:1; 687:1; 688:1; 689:1; 690:1; 691:1; 692:1; 693:1; 694:1; 695:1; 696:1; 697:1; 698:1; 699:1; 700:1; 701:1; 702:1; 703:1; 704:1; 705:1; 706:1; 707:1; 708:1; 709:1; 710:1; 711:1; 712:1; 713:1; 714:1; 715:1; 716:1; 717:1; 718:1; 719:1; 720:1; 721:1; 722:1; 723:1; 724:1; 725:1; 726:1; 727:1; 728:1; 729:1; 730:1; 731:1; 732:1; 733:1; 734:1; 735:1; 736:1; 737:1; 738:1; 739:1; 740:1; 741:1; 742:1; 743:1; 744:1; 745:1; 746:1; 747:1; 748:1; 749:1; 750:1; 751:1; 752:1; 753:1; 754:1; 755:1; 756:1; 757:1; 758:1; 759:1; 760:1; 761:1; 762:1; 763:1; 764:1; 765:1; 766:1; 767:1; 768:1; 769:1; 770:1; 771:1; 772:1; 773:1; 774:1; 775:1; 776:1; 777:1; 778:1; 779:1; 780:1; 781:1; 782:1; 783:1; 784:1; 785:1; 786:1; 787:1; 788:1; 789:1; 790:1; 791:1; 792:1; 793:1; 794:1; 795:1; 796:1; 797:1; 798:1; 799:1; 800:1; 801:1; 802:1; 803:1; 804:1; 805:1; 806:1; 807:1; 808:1; 809:1; 8010:1; 8011:1; 8012:1; 8013:1; 8014:1; 8015:1; 8016:1; 8017:1; 8018:1; 8019:1; 8020:1; 8021:1; 8022:1; 8023:1; 8024:1; 8025:1; 8026:1; 8027:1; 8028:1; 8029:1; 8030:1; 8031:1; 8032:1; 8033:1; 8034:1; 8035:1; 8036:1; 8037:1; 8038:1; 8039:1; 8040:1; 8041:1; 8042:1; 8043:1; 8044:1; 8045:1; 8046:1; 8047:1; 8048:1; 8049:1; 8050:1; 8051:1; 8052:1; 8053:1; 8054:1; 8055:1; 8056:1; 8057:1; 8058:1; 8059:1; 8060:1; 8061:1; 8062:1; 8063:1; 8064:1; 8065:1; 8066:1; 8067:1; 8068:1; 8069:1; 8070:1; 8071:1; 8072:1; 8073:1; 8074:1; 8075:1; 8076:1; 8077:1; 8078:1; 8079:1; 8080:1; 8081:1; 8082:1; 8083:1; 8084:1 |   |   |

## 10/20/99-Anti-Infective Drugs Advisory Committee: 67th Meeting

Basic Systems Applications

53:25; 54:19; 58:17; 75:13;  
 78:20; 85:10; 89:21; 111:1;  
 123:22; 127:5; 134:16; 191:18;  
 254:3; 260: 19, 22; 289: 72;  
 290:11, 22; 301:9, 15; 302:6,  
 24; 304:18; 313:24; 314:19;  
 315:7; 317:5; 326:13; 333:20;  
 335:8  
**Murray** [24] 5:18; 38:11;  
 53:24; 75:12; 78:19; 85:9;  
 89:20; 110:25; 112:22; 123:21;  
 173:4; 175: 289; 171:29; 170:8;  
 307:6; 312:18; 313:23; 317:4;  
 326:12; 330:14; 332:9; 333:19;  
 335:7, 23  
**mush** [1] 93:8  
**mutants** [1] 211:15  
**mutation** [3] 207:17; 210:17;  
 211:11  
**mutations** [10] 202:23;  
 206:18, 27, 23, 25; 211:1, 3, 8,  
 13; 220:5  
**mycoplasma** [1] 245:21  
**myriad** [1] 90:2  
**myself** [6] 47:6; 63:24; 82:22;  
 136:1; 147:5; 196:14

nK

## - N -

**name** [5] 5:10; 11:4; 39:14;  
 196:10, 24  
**named** [1] 207:6  
**namely** [2] 66:5; 310: 7  
**naphcillin** [2] 133:8, 10  
**naroxyn** [1] 316:10  
**narrow** [1] 798:24  
**narrower** [2] 40:15; 45:3  
**natural** [1] 35:5  
**nature** [3] 19:6; 289:24;  
 320:24  
**NCCLS** [7] 181:16; 183:22;  
 184:4, 16; 205:22; 267:1;  
 310:9  
**nd** [2] 127:14; 324:6  
**NDA** [15] 197:25; 198:5;  
 271:20; 272:19, 25; 274:13;  
 276:16, 27, 24; 278:9; 286:22;  
 287:6, 17, 15; 338:5  
**necrotizing** [4] 248:24;  
 249:14; 250:4; 318:8  
**needs** [22] 27:3; 49:19; 56:25;  
 57:12; 94:5; 95:19; 98:11;  
 103:20; 120:11; 128:16; 150:3;  
 170:5; 222:23; 265:18; 317:22;  
 319:4; 320:22; 326:7, 9;  
 331:11, 75; 335:15  
**Negative** [1] 21:18  
**negatives** [3] 141:5; 207:1;  
 229:15  
**negotiate** [1] 306:6  
**neonate** [3] 73:19; 103:5  
**neonates** [5] 70:21; 73:10, 7:1;  
 113:12, 18  
**nervous** [2] 149:6; 260:5  
**Netherlands** [1] 58:10  
**Network** [1] 215:24  
**neutropenia** [2] 42:16; 142:7  
**neutropenic** [8] 59:22, 23, 25;  
 102:23; 141:9, 18; 218:13, 2:1  
**Newborns** [1] 71:17  
**newer** [1] 50:13

**Newport** [1] 258:13  
**nice**[7] 27:8; 38:10; 73:14;  
 78:4; 24; 322:25; 326:24;  
 327:10  
**nicely** [1] 257:21  
**nichere** [1] 240:5  
**Nightingale** [1] 208:6  
**NIH**[4:6:11; 87:12; 100:22;  
 167:12  
**nine** [3] 189:2, 27; 282:25  
**nodes** [1] 192:8  
**noise** [1] 78:11  
**nomenclature** [1] 171:8  
**non** [1] 240:5  
**noln-bacterial** [1] 14:3  
**nan-coag**[1] 102:3  
**nan-IND** [1] 280:25  
**non-inferiority** [6] 40:3; 41:5;  
 42:7; 46:12; 93:4, 6  
**ncm-neutropenic**[1] 125:16  
**ncm-penicillin** [1] 254:25  
**ncn-sterile** [3] 153:2; 180:19;  
 191:2  
**ndn-tunneled** [1] 14:22  
**nonblood**[1] 86:10  
**noncoagulase** [1] 101:13  
 >noncomparative [9] 231:9,  
 14; 241:8; 273:10, 23; 274:7;  
 276:6; 277:8, 20  
**noncompetitive**[1] 231:3  
**Nonetheless** [1] 299:12  
**nonethetess** [2] 63:7; 290:25  
**ndnevaluable** [5] 281:25;  
 282:5; 285:8, 13; 286:4  
**nonspecific** [4] 30:19; 78:22;  
 25; 80:2  
**nonstandardized** [1] 76:7  
**nonsusceptible** [8] 169:17;  
 170:4, 6; 181:1; 184:3; 191:7,  
 9; 333:22  
**nontraditional** [1] 76:3  
**nontreated** [1] 38:22  
**NORDEN** [28] 6:17; 10:13;  
 27:8, 11, 27; 37:5; 120:20;  
 121:1, 5, 11, 78; 141:25;  
 143:10; 167:17; 192:3, 10;  
 256:13; 257:15; 259:14, 23;  
 260:2; 266: 7, 7; 267: 7; 1; 296:9;  
 318:16, 24; 319:2; 330:1  
**Norden** [14] 6:17; 10:11; 27:7;  
 28:18; 37:4; 38:1; 141:24;  
 165:1; 166:2; 167:17; 256:12;  
 261:4; 266:13; 329:25  
**normal** [8] 71:18; 116:19;  
 218:14, 25; 219:6, 17; 224:22;  
 332:6  
**normally** [2] 36:12; 266:5  
**North** [2] 221:13; 247:9  
**Norway** [1] 181:5  
**nosocomial** [2] 222:14, 76  
**note** [4] 11:19; 165:7; 185:1:1;  
 284:12  
**noted** [4] 8:3; 13:1; 166:14;  
 216:17  
**notice** [2] 35:9; 298:12  
**noticed** [4] 35: 17; 53:3;  
 197:24; 198:22  
**notwithstanding** [1] 165:17  
**novelty** [1] 221:5  
**nowadays** [1] 98:12  
**nuances** [2] 84:14, 78

**numbers** [30] 114:1, 25;  
 122:16; 161:14; 172:21;  
 177:12; 179:10; 181:9, 10;  
 182:3; 187:15, 23; 193:13;  
 209:2; 215:2; 227:11; 268:9;  
 279:4; 284:22; 288: 7; 289: 73,  
 25; 290:9; 291:20; 294: 7 9;  
 302:25; 307:20; 310:5; 326:1  
**numerai** [1] 95:22  
**numerical** [1] 272:16

- O -

**o'clock** [5] 67:22; 163:12, 75,  
 16; 338:8  
**O'FALLON** [11] 5:25; 156:17;  
 16:7; 1; 194:4; 252: 7; 302: 18;  
 303:17, 20; 317:8, 13; 333:14  
**O'Fallon**[1] 326:11  
**O'Fallon** [9] 5:25; 156:16;  
 167:1; 194:3; 252:11; 268:12;  
 317:7; 333:13; 335:25  
**object** [1] 331:1  
**objective** [8] 31:13; 79:11, 77;  
 80:4, 5; 158:20; 162:22; 267:8  
**objectively**[1] 166:1  
**obligation**[1] 227:21  
**obligatory**[1] 11:1  
**obliged** [1] 297:10  
**observation** [5] 31:14; 44:10;  
 137:2; 247:5; 268:13  
**observations**[3] 79: 12;  
 201:4; 244:10  
**observe** [1] 225:6  
**observed** [7] 79:14; 276:11;  
 284:20; 286:8, 25; 287:17  
**obtain** [3] 30:8; 159:20;  
 232:19  
**obtained** [12] 20:9, 14, 76, 19;  
 23:21:10; 60:18; 95:17;  
 97:23; 98:2; 148: 14; 165:4  
**obtaining** [1] 15:8  
**obvious** [5] 56:22; 95:12;  
 259: 17, 24; 260:6  
**Obviously** [3] 57:14; 60:6;  
 215:12  
**obviously** [ 14] 35: 74; 61:3;  
 63:21; 71:14; 75:19; 103:4;  
 104:18; 123:13; 256:24, 25;  
 260:3, 6; 299:15; 323:5  
**occasion**[1] 306:4  
**occur** [16] 12:24; 21:4, 22;  
 161:4; 184:1, 9; 187:9; 191:8;  
 206:25; 240:20; 241:13;  
 243:15; 279:19; 281:2; 305:2  
**occurred** [9] 68:6; 182:12;  
 183:2; 185:3; 232:23; 233:7;  
 242:8; 280:10, 75  
**occurring** [2] 188:6; 247:24  
**occurs** [2] 191:14; 219:7  
**October** [1] 338:11  
**odds**[4] 183:14, 23; 267:19;  
 268:7  
**offer** [2] 169:14; 170:19  
**Office** [4] 8:15; 24:7; 165:5;  
 168:6  
**office** [2] 9:4; 201:1  
**Officer** [3] 167:24; 269:25;  
 270:3  
**officer** [4] 7:2; 7 1:5; 240:9;  
 261:13

213:13  
**osteomyelitis** [5] 18:16; 21:9;  
 37:12; 143:22; 149:13  
**otitis** [2] 294:24; 295:17  
**ought** [6] 37:22; 173:10;  
 291:11; 320:7; 323:6; 327:25  
**ours** [1] 308:22  
**ourselves** [1] 311:16  
**out-patient** [2] 170:7; 259:8  
**outbreak** [12] 188:4, 7, 74, 75,  
 77; 189:2, 6, 24; 190:10, 13;  
 191:13; 217:4  
**outbreaks** [1] 189:12  
**outcome** [16] 41:20; 67:10;  
 69:7; 122:2; 123:13; 128:16;  
 134:20; 142:5; 181:14; 182:20;  
 195:5; 238:7; 239:2; 267:16;  
 281:11; 320:10  
**outcomes** [12] 22:13, 75;  
 28:7; 67:9, 77; 69:7; 94:10, 18;  
 95:2; 174:14; 235:21; 237:24  
**outgrowth** [1] 8:14  
**outlier** [1] 192:15  
**outlined** [3] 15:12; 158:15;  
 331:21  
**outside** [2] 82:2; 289:21  
**outweigh** [2] 112:4, 5  
**Overall** [3] 190:10; 217:6;  
 307:20  
**overall** [9] 39:19; 156:15;  
 772:24; 778:24; 246:17;  
 258:21; 277:25; 300:20;  
 303:24  
**overdo** [1] 33:7  
**overkill** [1] 44:4  
**overlap** [1] 304:22  
**overlapping** [1] 207:7  
**overlook** [1] 25:7  
**overlooking** [1] 24:18  
**overly** [1] 169:21  
**oversee** [1] 87:14  
**oversees** [1] 87:12  
**overuse** [6] 168:24; 169:5;  
 171:7, 72; 188:3; 326:18  
**overview** [3] 14:5; 199:11;  
 202:19  
**overwhelmed** [1] 252:13  
**overwhelming** [3] 187:20;  
 221:23; 225:19  
**owing** [5] 160:22; 225:9;  
 226:21; 294:8; 329:23

**- P -**

**p.m.** [6] 163:17, 78; 164:2;  
 269:19, 20; 338:9  
**PA** [1] 31:15  
**pace** [1] 41:1  
**package** [12] 122:12; 123:16;  
 224:19; 264:15; 268:25; 304:5;  
 310:13, 14, 24; 313:22;  
 324:19; 329:8  
**PAE** [1] 203:22  
**page** [5] 35:18; 48:3; 95:22;  
 96:22; 304:7  
**Pallares** [1] 181:21  
**Pan** [1] 204:22  
**pan** [1] 176:22  
**panel** [5] 44:17; 58:6; 176:9,  
 24; 186:21  
**panels** [1] 186:17

**paper** [8] 26:17, 79, 24;  
 184:23; 185:1; 194:10; 215:22;  
 216:16  
**Papua** [1] 220:23  
**paradigm** [1] 1:1:25  
**parallel** [1] 206:16  
**paralleled** [1] 205:16  
**parallels** [1] 58:4  
**parameter** [1] 137:10  
**parameters** [3] 33:15; 134:11;  
 208:11  
**parapsoriasis** [1] 48:15  
**parC** [6] 206:24; 210:14, 20;  
 211:4, 6, 9  
**parcel** [2] 129:4; 240:6  
**pardon** [1] 251:19  
**parE** [4] 206:24; 210:14;  
 211:4, 8  
**parenthetical** [1] 271:5  
**Parklawn** [1] 165:6  
**PARSONNET** [14] 6:15; 10:9;  
 32:13; 75:7, 93:2; 126:18;  
 127:11; 167:15; 290:2, 6;  
 318:15; 321:17; 330:11; 334:3  
**Parsonnet** [10] 6:15; 10:6;  
 32:12; 35:17; 93:1; 126:17;  
 165:2; 167:15; 321:16; 330:10  
**Part** [3] 94:5; 253:20; 321:2  
**part** [31] 7:10; 44:17; 50:4;  
 53:7; 66:7, 25; 69:10; 76:22;  
 86:7; 117:20; 118:8; 123:20;  
 125:9; 129:4; 153:6, 20;  
 164:10; 202:6; 225:10; 240:6;  
 242:20; 253:19; 278:13; 300:9;  
 303:20; 307:4; 320:24; 326:74;  
 333:12; 334:13, 14  
**PARTICIPANT** [2] 95:20;  
 792:78  
**participant** [3] 7:25; 166:17;  
 329:2  
**participants** [11] 7:15; 8:1, 4;  
 129:21; 164:15, 18; 165:24;  
 166:12, 75; 171:24; 172:1  
**participate** [1] 165:7  
**participated** [1] 166:5  
**participating** [3] 7:22; 164:22;  
 773:23  
**participation** [1] 165:25  
**party** [1] 113:5  
**Pass** [1] 317:12  
**pass** [3] 43:16, 27; 317:13  
**passaged** [1] 210:2  
**passages** [2] 207:16; 210:1  
**passing** [1] 44:25  
**Pathogen** [1] 171:19  
**pathogen** [6] 12:17; 82:6;  
 97:7; 774:4; 245:10; 256:1  
**pathogenesis** [7] 81:24;  
 82:20; 83:10, 20; 84:9, 12;  
 99:13  
**pathogenic** [4] 57:19; 131:9;  
 221:20; 253:25  
**Pathogens** [2] 168:4; 270:4  
**pathogens** [9] 13:5; 18:6;  
 19:2; 21:8; 61:4, 75, 76;  
 222:14; 327:12  
**pathomneumonic** [1] 13:18  
**Patients** [2] 18:10; 21:21  
**pattern** [3] 86:19; 173:13;  
 304:14  
**patterns** [2] 306:3; 307:10

**PBPs** [2] 204:6; 206:13  
**PCO2** [7] 78:1, 4, 75; 79:17;  
 80:11, 22; 81:2  
**PCO2s** [1] 79:9  
**PD** [3] 172:14; 292:3; 313:13  
**PDR** [1] 264:15  
**Peak** [1] 208:20  
**peak** [3] 209:8; 228:9; 242:25  
**Pediatric** [1] 6:22  
**pediatric** [6] 14:2; 35:12;  
 70:20; 73:8; 233:7; 335:14  
**pediatricians** [1] 295:16  
**Pediatrics** [1] 5:24  
**pediatrics** [4] 35:23; 71:14;  
 73:9; 74:4  
**pelvises** [1] 240:10  
**pen** [3] 232:25; 318:7, 8  
**pending** [1] 332:3  
**penetration** [2] 166:7; 249:19  
**Penicillin** [3] 180:2; 191:4;  
 263:15  
**penicillin-resistant** [5] 169:4;  
 770; 70; 177:24; 778:7; 779:4  
**penicillin-resistant** [1] 169:24  
**Penicillins** [2] 204:4; 206:10  
**penicillins** [6] 169:13; 206:8;  
 77; 222:2; 235:4; 241:3  
**percentage** [6] 133:14;  
 221:23; 223:6; 233:9; 258:24;  
 261:6  
**percutaneous** [1] 89:12  
**percutaneously** [5] 56:21;  
 61:21; 82:4; 83:2; 89:3  
**perfect** [3] 62:18; 67:5;  
 263:74  
**perfectly** [7] 37:74; 66:7;  
 151:16, 23; 159:25; 160:3;  
 263:71  
**perform** [4] 52:13; 289:7;  
 305:24; 334:7  
**performed** [3] 20:2; 226:77;  
 335:7  
**pericarditis** [1] 250:6  
**period** [5] 132:24; 157:17;  
 179:17; 221:14; 262:14;  
 329:24  
**Peripheral** [1] 20:15  
**peripherally** [5] 14:25; 95:77;  
 97:5; 151:7; 159:21  
**peripherals** [1] 115:15  
**peritoneal** [1] 15:5  
**permanent** [2] 145:6; 152:22  
**perpetuity** [1] 310:22  
**persisted** [1] 190:3  
**Persistent** [1] 22:3  
**persistent** [1] 155:10  
**person** [10] 10:6, 14; 103:5;  
 138:19; 155:6; 248:13; 253:6;  
 263:9; 264:20; 321:3  
**personal** [4] 63:24; 70:10;  
 120:5; 255:21  
**Personally** [1] 38:7  
**personally** [2] 266:7; 1; 327:23  
**personnel** [2] 175:12, 79  
**persons** [6] 175:6; 180:7, 8,  
 17; 187:6; 192:7  
**perspective** [12] 11:11;  
 24:19; 44:1; 45:24; 215:25;  
 244:21; 297:21; 305:13;  
 311:19; 319:25; 320:19; 337:4  
**Peter** [2] 203:15; 209:23

**PFGE** [1] 18:1  
**phagocytize** [1] 227:22  
**Pharmaceutical** [3] 171:25;  
 173:2; 196:72  
**pharmaceutical** [8] 76:75;  
 124:20; 168:19; 170:24; 297:6;  
 298:1; 300:4, 10  
**Pharmaceuticals** [1] 213:13  
**pharmacodynamic** [3]  
 201:10; 208:12; 219:2  
**pharmacodynamics** [3] 19:3;  
 225:3; 238:23  
**pharmacokinetic** [6] 166:6;  
 208:10; 222:22; 224:18;  
 315:19; 319:12  
**pharmacokinetics** [5] 19:2;  
 59:12; 201:10; 219:15; 230:13  
**Pharmacy** [2] 6:3; 167:4  
**Phase** [3] 288:24; 305:22;  
 333:24  
**phase** [1] 88:2  
**phenotypes** [1] 92:9  
**phonetic** [6] 42:15; 61:7;  
 133:8; 146:4; 192:9; 324:16  
**phrase** [4] 271:5; 293:20;  
 294:2; 335:10  
**phrased** [1] 327:3  
**phraseology** [2] 304:25;  
 326:22  
**phrasing** [1] 171:9  
**physician** [8] 54:25; 128:23;  
 193:3, 70; 258:7; 259:13;  
 298:7; 5, 24  
**physicians** [8] 193:4; 261:21;  
 295:7; 296:3; 298:7, 8; 323:7;  
 330:7  
**physiologically** [1] 112:23  
**physiology** [3] 79:21; 80:3;  
 112:7  
**pick** [4] 85:20; 138:13;  
 145:19; 266:1  
**picked** [1] 137:1  
**picking** [3] 84:15, 27, 23  
**picture** [3] 59:13; 298:18;  
 323:9  
**piecemeal** [1] 305:20  
**pieces** [1] 313:21  
**PIS** [1] 325:12  
**PISP** [40] 270:11; 271:3, 22;  
 276:24; 277:14, 23, 25; 278:2,  
 6, 75, 22; 279:1, 6; 281:20;  
 282:2, 8, 14, 23; 283:1, 7, 74,  
 23; 284:7, 76, 19; 285:10, 15,  
 24; 286:2, 3, 74; 287:21;  
 288:20; 289:15; 318:22;  
 319:19; 321:17; 324:11, 25;  
 325:2  
**pivotal** [24] 197:15, 27; 280:5,  
 6, 17, 79; 281:4, 7, 24; 282:4,  
 7, 8, 12, 15; 284:14, 15, 24,  
 25; 285:10, 25; 286:2; 287:19,  
 24; 289:20  
**PK** [3] 172:14; 292:3; 313:13  
**place** [31] 18:14; 20:22; 38:1,  
 18; 65:20; 66:5, 15; 80:11;  
 87:14; 109:3; 138:3, 70; 139:2,  
 18; 140:22; 146:22; 148:11;  
 149:21; 150:21, 23; 151:1;  
 154:18; 160:9; 161:18; 162:9,  
 18, 20, 23; 198:13; 246:14;  
 263:24

|   |  |  |   |
|---|--|--|---|
| placement [2] 87:12, 74<br>placements [1] 87:16<br>places [1] 162:22<br>placing [2] 293:20; 297:25<br>plain[1] 261:8<br>plan [2] 266:2<br>planning [4] 39:21; 46:8;<br>308:21, 24<br>plasma [12] 207:2; 225:18,<br>25; 226:2, 23; 227:7, 9, 14;<br>229:24; 230:14, 16; 301:11<br>plate [13] 60:25; 67: 79, 25;<br>62:5, 10; 63:18; 65:10, 15, 19,<br>25; 66:1, 9; 333:6<br>plausible[2] 66:18; 7 17:3<br>Please [3] 166:25; 260:21;<br>300:15<br>please [15] 39:25; 4 1:2; 42:3,<br>23; 45:12; 46:10; 163:15;<br>197:1; 270:13; 271:8; 272:17;<br>276:3; 287: 74; 286:5, 20<br>plenty [1] 9:17<br>pleural [9] 248:25; 249:15, 79,<br>25; 250:1; 318:6, 9; 335:4;<br>336:13<br>plot [1] 219:3<br>plus [9] 40:23; 49:17; 100:3;<br>251:17; 258:20; 263:25;<br>289:20; 294:21; 313:15<br>pneumo[1 1] 82:6; 221:6;<br>248:19; 252:8; 256:1; 275:21;<br>276:9, 79, 20; 286:12; 287:7<br>pneumococcal [31] 169:4,<br>25; 175:5; 181:15, 20; 182:21;<br>-- 188:9; 225:20; 234:25; 236: 14;<br>237:4, 9; 238: 75; 239: 11;<br>240:2; 244:15; 245:12; 247:7;<br>248:3, 24; 258: 74; 263:7;<br>267:9; 313:15; 315:11; 318:3,<br>9; 319:16; 325:6; 330:12;<br>335:2<br>Pneumococci [1] 222:13<br>pneumococcus [29] 172:25;<br>173:14; 175:10; 178:9; 179:5;<br>189:17; 196:25; 197:13;<br>198:23; 199:14, 16, 21; 222:3;<br>229:12; 232:16; 237:6; 252:24;<br>254:12, 74, 23; 256:16;<br>257:23; 263:8, 19; 267:6;<br>306:19; 313:2; 319:12; 334:18<br>Pneumonia [1] 169:11<br>pneumonias [4] 248:24;<br>249:14; 318:3, 9<br>podium [2] 244:20; 246:22<br>pointed [1] 69:21<br>pointing [3] 48:3; 181:7;<br>262:22<br>points[15] 11:18; 29:8; 31:10,<br>11; 39:20; 47:14; 53:9;<br>130:13; 169:19; 190:19;<br>205:25; 206:4; 247:1; 279:19;<br>296:8<br>polysaccharide [1] 189:7<br>pooled [1] 11:23<br>pooling [1] 12:8<br>poorer [1] 320:10<br>pop [1] 149:13<br>popping [1] 149:24<br>population [47] 14:2; 16:13;<br>22:20, 22; 23:1; 54:3, 12, 14,<br>20; 68:18; 69:6; 72:3; 73:12; <td>75: 79, 24; 78:9; 80: 17; 88:6;<br/>93:25; 103:5; 104:25; 105:4;<br/>151:10, 19 ; 153:21; 155:19,<br/>21; 159:9; 175:4, 5, 8; 177:2,<br/>4, 15; 178:19; 179:3, 23;<br/>178: 17;<br/>216:5; 233:2; 238: 14; 240: 1;<br/>301:16; 305:3; 314:23; 334:19;<br/>335:14<br/>populations [8] 70:12; 74:23;<br/>75:1; 94:17; 124:2; 179:10;<br/>190:25; 281:16<br/>port [1] 54:18<br/>Porta-caths [1] 14:24<br/>portal [1] 34:23<br/>portion [3] 52:21; 270:24;<br/>278: 72<br/>ports [2] 50:10; 107:20<br/>posed[1] 68:8<br/>position [1] 168:15<br/>positives[5] 75:22; 126: 1;<br/>229:12, 16, 2 0<br/>positivity [13] 50:15; 53:13;<br/>103:1 7; 105:17, 23; 107:25;<br/>108:24; 111:19, 24; 112:9;<br/>115:6; 116:25; 117:4<br/>possibility [1o] 37:23; 80:8;<br/>82:12; 116:1, 9, 23; 162:21;<br/>2 7 7: 72; 268: 18; 324:4<br/>post[28] 21:5, 10; 27:14;<br/>90:1; 92:21; 93:7, 19; 127:25;<br/>129:6; 189:23; 190:13; 203:19;<br/>237: 12; 243:9, 7 5, 23; 244:6;<br/>247:23; 259:18; 279:17;<br/>280:10, 13, 14, 16; 281:1, 3, 9<br/>poster [1] 219:25<br/>postulates [1] 107:15<br/>potassium [1] 116:16<br/>potassiums [1] 7 16:79<br/>potential[17] 19:25; 20: 74;<br/>24:18; 25:1; 43:12; 70:1, 74;<br/>96:5; 114:16; 164:18; 168:24;<br/>169:5; 171:12; 172:14; 223:11;<br/>327:4; 330:5<br/>potentially [7] 18:17; 42:2;<br/>45:8; 773: 74; 222:3; 303:9;<br/>306:7<br/>practical [7] 29:16; 37:10;<br/>39:21; 40:19, 21; 41:24; 111:6<br/>practicalities [1] 27:24<br/>practicality [1] 44:5<br/>practically [1] 27:22<br/>practice [8] 41:19; 58:10;<br/>131:13; 142:15; 147:16;<br/>255:22; 257:8; 261:7<br/>practicing [2] 143:11; 244:124<br/>practitioner [2] 256:8; 261:13<br/>practitioners [1] 325:4<br/>pragmatist [1] 84:8<br/>pre-study[3] 283:17, 22, 24<br/>preaching [1] 84:5<br/>precedents [2] 122:21;<br/>332:15<br/>precise [1] 112:19<br/>precisely [1] 269:1<br/>preclinical [4] 172:14; 202:9;<br/>292:3; 313:13<br/>preclude [2] 7:11; 164:11<br/>precluded [1] 266:24<br/>predicament [1] 168:22<br/>predicated [1] 229:7 <td>predict [6] 67:10; 122:1;<br/>219:16; 225:2; 239:22; 304:20<br/>predicted [4] 219:21; 230:20;<br/>238:22; 239:6<br/>predicting [1] 203:9<br/>predictions [1] 220:17<br/>predictive [6] 51:17, 24; 52:4,<br/>6; 57:15; 107:2<br/>predictor [2] 89:19; 185:23<br/>predictors [1] 185:21<br/>prefer [1] 330:4<br/>preferable [1] 98:77<br/>preference [2] 264:1; 321:23<br/>preferential [1] 205: 1/<br/>preferred [2] 15:19; 19:8<br/>preliminary [1] 187:2<br/>premature [5] 73:11, 79;<br/>113:12, 77<br/>prematures [2] 70:21; 71:7<br/>premise [1] 47:16<br/>prepared [1] 39:17<br/>prescribed [1] 295:19<br/>prescriber [1] 325:25<br/>prescribing [5] 193:3, 5;<br/>298:24; 329: 1; 332:25<br/>prescriptions [4] 217:15;<br/>243:6; 244:7; 316:11<br/>presence [6] 183:5; 211:21;<br/>212:1, 2; 254:11, 72<br/>present [26] 10:2; 23:12, 17;<br/>32:17; 158:21; 164:18; 166:21;<br/>171:20; 182:9; 187:25; 196:19;<br/>200:2, 8, 25; 209:5; 212:5;<br/>284:20; 285: 7; 286:6; 29:1:8;<br/>296: 1 7, 75; 297: 78; 308:20;<br/>313:2; 330:7<br/>presentation [28] 10:25;<br/>24:12; 27:9; 39:23; 46:23;<br/>96:15; 192:2; 195:25; 196:4;<br/>199:9; 201:16; 202:7; 220:1;<br/>247:2; 248:1 1; 249:5, 72;<br/>250:3; 267:12; 269:11, 13, 76,<br/>24; 270:5, 10, 14; 288:3, 9<br/>presentations [2] 39:10;<br/>248:9<br/>presented [20] 29:9; 50:16;<br/>101:12; 161:8; 172:7; 212:6;<br/>230:24; 257:20, 2 7; 260: 17;<br/>268:6, 9; 276:5; 293:6; 294:23;<br/>310:6; 313:13, 14, 76; 324:22<br/>presenting [5] 11:6; 208:15;<br/>210:4; 235:13; 270:5<br/>preserve [1] 335:11<br/>preset [1] 125:4<br/>President [1] 196:11<br/>press [1] 182:6<br/>pressors [1 ] 233:20<br/>pressure [5] 36:6; 71:16;<br/>148:3; 233: 19; 250: 76<br/>presumably [1] 148:19<br/>presumed [2] 158:14; 275:6<br/>presumption [1] 320: 7 1<br/>pretty[11] 75:11; 78:21;<br/>79:13; 104:1; 179:22; 189:10;<br/>223:19; 238:8; 241:16, 19;<br/>279:5<br/>prevalence [ 15] 178:24;<br/>179:4; 180:1, 6, 21; 181:1, 5;<br/>183:25; 185:2, 6, 10, 78;<br/>187:11; 190:23; 327:15<br/>prevent [2] 37:21; 337:20 <td>prevented [1] 38:22<br/>preventing [2] 63:20; 337:12<br/>Prevention [1] 168:14<br/>previous [9] 8:6; 13:19; 46:7;<br/>166:17; 205:19; 213:11; 232:2;<br/>294:8; 304:2<br/>previously [6] 127:16; 166:2,<br/>5; 214:21; 248:25; 326:8<br/>PRI [5] 196:14; 197:6; 200:5;<br/>270: 75; 289:22<br/>primacy [2] 97:13; 150:4<br/>primam[1] 240:4<br/>primarily [4] 135:17; 240:25;<br/>241:3; 244:4<br/>primary [15] 12:15; 22:11;<br/>34:12; 99:18; 100:1, 6; 103:2;<br/>115:11; 154:1, 4; 204:9, 12,<br/>20; 205:7; 206:10<br/>prime [2] 65:21; 88:10<br/>principle [1] 40:7<br/>print [1] 128:16<br/>prior [4] 11:16; 217:17;<br/>242: 7 1; 283:20<br/>priori [1] 115:1<br/>prioritize [1] 127:3<br/>probability [5] 44:17; 51:21;<br/>88:14; 239:2; 324:4<br/>probable [9] 50:1, 3; 53:10,<br/>14; 117:13, 77; 118:3, 7;<br/>126:25<br/>problem [25] 55:19; 65:7;<br/>91:20; 92:8; 104:14; 105:6;<br/>108:2; 115:2; 138:18; 145:18;<br/>151:9; 177:6; 193:10; 194:2;<br/>246:10; 252:15; 298:21; 301:8;<br/>302:23; 305: 72; 306:5; 307:9;<br/>314:7; 316:17; 319:15<br/>problems [1o] 12:7; 13:19;<br/>35:3; 70:9; 79:1; 80:21;<br/>178: 15; 188:2; 298:25<br/>procedures [1] 318:6<br/>proceed [2] 298:16; 328:22<br/>process [3] 8:17; 169:2;<br/>198:5<br/>produce [1] 275:9<br/>produced [1] 201:15<br/>product [14] 7:18; 9:24; 70:5;<br/>102:21; 123:2; 247:25; 288:19;<br/>298:5, 6, 7; 322:19; 328:14;<br/>332:11, 14<br/>Products [7] 7:5; 8:15; 11:6,<br/>77; 13:13; 171:20; 270:4<br/>products [9] 7.79, 24; 8:7, 25;<br/>9:5; 165:12; 166:10, 78; 291:4<br/>professional [ 1] 329:3<br/>professionals [1] 337: 19<br/>Professor [2] 200:23; 201:18<br/>professor [2] 47:8; 201:8<br/>profile [a] 200:18; 222:22;<br/>223:15; 243:9; 244:3, 6, 72;<br/>247:20<br/>profiles [3] 88:11, 21; 208:12<br/>progenitor [1] 229:1<br/>program [8] 197:6, 23; 198:2,<br/>27; 199:6; 200:3, 7; 306:1<br/>prolong [1] 171:2<br/>prolongation [3] 242:9, 17;<br/>243:3<br/>prolonged [1] 21:6<br/>prominent [1] 212:16<br/>promote [7] 193:23; 322:10;</td> </td></td> | 75: 79, 24; 78:9; 80: 17; 88:6;<br>93:25; 103:5; 104:25; 105:4;<br>151:10, 19 ; 153:21; 155:19,<br>21; 159:9; 175:4, 5, 8; 177:2,<br>4, 15; 178:19; 179:3, 23;<br>178: 17;<br>216:5; 233:2; 238: 14; 240: 1;<br>301:16; 305:3; 314:23; 334:19;<br>335:14<br>populations [8] 70:12; 74:23;<br>75:1; 94:17; 124:2; 179:10;<br>190:25; 281:16<br>port [1] 54:18<br>Porta-caths [1] 14:24<br>portal [1] 34:23<br>portion [3] 52:21; 270:24;<br>278: 72<br>ports [2] 50:10; 107:20<br>posed[1] 68:8<br>position [1] 168:15<br>positives[5] 75:22; 126: 1;<br>229:12, 16, 2 0<br>positivity [13] 50:15; 53:13;<br>103:1 7; 105:17, 23; 107:25;<br>108:24; 111:19, 24; 112:9;<br>115:6; 116:25; 117:4<br>possibility [1o] 37:23; 80:8;<br>82:12; 116:1, 9, 23; 162:21;<br>2 7 7: 72; 268: 18; 324:4<br>post[28] 21:5, 10; 27:14;<br>90:1; 92:21; 93:7, 19; 127:25;<br>129:6; 189:23; 190:13; 203:19;<br>237: 12; 243:9, 7 5, 23; 244:6;<br>247:23; 259:18; 279:17;<br>280:10, 13, 14, 16; 281:1, 3, 9<br>poster [1] 219:25<br>postulates [1] 107:15<br>potassium [1] 116:16<br>potassiums [1] 7 16:79<br>potential[17] 19:25; 20: 74;<br>24:18; 25:1; 43:12; 70:1, 74;<br>96:5; 114:16; 164:18; 168:24;<br>169:5; 171:12; 172:14; 223:11;<br>327:4; 330:5<br>potentially [7] 18:17; 42:2;<br>45:8; 773: 74; 222:3; 303:9;<br>306:7<br>practical [7] 29:16; 37:10;<br>39:21; 40:19, 21; 41:24; 111:6<br>practicalities [1] 27:24<br>practicality [1] 44:5<br>practically [1] 27:22<br>practice [8] 41:19; 58:10;<br>131:13; 142:15; 147:16;<br>255:22; 257:8; 261:7<br>practicing [2] 143:11; 244:124<br>practitioner [2] 256:8; 261:13<br>practitioners [1] 325:4<br>pragmatist [1] 84:8<br>pre-study[3] 283:17, 22, 24<br>preaching [1] 84:5<br>precedents [2] 122:21;<br>332:15<br>precise [1] 112:19<br>precisely [1] 269:1<br>preclinical [4] 172:14; 202:9;<br>292:3; 313:13<br>preclude [2] 7:11; 164:11<br>precluded [1] 266:24<br>predicament [1] 168:22<br>predicated [1] 229:7 <td>predict [6] 67:10; 122:1;<br/>219:16; 225:2; 239:22; 304:20<br/>predicted [4] 219:21; 230:20;<br/>238:22; 239:6<br/>predicting [1] 203:9<br/>predictions [1] 220:17<br/>predictive [6] 51:17, 24; 52:4,<br/>6; 57:15; 107:2<br/>predictor [2] 89:19; 185:23<br/>predictors [1] 185:21<br/>prefer [1] 330:4<br/>preferable [1] 98:77<br/>preference [2] 264:1; 321:23<br/>preferential [1] 205: 1/<br/>preferred [2] 15:19; 19:8<br/>preliminary [1] 187:2<br/>premature [5] 73:11, 79;<br/>113:12, 77<br/>prematures [2] 70:21; 71:7<br/>premise [1] 47:16<br/>prepared [1] 39:17<br/>prescribed [1] 295:19<br/>prescriber [1] 325:25<br/>prescribing [5] 193:3, 5;<br/>298:24; 329: 1; 332:25<br/>prescriptions [4] 217:15;<br/>243:6; 244:7; 316:11<br/>presence [6] 183:5; 211:21;<br/>212:1, 2; 254:11, 72<br/>present [26] 10:2; 23:12, 17;<br/>32:17; 158:21; 164:18; 166:21;<br/>171:20; 182:9; 187:25; 196:19;<br/>200:2, 8, 25; 209:5; 212:5;<br/>284:20; 285: 7; 286:6; 29:1:8;<br/>296: 1 7, 75; 297: 78; 308:20;<br/>313:2; 330:7<br/>presentation [28] 10:25;<br/>24:12; 27:9; 39:23; 46:23;<br/>96:15; 192:2; 195:25; 196:4;<br/>199:9; 201:16; 202:7; 220:1;<br/>247:2; 248:1 1; 249:5, 72;<br/>250:3; 267:12; 269:11, 13, 76,<br/>24; 270:5, 10, 14; 288:3, 9<br/>presentations [2] 39:10;<br/>248:9<br/>presented [20] 29:9; 50:16;<br/>101:12; 161:8; 172:7; 212:6;<br/>230:24; 257:20, 2 7; 260: 17;<br/>268:6, 9; 276:5; 293:6; 294:23;<br/>310:6; 313:13, 14, 76; 324:22<br/>presenting [5] 11:6; 208:15;<br/>210:4; 235:13; 270:5<br/>preserve [1] 335:11<br/>preset [1] 125:4<br/>President [1] 196:11<br/>press [1] 182:6<br/>pressors [1 ] 233:20<br/>pressure [5] 36:6; 71:16;<br/>148:3; 233: 19; 250: 76<br/>presumably [1] 148:19<br/>presumed [2] 158:14; 275:6<br/>presumption [1] 320: 7 1<br/>pretty[11] 75:11; 78:21;<br/>79:13; 104:1; 179:22; 189:10;<br/>223:19; 238:8; 241:16, 19;<br/>279:5<br/>prevalence [ 15] 178:24;<br/>179:4; 180:1, 6, 21; 181:1, 5;<br/>183:25; 185:2, 6, 10, 78;<br/>187:11; 190:23; 327:15<br/>prevent [2] 37:21; 337:20 <td>prevented [1] 38:22<br/>preventing [2] 63:20; 337:12<br/>Prevention [1] 168:14<br/>previous [9] 8:6; 13:19; 46:7;<br/>166:17; 205:19; 213:11; 232:2;<br/>294:8; 304:2<br/>previously [6] 127:16; 166:2,<br/>5; 214:21; 248:25; 326:8<br/>PRI [5] 196:14; 197:6; 200:5;<br/>270: 75; 289:22<br/>primacy [2] 97:13; 150:4<br/>primam[1] 240:4<br/>primarily [4] 135:17; 240:25;<br/>241:3; 244:4<br/>primary [15] 12:15; 22:11;<br/>34:12; 99:18; 100:1, 6; 103:2;<br/>115:11; 154:1, 4; 204:9, 12,<br/>20; 205:7; 206:10<br/>prime [2] 65:21; 88:10<br/>principle [1] 40:7<br/>print [1] 128:16<br/>prior [4] 11:16; 217:17;<br/>242: 7 1; 283:20<br/>priori [1] 115:1<br/>prioritize [1] 127:3<br/>probability [5] 44:17; 51:21;<br/>88:14; 239:2; 324:4<br/>probable [9] 50:1, 3; 53:10,<br/>14; 117:13, 77; 118:3, 7;<br/>126:25<br/>problem [25] 55:19; 65:7;<br/>91:20; 92:8; 104:14; 105:6;<br/>108:2; 115:2; 138:18; 145:18;<br/>151:9; 177:6; 193:10; 194:2;<br/>246:10; 252:15; 298:21; 301:8;<br/>302:23; 305: 72; 306:5; 307:9;<br/>314:7; 316:17; 319:15<br/>problems [1o] 12:7; 13:19;<br/>35:3; 70:9; 79:1; 80:21;<br/>178: 15; 188:2; 298:25<br/>procedures [1] 318:6<br/>proceed [2] 298:16; 328:22<br/>process [3] 8:17; 169:2;<br/>198:5<br/>produce [1] 275:9<br/>produced [1] 201:15<br/>product [14] 7:18; 9:24; 70:5;<br/>102:21; 123:2; 247:25; 288:19;<br/>298:5, 6, 7; 322:19; 328:14;<br/>332:11, 14<br/>Products [7] 7:5; 8:15; 11:6,<br/>77; 13:13; 171:20; 270:4<br/>products [9] 7.79, 24; 8:7, 25;<br/>9:5; 165:12; 166:10, 78; 291:4<br/>professional [ 1] 329:3<br/>professionals [1] 337: 19<br/>Professor [2] 200:23; 201:18<br/>professor [2] 47:8; 201:8<br/>profile [a] 200:18; 222:22;<br/>223:15; 243:9; 244:3, 6, 72;<br/>247:20<br/>profiles [3] 88:11, 21; 208:12<br/>progenitor [1] 229:1<br/>program [8] 197:6, 23; 198:2,<br/>27; 199:6; 200:3, 7; 306:1<br/>prolong [1] 171:2<br/>prolongation [3] 242:9, 17;<br/>243:3<br/>prolonged [1] 21:6<br/>prominent [1] 212:16<br/>promote [7] 193:23; 322:10;</td> </td> | predict [6] 67:10; 122:1;<br>219:16; 225:2; 239:22; 304:20<br>predicted [4] 219:21; 230:20;<br>238:22; 239:6<br>predicting [1] 203:9<br>predictions [1] 220:17<br>predictive [6] 51:17, 24; 52:4,<br>6; 57:15; 107:2<br>predictor [2] 89:19; 185:23<br>predictors [1] 185:21<br>prefer [1] 330:4<br>preferable [1] 98:77<br>preference [2] 264:1; 321:23<br>preferential [1] 205: 1/<br>preferred [2] 15:19; 19:8<br>preliminary [1] 187:2<br>premature [5] 73:11, 79;<br>113:12, 77<br>prematures [2] 70:21; 71:7<br>premise [1] 47:16<br>prepared [1] 39:17<br>prescribed [1] 295:19<br>prescriber [1] 325:25<br>prescribing [5] 193:3, 5;<br>298:24; 329: 1; 332:25<br>prescriptions [4] 217:15;<br>243:6; 244:7; 316:11<br>presence [6] 183:5; 211:21;<br>212:1, 2; 254:11, 72<br>present [26] 10:2; 23:12, 17;<br>32:17; 158:21; 164:18; 166:21;<br>171:20; 182:9; 187:25; 196:19;<br>200:2, 8, 25; 209:5; 212:5;<br>284:20; 285: 7; 286:6; 29:1:8;<br>296: 1 7, 75; 297: 78; 308:20;<br>313:2; 330:7<br>presentation [28] 10:25;<br>24:12; 27:9; 39:23; 46:23;<br>96:15; 192:2; 195:25; 196:4;<br>199:9; 201:16; 202:7; 220:1;<br>247:2; 248:1 1; 249:5, 72;<br>250:3; 267:12; 269:11, 13, 76,<br>24; 270:5, 10, 14; 288:3, 9<br>presentations [2] 39:10;<br>248:9<br>presented [20] 29:9; 50:16;<br>101:12; 161:8; 172:7; 212:6;<br>230:24; 257:20, 2 7; 260: 17;<br>268:6, 9; 276:5; 293:6; 294:23;<br>310:6; 313:13, 14, 76; 324:22<br>presenting [5] 11:6; 208:15;<br>210:4; 235:13; 270:5<br>preserve [1] 335:11<br>preset [1] 125:4<br>President [1] 196:11<br>press [1] 182:6<br>pressors [1 ] 233:20<br>pressure [5] 36:6; 71:16;<br>148:3; 233: 19; 250: 76<br>presumably [1] 148:19<br>presumed [2] 158:14; 275:6<br>presumption [1] 320: 7 1<br>pretty[11] 75:11; 78:21;<br>79:13; 104:1; 179:22; 189:10;<br>223:19; 238:8; 241:16, 19;<br>279:5<br>prevalence [ 15] 178:24;<br>179:4; 180:1, 6, 21; 181:1, 5;<br>183:25; 185:2, 6, 10, 78;<br>187:11; 190:23; 327:15<br>prevent [2] 37:21; 337:20 <td>prevented [1] 38:22<br/>preventing [2] 63:20; 337:12<br/>Prevention [1] 168:14<br/>previous [9] 8:6; 13:19; 46:7;<br/>166:17; 205:19; 213:11; 232:2;<br/>294:8; 304:2<br/>previously [6] 127:16; 166:2,<br/>5; 214:21; 248:25; 326:8<br/>PRI [5] 196:14; 197:6; 200:5;<br/>270: 75; 289:22<br/>primacy [2] 97:13; 150:4<br/>primam[1] 240:4<br/>primarily [4] 135:17; 240:25;<br/>241:3; 244:4<br/>primary [15] 12:15; 22:11;<br/>34:12; 99:18; 100:1, 6; 103:2;<br/>115:11; 154:1, 4; 204:9, 12,<br/>20; 205:7; 206:10<br/>prime [2] 65:21; 88:10<br/>principle [1] 40:7<br/>print [1] 128:16<br/>prior [4] 11:16; 217:17;<br/>242: 7 1; 283:20<br/>priori [1] 115:1<br/>prioritize [1] 127:3<br/>probability [5] 44:17; 51:21;<br/>88:14; 239:2; 324:4<br/>probable [9] 50:1, 3; 53:10,<br/>14; 117:13, 77; 118:3, 7;<br/>126:25<br/>problem [25] 55:19; 65:7;<br/>91:20; 92:8; 104:14; 105:6;<br/>108:2; 115:2; 138:18; 145:18;<br/>151:9; 177:6; 193:10; 194:2;<br/>246:10; 252:15; 298:21; 301:8;<br/>302:23; 305: 72; 306:5; 307:9;<br/>314:7; 316:17; 319:15<br/>problems [1o] 12:7; 13:19;<br/>35:3; 70:9; 79:1; 80:21;<br/>178: 15; 188:2; 298:25<br/>procedures [1] 318:6<br/>proceed [2] 298:16; 328:22<br/>process [3] 8:17; 169:2;<br/>198:5<br/>produce [1] 275:9<br/>produced [1] 201:15<br/>product [14] 7:18; 9:24; 70:5;<br/>102:21; 123:2; 247:25; 288:19;<br/>298:5, 6, 7; 322:19; 328:14;<br/>332:11, 14<br/>Products [7] 7:5; 8:15; 11:6,<br/>77; 13:13; 171:20; 270:4<br/>products [9] 7.79, 24; 8:7, 25;<br/>9:5; 165:12; 166:10, 78; 291:4<br/>professional [ 1] 329:3<br/>professionals [1] 337: 19<br/>Professor [2] 200:23; 201:18<br/>professor [2] 47:8; 201:8<br/>profile [a] 200:18; 222:22;<br/>223:15; 243:9; 244:3, 6, 72;<br/>247:20<br/>profiles [3] 88:11, 21; 208:12<br/>progenitor [1] 229:1<br/>program [8] 197:6, 23; 198:2,<br/>27; 199:6; 200:3, 7; 306:1<br/>prolong [1] 171:2<br/>prolongation [3] 242:9, 17;<br/>243:3<br/>prolonged [1] 21:6<br/>prominent [1] 212:16<br/>promote [7] 193:23; 322:10;</td> | prevented [1] 38:22<br>preventing [2] 63:20; 337:12<br>Prevention [1] 168:14<br>previous [9] 8:6; 13:19; 46:7;<br>166:17; 205:19; 213:11; 232:2;<br>294:8; 304:2<br>previously [6] 127:16; 166:2,<br>5; 214:21; 248:25; 326:8<br>PRI [5] 196:14; 197:6; 200:5;<br>270: 75; 289:22<br>primacy [2] 97:13; 150:4<br>primam[1] 240:4<br>primarily [4] 135:17; 240:25;<br>241:3; 244:4<br>primary [15] 12:15; 22:11;<br>34:12; 99:18; 100:1, 6; 103:2;<br>115:11; 154:1, 4; 204:9, 12,<br>20; 205:7; 206:10<br>prime [2] 65:21; 88:10<br>principle [1] 40:7<br>print [1] 128:16<br>prior [4] 11:16; 217:17;<br>242: 7 1; 283:20<br>priori [1] 115:1<br>prioritize [1] 127:3<br>probability [5] 44:17; 51:21;<br>88:14; 239:2; 324:4<br>probable [9] 50:1, 3; 53:10,<br>14; 117:13, 77; 118:3, 7;<br>126:25<br>problem [25] 55:19; 65:7;<br>91:20; 92:8; 104:14; 105:6;<br>108:2; 115:2; 138:18; 145:18;<br>151:9; 177:6; 193:10; 194:2;<br>246:10; 252:15; 298:21; 301:8;<br>302:23; 305: 72; 306:5; 307:9;<br>314:7; 316:17; 319:15<br>problems [1o] 12:7; 13:19;<br>35:3; 70:9; 79:1; 80:21;<br>178: 15; 188:2; 298:25<br>procedures [1] 318:6<br>proceed [2] 298:16; 328:22<br>process [3] 8:17; 169:2;<br>198:5<br>produce [1] 275:9<br>produced [1] 201:15<br>product [14] 7:18; 9:24; 70:5;<br>102:21; 123:2; 247:25; 288:19;<br>298:5, 6, 7; 322:19; 328:14;<br>332:11, 14<br>Products [7] 7:5; 8:15; 11:6,<br>77; 13:13; 171:20; 270:4<br>products [9] 7.79, 24; 8:7, 25;<br>9:5; 165:12; 166:10, 78; 291:4<br>professional [ 1] 329:3<br>professionals [1] 337: 19<br>Professor [2] 200:23; 201:18<br>professor [2] 47:8; 201:8<br>profile [a] 200:18; 222:22;<br>223:15; 243:9; 244:3, 6, 72;<br>247:20<br>profiles [3] 88:11, 21; 208:12<br>progenitor [1] 229:1<br>program [8] 197:6, 23; 198:2,<br>27; 199:6; 200:3, 7; 306:1<br>prolong [1] 171:2<br>prolongation [3] 242:9, 17;<br>243:3<br>prolonged [1] 21:6<br>prominent [1] 212:16<br>promote [7] 193:23; 322:10; |
|---|--|--|---|

|   |   |   |
|---|---|---|
| <p>328:14; 332:6, 12, 13; 333:8<br/>promoting [2] 324:5; 327:4<br/>promotion [2] 299:6, 7<br/>promotional [8] 171:10;<br/>297:24; 298:2, 16; 299:4;<br/>322:18; 323:2, 8<br/><b>Proof</b> [1] 223:11<br/>proof [1] 95:5<br/>propagate [1] 140:25<br/>properly [1] 92: 73<br/>proportion [15] 33:11;<br/>176:18, 22, 24; 177:13;<br/>178:19; 184:12; 186:18, 21;<br/>187:4; 193:2, 17; 215:13;<br/>245:14; 268:10<br/>proportionately [1] 193:15<br/>proportions [1] 45:21<br/>proposals [1] 14:8<br/>propose [4] 16:16; 18:8;<br/>262:7; 329:4<br/>proposed [9] 11:13; 14:17;<br/>24:9; 40:7; 170:22; 271:4;<br/>305:12; 317:17; 327:21<br/>prospect [1] 73:1<br/>prospective [6] 50:25; 55:7;<br/>57:4; 82:17; 199:6; 231:9<br/>prospectively [2] 198:4;<br/>242:20<br/>prostheses [1] 114:24<br/>prosthetic [4] 15:4; 18:12;<br/>60:4; 100:17<br/>protein [1] 206: 7 7<br/>proteins [1] 204:6<br/>protocol [9] 18:21; 19:11;<br/>23:1; 27:22; 59:3; 128:12;<br/>148:23; 280:7; 281:2<br/>protocols [1] 231:22<br/>prove [5] 102:23; 134:10;<br/>255:25; 256:9; 326:5<br/>proved [1] 256:7<br/>proven [3] 15:22; 109:5;<br/>237:11<br/>provide [11] 9:19; 13:21;<br/>20:23; 135:24; 170:9; 195:25;<br/>197:3; 272:6; 276:16; 281:16;<br/>298:18<br/>provided [5] 18:21; 173:3;<br/>278:14; 294:16<br/>Providence [1] 244:25<br/>provides [3] 9:23; 39:20;<br/>278:4<br/>PRSP [31] 220:2; 270:11;<br/>271:2, 22; 276:25; 277:13, 27,<br/>25; 278:6, 75, 22, 24; 279:6;<br/>281:20, 22; 282:8, 21; 283:13,<br/>21; 284:4, 74, 79, 24; 285:6,<br/>24; 287:16; 288:14; 289:19;<br/>290:5, 6; 325:2<br/>prudently [1] 296:3<br/>pseudo [1] 116:17<br/>Pseudomonas [5] 12: 71;<br/>101:23; 144:24; 223:3, 6<br/>public [10] 9:13, 15; 168:8,<br/>17; 198:10; 266:21; 300:5;<br/>315:1; 337:14, 7 9<br/>publications [1] 84:11<br/>publicize [1] 322:4<br/>published [20] 9:14; 31:9;<br/>50:25; 55:11; 60:24; 101:12;<br/>104:10; 106:10; 157:14; 163:5;<br/>182:1, 15; 186:9; 204:22, 24;</p> | <p>205:5; 207:11; 208:6; 224:20;<br/>259:7<br/>pudding [1] 223:11<br/>pull [4] 27:16; 18; 28:4, 7<br/>pulled [4] 26:12; 33:18; 136:6;<br/>145:3<br/>pulmonary [3] 227:10;<br/>244:11; 247:15<br/>pulse [32] 17:25; 69:2; 81:17,<br/>23; 82:8, 27; 83:6, 23; 84:9,<br/>76; 85:3, 77, 17; 86:15, 78;<br/>87:2, 17, 21, 24; 90:21, 24;<br/>91:8, 12; 92:20; 98:6, 76;<br/>102:10, 79; 113:17, 21, 22;<br/>115:10<br/>pump [4] 211:18, 79, 22;<br/>212:1<br/>puppies[1] 335:12<br/>purpose [3] 85:20; 90:3;<br/>98:23<br/>purposes [8] 15:9; 77:15;<br/>7:20; 98:15; 99:6; 149:7, 22;<br/>53:16<br/>pursued [1] 268:5<br/>urulence [1] 125:24<br/>urulent [1] 16:24<br/>urview [1] 83:9<br/>push[3] 5:12; 84:11; 260:9<br/>pushing [1] 129:17<br/>puts [1] 66:4<br/>putting [6] 39:17; 70:5; 74:18;<br/>97:22; 298:11; 324:22</p> <p style="text-align: center;"><b>- Q -</b></p> <p>QT [3] 242:9; 17; 243:3<br/>quagmire [1] 7 13:1<br/>qualifications [1] 318:19<br/>qualifier [1] 329:17<br/>qualifies [1] 128:5<br/>quanti [1] 112:20<br/>quantitated [1] 120:23<br/>quantitation [12] 49:19, 22;<br/>56:25; 57:17; 60:12; 105:11;<br/>111:23; 112:8; 114:11; 115:5;<br/>121:2, 7 7<br/>Quantitative [1] 50:21<br/>quantitative [40] 17:9; 48:7,<br/>20; 49:2; 50:6; 53:11, 12;<br/>51:9; 62:23; 65:1; 66:1; 97:4;<br/>99:7, 70; 103:10, 25; 104:20,<br/>23; 105:18; 106:18, 21, 22;<br/>107:5; 108:1, 3, 9, 75; 109:7;<br/>111:8, 20; 112:16; 114:10;<br/>115:3, 7; 117:9, 11, 23, 24, 25<br/>quantity [2] 105:20; 223:1<br/>quarter [1] 178:3<br/>queries [1] 248:13<br/>Question [8] 305:21; 310:13;<br/>312:19; 315:8, 9; 320:24;<br/>333:23; 335:17<br/>questionable [2] 26:25;<br/>317:22<br/>questioning [1] 85:16<br/>Questions [1] 248:14<br/>quick [5] 53:2; 56:5; 75:7;<br/>245:22; 260:20<br/>quickly [5] 105:20; 137:9;<br/>161:11; 257:10; 284:3<br/>quinalone [10] 173:15; 207:4;<br/>210:7; 217:14, 18; 221:25;</p> | <p>235:2; 256:17; 259:3; 262:11<br/>Quinalones [1] 206:21<br/>quinolones [16] 204:3, 7, 10;<br/>206:9; 207:11, 12, 20; 222:2;<br/>227:25; 235:4; 241:2, 25;<br/>257:2; 258:3; 261:12, 14<br/>quindomycin [1] 188:19<br/>Quinton [1] 15:1<br/>quoted [3] 105:10; 224:21;<br/>335:10<br/>quotes [1] 64:19<br/>quoting [1] 131:15</p> <p style="text-align: center;"><b>- R -</b></p> <p>R.W. [4] 171:25; 173:1, 8;<br/>196:12<br/>RAAD[24] 46:25; 47:5; 54:13;<br/>55:4; 56:11, 24; 57:3, 25;<br/>59:21; 60:5, 27; 62:5; 90:5;<br/>107:8; 116:6; 117:4; 118:7;<br/>131:22; 132:12; 140:2; 141:13;<br/>145:22; 157:10; 162:1<br/>Raad[18] 46:23; 47:7; 58:24;<br/>59:15; 60:9; 66:2; 81:20;<br/>82:22; 90:4; 109:17; 114:1;<br/>125:17; 129:24; 131:14; 138:7;<br/>139:22; 142:11; 161:8<br/>race [2] 180:5; 183:4<br/>radical[1] 789:10<br/>raise [2] 36:1; 85:24<br/>raised [12] 28:21; 63:22;<br/>84:18; 85:1, 89: 1; 116:1;<br/>122:16; 221:1; 254:6; 291:19;<br/>296:17; 307:6</p> <p>raises [2] 35:20; 109:17<br/>raising [1] 62:21<br/>random [1] 308:12<br/>randomization [2] 19:19; 24:2<br/>randomized [10] 22:23; 55:7;<br/>1:37:14; 231:2, 14; 267:18;<br/>2:73:2; 277:6, 11; 278:18<br/>randomness [1] 93:13<br/>range [19] 133:24; 179:1;<br/>184:8; 191:7; 192:4, 21;<br/>2:10:23; 211:7, 8, 10; 219:12,<br/>2:1; 230:17; 233:15; 238:8, 25;<br/>2:76:1; 287:3, 8<br/>ranged [6] 208:21, 22, 25;<br/>209:9, 10<br/>ranging[2] 44:14; 68:6<br/>rapid [5] 78:4; 81:5; 208:2;<br/>260:3; 316:6<br/>rapidity [2] 134:17; 137:16<br/>rapidly [5] 203:14; 207:21;<br/>210:7; 256:19; 295:7<br/>rare[3] 258:15; 294:25;<br/>302:22<br/>rarely [1] 73:20<br/>rate (46) 31:13, 74, 75; 33:10,<br/>36:7; 40:14, 16; 41:9, 75, 78;<br/>43:7, 74, 20; 44:18; 45:1, 77,<br/>14, 75, 16, 25; 46:13; 71:17;<br/>77:25; 78:4, 27; 79:8; 81:6;<br/>135:5; 155:2; 161:18, 22;<br/>162:2; 197:20, 21; 229:16;<br/>233:21; 236:2; 237:18; 250:18<br/>253:12;<br/>257:25; 275:12; 285:1; 290:3;<br/>295:6<br/>rates [20] 33:13; 71:18;</p> |
|---|---|---|

186:12; 190:20; 231:24;  
 248:22, 23; 250:20; 255:20, 23  
 Recently [1] 207:3  
 recently [3] 43:4; 217:4; 232:7  
 -recessed [1] 163:18  
 recognition [2] 258:21; 305:8  
 recognize [6] 15:14; 28:1;  
 59:5; 114:9; 199:1; 269:5  
 recognized [3] 26:3; 31:18;  
 66:6  
 Recognizing [1] 60:12  
 recognizing [2] 248: 77;  
 332:24  
 recollection [1] 254:16  
 recommend [5] 15:10; 20:16;  
 131:11; 288:18; 318:21  
 recommendation [2] 13:8, 7 7  
 recommendations [ 14]  
 12:13; 34:5; 135:19; 288:24;  
 289:3, 4; 292:25; 305:22;  
 307:4; 321:18; 323:17; 333:24;  
 335:18, 7 9  
 recommended [4] 18: 1;  
 97:10; 295:3; 309:25  
 recommends [1] 310:8  
 reconvene [3] 163:18; 338:7,  
 10  
 record [13] 5:12; 7:11; 8:3;  
 56:2; 67:24, 25; 111:2; 164:11;  
 166:14; 183:8; 269:19, 20;  
 294: 7 1  
 recorded [2] 5: 74; 146:23  
 records [1] 175:14  
 recover [3] 7 15:21; 139:25;  
 146:15  
 recovering [1] 161:12  
 recovers [1] 126:9  
 recrudescence [2] 281:7, 13  
 rectal [4] 74:6, 8, 10; 120:9  
 recur [2] 133:3  
 recurrence [2] 53:20; 132:2  
 recurs [1] 155:5  
 red [2] 180:9; 225:24  
 redone [3] 71:19; 314:3, 4  
 reduce [3] 42:2; 43:23; 84:1  
 reduced [1] 187:16  
 reducing [1] 171:12  
 reduction [1] 228:24  
 reductions [ 1] 228:22  
 reemphasize [2] 7 79: 76;  
 212:10  
 refer [3] 196:14; 270:10;  
 330:21  
 reference [16] 25:22; 26.5, 6,  
 8, 9, 10, 72, 17; 29:11; 95:17;  
 107:13; 175:17; 183:16, 20;  
 330:12  
 referred [3] 89:16; 213:10;  
 309:8  
 referring [3] 30:3; 282: 7 7;  
 289:25  
 refers [1] 26:19  
 reflect [3] 51:22; 55:23;  
 306:24  
 reflects [4] 127:5; 146:8;  
 195:1; 281:21  
 refresh [1] 290:25  
 regard [9] 7:10; 9:24; 164:10;  
 174:3, 14; 313:3; 323:19, 24;  
 336:17  
 Regarding [2] 131:14; 192:13

regarding [9] 165:9; 169:6;  
 171:8; 222:20; 281:17; 288:24;  
 305:22; 330:3; 333:24  
 regardless [16] 97:7; 148:16;  
 203:17; 214:13; 237:1, 76;  
 241:21; 243:25; 244:16, 77;  
 304:15; 322:11; 326:23; 332:9;  
 333:21; 335:4  
 regards [11] 39:2; 56: 7 7;  
 69:22; 84:19; 125:17; 174:10;  
 272:19; 280:18; 282:24; 288:9;  
 309:25  
 regimen [5] 15:16; 264:19;  
 273:3, 21; 275:24  
 regimens [1] 23:25  
 regiments [1] 137:14  
 Register [2] 9:15; 163:5  
 registration [1] 15:9  
 regression [3] 183:3; 185:21;  
 194:5  
 regrettably [ 1] 236:9  
 regrown [1] 141:21  
 regulated [2] 164:16; 322:2  
 Regulatory [1] 196:11  
 regulatory [6] 11:11; 40:10;  
 44:7; 46:18; 297:20; 337:4  
 reiterate [2] 70:18; 247:1  
 relapse [9] 21:25; 131:25;  
 138:4; 139:12; 145:10, 12, 19 ;  
 161:23; 162:1  
 relapsed [1] 138:4  
 relapses [1] 147:2  
 relapsing [1] 22:3  
 relates [1] 202: 10  
 relating [1] 247:2  
 relation [ 1] 99:14  
 relationship[8] 112: 79;  
 187:12, 14; 227:14; 241:21;  
 243:25; 244:1; 313:7  
 relationships [1] 65:2  
 relative [2] 7 15:5; 227: 74  
 relatively[7] 30:18; 33:11;  
 47:25; 176:25; 193:17; 300:18;  
 316:16  
 release [3] 49:9; 62:12, 76  
 relevance [1] 179:6  
 relevant [3] 45:22; 76:11;  
 83:18  
 reliable [1] 112:17  
 reliably [1] 169:10  
 Reller[18] 5:16; 29:7; 38:16;  
 60:7; 77:22; 86:4; 97:8;  
 111:21; 117:7; 147:12; 157:9;  
 158:12; 164:4; 171:24; 251:10;  
 260:13; 319:18; 321:11  
 reluctant [1] 102:1  
 rely [2] 32:18; 107:24  
 remain [4] 155:4; 177:2;  
 178:6; 199:17  
 remained [3] 214:13, 23;  
 221:24  
 remaining [1] 153:8  
 remains [3] 186:23; 203:3;  
 213:6  
 remarks [3] 292:2; 309:12;  
 336:9  
 remember [8] 116:4; 118:19;  
 172:3; 223:2, 27; 227:2;  
 249:23; 250:9  
 remind[5] 201:23; 248: 1;  
 249:22; 290:12; 335:10

removal [13] 16:9; 18:19;  
 19:16, 22; 22:2; 27:13; 28:11;  
 38:19; 54:16; 128:9; 145:25;  
 147:20; 149:5  
 remove [13] 54:21, 23; 55:17;  
 89:14; 107:22; 108:6; 118:21;  
 144:4; 147:24; 148:4; 149:9;  
 154:22; 155:7  
 removed [45] 19:21; 20:18;  
 37:13; 39:3; 50:11; 52:20;  
 54:24; 55:1, 3, 72; 58:14;  
 60:19; 99:2, 3; 110:21; 111:17;  
 115:4; 120:15; 121:8, 13, 23;  
 122:10, 78; 123:19, 25;  
 124:19, 24; 125:7, 10; 126:24;  
 129:8; 132:1; 147:19; 148:6,  
 73; 149:16;  
 150:7, 19; 152:13; 154:6;  
 155:25; 156:3; 162:23; 280:1  
 removing [4] 54:6; 123:7;  
 140:20; 152:15  
 renal [a] 18:20; 53:1, 2, 4;  
 58:25; 74:25; 132:9; 151:14  
 repeat [a] 56:7; 75:20;  
 131:11; 133:19; 147:7; 192:18;  
 237:12; 334:14  
 repeated [2] 89:11; 131:16  
 repeatedly [1] 309:14  
 repeats [2] 162:17, 20  
 rephrase [1] 59:2  
 replacement [2] 33:18, 25  
 replicate [1] 7 72: 7 7  
 replication [1] 112:15  
 report [2] 263:16; 265:11  
 reported [la] 7:14; 164:14,  
 77; 178:16; 203:23; 204:14;  
 208:5; 210:24; 211:16, 77;  
 212:11; 216:2, 12; 217:3;  
 218:21; 231:20; 243:25  
 reporting [6] 175:15; 216:21;  
 221:11; 243:12, 74, 24  
 reports [8] 179:8; 181:14;  
 212:12; 243:15, 21; 245:12;  
 248:22  
 represent [4] 34:7; 35:4;  
 196:15; 248:18  
 Representative [1] 56:4  
 represented [2] 180:9; 215:10  
 representing [1] 73:8  
 represents [6] 217:4; 219:5;  
 239:7; 270:24; 282:11, 15  
 reproducible [ 1] 7 14:13  
 request [3] 9: 15; 165:4; 196:2  
 requested [7] 205:2; 288:25;  
 293:7; 305:23; 319:22; 320:21;  
 333:25  
 require [7] 40:24; 71:8; 97:19;  
 98:6; 119:25; 134:8; 150:15  
 required [lo] 30:5; 40:3; 51:5;  
 55:14; 81:23; 93:19; 122:3;  
 148:14; 204:2; 288:16  
 requirement[4] 43:8; 46: 78;  
 134:21; 155:17  
 requirements [2] 34:5; 322:5  
 requires [4] 41:22; 202:23;  
 220:5; 300:9  
 requiring [5] 22:1; 83:23;  
 91:13; 102:10; 146:20  
 Research [3] 164:17; 196:11,  
 72  
 research [5] 47:1, 9; 92:14;

112:23; 200:6  
 reservations [2] 299: 74;  
 320:1  
 residence [1] 263:16  
 resident [1] 175:11  
 residents [7] 188:12, 74;  
 189:2, 8; 190:8, 12; 263:12  
 Resistance [1] 216:17  
 Resistances [1] 301:9  
 resistances [7] 176:13; 177:6;  
 207:2; 302:25; 303:25; 304:23;  
 307:7  
 resistant[2] 252:8; 293: 19  
 resolution [3] 21:16, 23;  
 163:8  
 resolve [1] 146:19  
 resolves [1] 135:1  
 resort[1] 295:10  
 resources [1] 300:9  
 respect[16] 8:4; 13:22; 15:8;  
 16:12; 17:2; 18:25; 20:8, 23;  
 22:7, 20; 23:9; 68:16; 166:15;  
 222:3; 231:10; 253:5  
 Respecting [1] 77:23  
 Respiratory [1] 201:13  
 respiratory [24] 31:14, 75;  
 36:7; 77:25; 78:4, 27; 79:8;  
 80:21; 81:6; 171:5; 180:24;  
 181:2; 186:3; 197:10; 213:16;  
 18; 214:21; 216:2; 218:4;  
 233:21; 250:18; 308:2, 6;  
 327:12  
 respond [7] 66:10; 141:25;  
 151:12, 75; 159:8; 169:11;  
 264:25  
 responded [1] 37:15  
 responding [1] 253:18  
 responds [2] 72:4; 115: 16  
 Response [ 1] 239:15  
 response [36] 20:25; 21:13;  
 29:23; 35:16, 17; 39:4; 40:14;  
 16; 43:20; 44:18, 23, 24; 45:1,  
 77, 74, 75, 25; 46:2, 21; 67:20;  
 70:3, 74; 76:20; 81:13; 135:20;  
 154:2; 155:22, 24; 171:17;  
 193:6; 195:22; 218:19, 23;  
 293:4; 324:7  
 rest [2] 37:6; 261:8  
 restated [ 1] 293: 17  
 resting [1] 250:18  
 restrict [2] 253:11, 72  
 restricted [3] 90:18; 98:14;  
 231:21  
 restriction [1] 109:12  
 rests [1] 336:19  
 result [5] 36:22; 109:20;  
 154:12; 170:2; 171:7  
 resulted [2] 210:21; 211:22  
 resulting [2] 14:17; 228:25  
 results [ 16] 12:8; 20:12;  
 41:21; 108:4, 7, 11, 15; 130:2;  
 155:20; 175:22; 179:23; 183:3;  
 187:2; 206:14; 274:11; 284:19  
 retain [1] 12:15  
 retained [1] 126:24  
 retard [1] 230:20  
 retrospective [ 1] 55:9  
 revealed [2] 61:4, 5  
 reverse [1] 335:23  
 review [5] 39: 7 7; 226: 72;  
 231:17; 237:14; 338:4

|  |  |   |   |
|--|--|---|---|
| reviewed [3] 95:1; 110:4; 115:25   | Rousseau [1] 197:7   | 25:21; 35:7; 49:24; 51:3; 53:17; 76:22; 87:9; 98:3; 99:4; 151:20; 152:2; 157:6; 222:13; 230:6; 253:5; 256:21; 266:3; 269:23; 273:8; 278:17; 280:75; 294:25; 314:14; 319:9; 321:25; 322:12 | sequelaes [6] 21:9, 20; 22:5; 18:3; 37:8, 21  |
| reviewer [1] 26:1  | Routinely [1] 132:25   | Secondary [1] 22:14   | Serial [1] 209:25   |
| reviewing [4] 54:13; 174:9; 13; 220:21   | rautinely [6] 58:12; 59:1; 61:10; 108:10; 131:10; 133:1  | secondary [12] 42:20; 152:6; 153:24; 154:8, 9, 11; 156:4, 5, 10; 162:22; 271:14; 276:19   | serial[1] 207:15  |
| revised [1] 73:2   | row [1] 281:18   | Secondly [1] 223:9  | series [3] 42:10; 89:17; 210:25   |
| revising [1] 33:3  | rows [1] 44:23   | secondly [3] 46:16; 272:1; 279:23   | sirrine [2] 210:18, 20  |
| Rhode [1] 244:25   | RPR [1] 41:9   | secretions [1] 186:4  | serious [6] 19:6; 40:21, 22; 42:19; 188:8; 261:18   |
| Rhode-Poulenc [1] 39:15  | rub [1] 76:5   | Section [2] 95:1, 21  | seriously [1] 245:6   |
| Rhonda [6] 6:12; 7:6; 8:8; 164:7; 166:19; 167:13   | rubber [1] 118:4   | section [7] 95:12; 122:24; 202:1; 288:21; 293:21; 294:2; 318:23   | seriousness [1] 70:7  |
| Rhone-Poulenc [2] 39:11; 165:10  | rule [8] 32:15; 40:13; 44:25; 87:4; 240:4; 315:14, 17; 322:13  | sections [2] 278:8; 292:24  | serotype [1] 188:15   |
| rid [1] 157:1  | rules [2] 291:13; 317:9  | seeded [3] 135:8, 12; 152:17  | serotyping [1] 175:18   |
| rifampin [4] 90:20; 188:22; 189:9, 24  | run [6] 39:9; 138:21; 255:22; 261:20; 308:18; 332:15   | seeding [1] 38:1  | serum [1] 182:17  |
| Right [14] 26:21; 27:20; 31:2; 36:10; 67:3; 105:5; 107:1; 121:11; 191:25; 259:22, 25; 260:2; 301:14; 315:7   | running [3] 8:12; 84:23; 85:5  | seeking [3] 168:19; 172:12; 308:14  | sewe [2] 47:25; 321:21  |
| right [28] 11:23; 65:3; 67:19; 72:10; 77:8; 85:20; 88:5; 94:12; 95:3; 96:23; 106:16, 25; 116:7; 127:9; 143:14, 20; 144:18, 25; 149:25; 150:15; 194:19, 22; 272:10; 305:20; 307:17; 314:12; 315:18; 331:3 | - S -  | seeks [1] 271:2   | served [1] 166:2  |
| rigid [1] 36:5   | afe [4] 123:3; 288:13; 93:18; 316:25   | segment [5] 17:13, 15, 16, 19; 119:12   | sewes [1] 337:2   |
| rigor [5] 56:17; 70:11; 84:19; 102:10, 22  | afer [1] 318:4   | seizure [1] 242:1   | service [1] 10:4  |
| rigorous [3] 23:21; 102:18; 103:13   | afety [19] 15:9; 200:17; 23:15; 240:6, 15; 243:9; 44:2, 3, 6, 12; 247:20; 92:11; 314:21, 22, 25; 329:9; 37:13                            | select [4] 78:8; 79:3; 224:8; 257:9   | sessile [1] 62:17   |
| rigors [2] 83:6; 89:9  | ahm [1] 213:14   | selected [3] 72:3; 209:19; 273:24   | session [4] 8:13; 39:9; 164:5; 269:23   |
| ripe [2] 128:20; 297:2   | ake [2] 197:2; 229:9   | s#electing [3] 28:25; 80:17; 210:7  | sets [4] 209:14; 211:17; 217:13; 332:14   |
| ripeness [4] 297:2; 309:7; 324:16; 330:3   | am [16] 53:25; 56:5; 60:22; 1:6; 62:4; 63:16; 89:16; 04:6; 115:23; 118:2; 124:10; 30:14; 131:18; 134:22; 61:21                           | selection [1] 18:25; 19:5; 40:16, 17; 78:17; 202:14; 207:9; 208:2; 209:22; 210:16; 246:9  | settings [2] 134:19; 334:21   |
| risk [27] 32:5; 45:9, 18; 46:6; 59:6; 89:2; 101:19; 104:16; 123:8, 12; 131:16; 183:10; 231:18; 232:10, 24; 248:18; 265:16; 299:22; 301:17; 322:24; 332:25; 337:8, 15, 16, 17, 20                         | ample [7] 41:6, 14, 22; 43:7; 27:15; 179:24; 303:23  | selected [3] 72:3; 209:19; 273:24   | seventh [1] 207:19  |
| road [4] 118:4; 139:12; 142:6  | amples [1] 179:11  | s#electing [3] 28:25; 80:17; 210:7  | sieventy [1] 44:19  |
| Robert [3] 6:20; 165:1; 182:15   | ampling [1] 41:21  | selection [1] 18:25; 19:5; 40:16, 17; 78:17; 202:14; 207:9; 208:2; 209:22; 210:16; 246:9  | sieventy-five [1] 216:14  |
| robust [1] 252:23  | and [1] 38:20  | selects [1] 257:5   | severe [22] 231:11, 72; 233:17, 23; 236:22; 237:16; 244:18; 247:18; 250:14, 23; 255:6; 265:6; 274:3; 283:6, 8; 284:6, 8; 318:8; 334:17; 335:16  |
| rod [1] 101:15   | iandra [1] 168:5   | selling [1] 217:18  | severely [3] 237:15; 239:17; 245:6  |
| RODVOLD [6] 6:2; 25:6; 167:3; 317:15; 325:8; 333:3   | satisfied [1] 63:14  | siemi [1] 65:25   | severity [2] 250:13   |
| Rodvold [8] 6:2; 165:2, 8, 79; 166:5; 167:3; 325:7; 336:1  | ratisfy [1] 32:25  | siemi-quantitation [1] 7:17:10  | severity [10] 191:21; 192:2; 236:17, 19; 237:1; 239:17; 249:16; 250:12; 273:25; 283:4   |
| role [4] 60:16; 87:13; 104:22; 295:5   | ave [2] 148:10; 315:9  | s;emi-quantitative [5] 49:2; 99:1, 10; 114:10; 115:3  | sewn [1] 328:6  |
| roil [14] 60:25; 61:19, 25; 62:5, 10; 63:18; 65:10, 14, 19, 25; 66:1, 9; 113:25; 121:10  | saying [17] 34:10; 64:25; 70:24; 75:15; 88:16; 96:13; 102:13; 118:2; 121:3; 149:8; 156:18; 262:18; 290:22; 312:20; 321:18; 322:4; 331:24 | s;end [2] 92:19; 309:10   | shakier [1] 106:6   |
| rolling [3] 61:5; 96:7; 126:7  | scale [1] 40:18  | siense [18] 30:5; 40:7; 49:3; 70:7; 106:8; 112:21, 24; 133:19; 193:1; 255:9; 292:18; 300:19; 321:7, 14; 323:3; 328:8; 329:22; 336:16  | shaking [2] 74:19; 138:22   |
| Roman [1] 95:22  | scenario [2] 83:19; 125:21   | sensibly [1] 328:15   | shaky [2] 70:11; 104:1  |
| Room [1] 165:5   | schedule [1] 8:13  | sensitive [1o] 64:18; 66:2; 114:13; 194:1; 199:18; 286:15   | share [3] 223:12, 16; 240:24  |
| room [5] 5:9; 8:21; 84:22; 71:7, 12; 256:5   | !scheduled [3] 23:5, 7; 269:12   | 114:13; 194:1; 199:18; 286:15   | shift [3] 16:19; 40:12; 181:12  |
| Rorer [3] 39:12, 15; 165:10  | !Schmidt [1] 116:6   | 19:317:18; 325:14, 16   | shifts [1] 268:8  |
| ROSS [22] 7:1; 11:1; 24:17; 25:25; 27:10, 20, 23; 30:1; 31:22; 32:2, 16; 34:3, 18, 22; 35:1; 36:10, 24; 58:22; 68:16; 77:7; 96:11; 109:16  | 'School (4) 5:19; 6:21; 167:19, 21   | sensitivity [15] 61:13, 25; 62:8; 104:23; 105:1; 114:2, 1, 6  | shortening [1] 169:1  |
| Ross [4] 7:1; 10:25; 11:4; 109:15  | scientific [7] 9:25; 70:11; 99:6; 122:25; 297:13; 320:21; 337:3  | 126:14; 260:3; 261:25; 262:9; 307:1; 319:13, 14; 334:7  | show [28] 28:25; 38:15; 49:6; 63:8; 134:3; 138:24; 180:20; 200:9; 203:8, 19; 208:11; 218:10; 219:15; 220:17; 224:18; 225:23; 228:6; 230:6; 232:12; 235:21; 240:5, 15; 241:6; 243:11; 264:22; 267:23; 293:23; 307:16 |
| rotating [2] 9:22; 10:15   | scientifically [6] 30:22; 68:15  | sentence [2] 95:11; 315:10  | showing [16] 23:20; 127:18; 131:15; 149:23; 178:19; 180:17, 22; 194:7; 210:17; 218:6, 18; 227:9; 240:18; 307:17, 18   |
| roughly [1] 278:1  | score [4] 24:4; 31:19; 88:14; 250:21   | sentiment [1] 254:17  | shows [10] 38:4; 217:14; 226:11, 12; 228:9; 232:15; 234:3, 17; 237:22; 270:23   |

|   |  |   |  |
|---|--|---|--|
| shunts [1] 15:5   | skip [1] 255:21  | 104:16; 106:20; 107:11, 19, 24; 109:4, 10; 115:15; 117:16; 131:11; 251:20   | squeakiness [1] 105:25   |
| shut [1] 302:14   | skirt [1] 309:8  | sources [2] 16:4; 212:8   | squeeze [1] 246: 14  |
| sick[9] 64:13, 15; 79:21; 80:6, 7; 136:15, 17; 137:5; 155:6   | Slide [2] 251:17; 308:3  | South [5] 6:9; 167:10; 201:13; 221:2; 255:15  | Squibb [1] 165:11  |
| sign [1] 11:21  | slides [6] 46:7; 245:1; 278:8; 281:17; 282:10; 307:15  | southeast [1] 178:13  | St[1] 74:9   |
| signal [1] 30:8   | slight [1] 289:24  | space [2] 226:7; 263:9  | stable [1] 176:25  |
| significance [1] 297: 16  | slightly [7] 31:20; 181:9, 10; 2 15:25; 219:8; 289: 13; 293:8  | Spain [1] 58:7  | staff [3] 188:13; 190:11; 200:5  |
| significant [13] 25:3; 33:12; 36:13; 83:1; 176:14, 17; 183: 15; 228: 19; 246: 10; 254:2; 261:16; 283:9; 297:18  | slippery [1] 134:20  | sparfloxacin [3] 205:6; 207:14; 208: 1  | stain[4] 36:18; 58:2; 125:23; 126:8  |
| significantly [4] 212:3; 218:7; 228:3; 233:2  | slipping [2] 262:11; 265:9   | sparfloxafin[1] 204:25  | standard [13] 23: 18; 24: 15; 35:25; 41:18; 72:1, 2; 81:24; 84: 10; 113:5; 128: 12; 260:25; 261:9; 291:3                           |
| signs [18] 13:18; 16:22; 20:10; 21:16, 23; 52:19; 53:20; 77:4, 12; 95: 12; 97: 11; 142:24; 151:12, 15; 159:8; 187:23  | slope [1] 134:20   | sparingly [1] 261:12  | standardization [1] 64:21  |
| silly [1] 81:11   | slow [5] 40:14; 202:22; 220:7; 257:13; 316:16  | Spartanburg [1] 201:13  | standardize [1] 279:22   |
| simple [4] 85:4; 149:8, 9; 329:22   | slowly [2] 133:17; 256:18  | speak[6] 47:18; 115:23; 119:12; 251:12; 312:18; 329:2   | standardized [5] 49:14; 65:25; 76:12; 128:17; 324:9  |
| simulated [1] 208:10  | smaller [2] 184:12; 225:11   | speaker [1] 5:13  | standing [1] 268:1   |
| simultaneous [3] 50:19; 107:25; 225:25  | smarter [1] 253:6  | speaking [2] 20:13; 327:23  | standpoint [3] 29: 16; 77:16; 337:22   |
| simultaneously [3] 35:13; 70:20; 284:21   | smattering [1] 24 1: 1   | speaks [1] 10:4   | Stanford [3] 6:16; 10:7; 167:16  |
| Sine [1] 198:12   | snake [1] 256:6  | Special [3] 168:4; 171:19; 270:3  | staph [1] 27:18  |
| single [23] 15:11; 25:15; 42:7, 12, 22; 46: 16; 86:8; 9 1: 15; 101:8; 125:17; 175:24; 194:5; 210:17, 20; 211:6, 11; 231:4; 235:14; 251: 16; 280:9; 283:19; 302:10; 314:5                                      | societies [1] 329:3  | Staphylococcal [1] 161:16   | Staphylococci [9] 12:12; 18:2; 82:2; 93:18; 98:6, 8; 115:14; 148:8; 158:17   |
| sinusitis [1] 295:17  | Society [1] 29:22  | Staphylococcus [8] 66:12; 100:12; 101:14; 114:20, 23; 159:22; 160:1; 205:10   | star [1] 263:15  |
| SIRS [17] 29:22; 30:17, 20; 31:9, 12; 36:4; 71:23; 72:1; 73:1; 78:3; 79:17, 19; 80:1, 8, 12, 25; 97:12  | sold [2] 217:16, 17  | start [28] 5:15; 11:11; 14:6; 41:3; 47:6, 16; 64:23; 69:10, 14; 81:19; 83:25; 96:23; 112:13; 160:18; 163:12; 199: 10; 202:6; 258:2; 263: 1; 269:15; 270:18; 272:18; 276:23; 279:11; 286:10; 317:21; 334:6 | started [7] 101:18; 113:3; 175:2; 188:7, 17; 198:2; 263:14   |
| site[31] 16:23, 25; 17:21; 20:11; 25:1; 34:1; 36:17; 48:17; 52:20; 57:17, 21; 58:3; 66:13; 75:8; 95:13; 96:5; 100:14; 109:3; 114:24; 117:16, 18; 125:22; 175:10; 179:21; 180: 17, 19; 222:24; 223:8; 314:3, 6 | solely [1] 298:15  | starting [2] 55:7; 133:6  | starts [1] 60:14   |
| sites [17] 12:8, 16; 16:6; 41:12; 101:19; 120:7; 135:9; 152:17; 153:3; 160:1; 161:13; 191:3; 213:23; 238:9; 289:6; 335:21   | somebody [17] 26:5; 33:22; 79:7; 80:4, 20; 81:1, 9; 92:13; 137:23; 146:11; 151:16; 159:5; 162:7; 201:1, 2; 265:11; 316:1 | State [1] 178:21  | State [5] 178:25; 234:25; 296:7; 313:18; 332:6   |
| sitting[2] 47:4; 84:21  | Someone [1] 152:3  | state [8] 75:10; 85:11; 197:23; 266:14; 309:14; 310:9; 319:4; 324:12  | stated [8] 75:10; 85:11; 197:23; 266:14; 309:14; 310:9; 319:4; 324:12  |
| situ [3] 152:13; 154:15; 155:4  | someone [12] 56:20; 75:16; 108:25; 136:1, 5 ; 138:10; 246:13; 255:13,20; 290:12; 3 12:20; 324:4                          | statement [8] 7:7; 164:7; 260:22; 310:19; 312:24; 320: 16; 328: 16; 329:22  | statement [8] 7:7; 164:7; 260:22; 310:19; 312:24; 320: 16; 328: 16; 329:22   |
| situation [12] 24:20; 90:8; 93:18; 111:16; 139:1; 151:8; 154:21; 171:6; 175:9; 190:16; 292:15; 323:9  | someplace [1] 325:20   | statements [3] 165:3; 299:19; 322:13  | statements [3] 165:3; 299:19; 322:13   |
| situations [6] 68:23; 69:2; 81:15; 134:5; 138:2; 145:24   | somewhat[6] 63:22; 188:16; 225:10,11; 241:10; 245:5  | States [16] 7:20; 171:7; 164:25; 165: 15; 170: 1 7; 174:19; 178:14; 197:7; 198:17; 213:12; 221:17; 231:1; 235:6; 243:8, 16; 308:25  | States [16] 7:20; 171:7; 164:25; 165: 15; 170: 1 7; 174:19; 178:14; 197:7; 198:17; 213:12; 221:17; 231:1; 235:6; 243:8, 16; 308:25 |
| Six [2] 147:1; 277:13   | somewhere [8] 184:10; 229:6, 8, 13; 258:16, 21; 268:7; 330: 13   | states [1] 175:3  | states [1] 175:3   |
| six [13] 37:12,18; 43:10; 146:25; 149:13; 184:18; 189:18; 218:20; 237:6, 7; 283:12,14; 284:13   | sonicated [2] 99:1 1   | static [3] 219:6, 7, 15   | static [3] 219:6, 7, 15  |
| size [6] 41:6, 74, 22; 43:7; 127:15; 225:11   | sonication [7] 49:8; 61:17; 62:14, 19, 20; 117:11  | stating [1] 259:17  | statistical [4] 14:13; 23:9; 44:8; 303:12  |
| skeptically [1] 264:22  | sonification [1] 63:23   | statistically [1] 183:15  | statistician [1] 300:24  |
| skin [10] 36:21; 42:15; 56:13; 57:17; 58:1; 60:12; 83:12; 104:22; 107:2; 197:10   | SOPER [10] 6:8; 167:9; 193:1, 14; 252:7; 305:6; 318:12; 324:14; 331:14; 332:17   | statistics [1] 300:24   | statistics [1] 300:24  |
| skiing [1] 42:15  | Soper [7] 6:8; 167:9; 192:25; 318:11; 324:13; 331:13; 336:6  | status [2] 9:7; 195:1   | status [2] 9:7; 195:1  |
| shunts to stayed  | Sorry [2] 25:5; 47:5   | stay [4] 301:6, 8; 310:9; 319:4; 324:12   | stay [4] 301:6, 8; 310:9; 319:4; 324:12  |

|  |  |  |       |
|--|--|--|-------|
| 12, 20; 205:7; 206:10,21;<br>330: 22<br><b>targeted</b> [1] 306: 1<br><b>taught</b> [2] 28:4; 264:12<br><b>teaching</b> [1] 244:24<br><b>Team</b> [1] 168:1<br><b>team</b> [3] 39:17; 199:12;<br>248:13<br><b>tease</b> [3] 82:22; 135:12;<br>137:15<br><b>technical</b> [1] 313:24<br><b>technically</b> [1] 269:22<br><b>technique</b> [8] 17:14, 15;<br>49: 13; 62:23; 65: 11; 113:25;<br>714:15; 228:12<br><b>techniques</b> [2] 49:8; 7 14:9<br><b>technology</b> [1] 83: 7 1<br><b>TEE</b> [1] 136:4<br><b>telling</b> [3] 88:23; 113:13;<br>258:20<br><b>tells</b> [1] 125:8<br><b>temperature</b> [12] 16:18; 30:5;<br>31:5; 74:5, 7, 8, 10; 75:8; 76:2;<br>84:22; 97:12, 13<br><b>temperatures</b> [3] 76:8, 10, 11<br><b>temporarily</b> [1] 38:20<br><b>temporary</b> [2] 152:10, 77<br><b>ten</b> [45] 17:16, 78; 41:4; 43:3,<br>13, 23; 44:3, 15; 47:10; 49:20;<br>54: 11; 56:20; 57:7, 16; 67:22;<br>103:14; 107:10; 112:1; 122:9,<br>10; 125:7; 148:22; 155:17;<br>172:23; 178:23; 198:16;<br>207:19; 209:24; 210:6; 217:5;<br>225:8; 229:3, 21; 243:7; 261:7;<br>283:23;<br>290:14; 291:6; 315:14, 15, 16,<br>17<br><b>tend</b> [7] 38:12; 124:15; 180:9;<br>225:25; 228:1; 302:1; 305:2<br><b>tended</b> [3] 206:16; 249:4<br><b>tender</b> [1] 77:9<br><b>tenderness</b> [1] 16:23<br><b>tends</b> [2] 72:17; 225:9<br><b>Tennessee</b> [2] 5:24; 178:14<br><b>Tennover</b> [1] 210:25<br><b>Tenny</b> [1] 157:19<br><b>tenure</b> [1] 10:17<br><b>Term</b> [1] 188:10<br><b>term</b> [26] 10:15; 14:23; 50:9;<br>54:18; 58:8; 104:11, 13, 21,<br>25; 106:10, 14; 107:3, 19, 21;<br>140:3, 24; 145:15; 153:16, 17,<br>18; 157:21; 169:17; 188:10;<br>189:5, 12; 297:1<br><b>terrible</b> [1] 72:2<br><b>test</b> [32] 21:4, 18; 23:25;<br>31:24; 41:17; 51:5, 12; 53:18;<br>92:1; 121:10; 129:17, 24;<br>130:13, 25; 131:5; 132:17;<br>133:1; 134:5; 138:24; 159:10;<br>237:12; 274:18; 275:8; 279:16;<br>280:9, 12; 281:8; 285:3;<br>289:21, 22; 303:12<br><b>tested</b> [5] 91:23; 199:22;<br>205: 11; 234: 19; 236: 10<br><b>testing</b> [8] 175:18; 186:17;<br>2 13: 19, 22; 3 19:6; 322: 16, 23;<br>324:9<br><b>tests</b> [4] 121:22; 126:15;<br>299:21; 302:16 | <b>tetracycline</b> [5] 92:2, 6;<br>177: 18; 178:3; 188:20<br><b>tetracyclines</b> [1] 245:19<br><b>Texas</b> [1] 5:19<br><b>text</b> [1] 270:24<br><b>Thank</b> [39] 8:8; 10:13, 79, 20,<br>23; 27:10; 37:2; 39:7, 13;<br>46: 19, 22; 53:22; 58:22; 69:9;<br>166:19; 168:7, 12; 171:14, 22;<br>173:25; 192:10, 24; 195:23;<br>220:19; 244:22; 248:6, 7;<br>249:21; 251:10; 255:16;<br>257:15; 260:18; 309:4; 318:10;<br>327:6, 7;<br>329:7; 335:6; 336:5<br><b>thank</b> [7] 24:6; 37:1; 173:22;<br>196:17; 314:8; 336:22; 337:25<br><b>Thanks</b> [4] 10:8, 9, 12; 69:17<br><b>thanks</b> [2] 173:7; 338:5<br><b>theoretically</b> [2] 30: 120; 63:1<br><b>therapeutic</b> [2] 83:7; 221:21<br><b>therapies</b> [1] 42:1<br><b>Therapy</b> [1] 201:13<br><b>there'll</b> [3] 9:17; 139:11; 305:8<br><b>therefrom</b> [1] 196:5<br><b>they'd</b> [2] 96:25; 193:11<br><b>They're</b> [7] 86:17; 153:12;<br>243:25; 253:24; 255:24;<br>289:17, 1 8<br><b>They've</b> [1] 160:12<br><b>they've</b> [11] 29:24; 64:13;<br>111:16; 114:18, 19; 136:19;<br>158:18; 185:9; 255:7; 270:16;<br>333:5<br><b>thigh</b> [3] 218:11, 21; 219:4<br><b>thinking</b> [11] 28:2; 32:8; 34:3;<br>42:18; 67:13; 82:14; 102:18;<br>265:21; 299:2; 316:2<br><b>third</b> [lo] 17:16, 18; 35:16;<br>90:11; 209:21; 246:1, 7;<br>250:10; 275:11; 278:18<br><b>Thirty-four</b> [l] 233:13<br><b>Thirty-nine</b> [1] 233: 16<br><b>Thirty-seven</b> [1] 282:3<br><b>thoracotomy</b> [1] 318:6<br><b>Thomsberry</b> [1] 213:14<br><b>thorough</b> [1] 56:23<br><b>thoroughness</b> [1] 298:20<br><b>thoughts</b> ([) 30:14<br><b>thousands</b> [4] 128:22; 303:1<br><b>Three</b> [4] 9:21; 146:14;<br>159:19; 277:7<br><b>three-day</b> [1] 8:23<br><b>three-quarters</b> [1] 269:21<br><b>three-to-one</b> [1] 17:9<br><b>threefold</b> [1] 131:15<br><b>threshold</b> [2] 193:16; 258:7<br><b>thrive</b> [1] 75:17<br><b>thrombophlebitis</b> [2] 18:13;<br>136:18<br><b>throwing</b> [3] 84:2; 124:19;<br>127:14<br><b>Thursday</b> [1] 338:10<br><b>tidbit</b> [1] 74:22<br><b>tier</b> [1] 99:4<br><b>till</b> [1] 47:17<br><b>times</b> [12] 43:11; 127:22;<br>152:5; 207:16, 19, 23; 208:1;<br>216:11; 223:20, 21; 250:25<br><b>timing</b> [3] 20:8; 34:1; 285:3<br><b>tiny</b> [1] 75:14 | 39:22, 24; 40:4; 41:11; 42:7,<br>12, 22; 46: 17; 54:9; 59:16;<br>60:15; 97:20; 122:23; 143:14;<br>149:8; 152:20; 156:1; 201:14;<br>226:13; 231:2, 5; 242:12, 13,<br>21; 256:10; 274:12<br><b>Trimetheprim</b> [1] 308:12<br><b>trimetheprim</b> [to] 90:19;<br>92:3; 175:24; 188:19; 213:1;<br>234:22; 245:18; 254: 11; 263:3;<br>323:19<br><b>triple</b> [1] 104:25<br><b>trouble</b> [5] 54:6; 156:6;<br>259:16, 20; 261:18<br><b>trovafloxacin</b> [6] 166:8;<br>176:8; 177:20; 178:6; 186:21;<br>187:8<br><b>trovafloxin</b> [1] 190:15<br><b>True</b> [1] 133:24<br><b>true</b> [25] 12:9; 18:6; 25:18;<br>27:6; 44:18; 55:21; 59:24;<br>89:19; 90:22; 102:11; 113:6;<br>117:14; 119:12; 140:20;<br>146:24; 181:3; 195:5; 222:3;<br>234:16; 255:5; 257:25; 264:3;<br>280:2; 302:6; 304:23<br><b>truly</b> [4] 241:22; 245:22;<br>257:23; 306:16<br><b>Trust</b> [12] 213:5, 10; 214:4, 5,<br>20; 215:10, 21; 216:23;<br>2 19:24; 304: 17; 307: 17;<br>328:18<br><b>trust</b> [1] 259:6<br><b>TSN</b> [2] 179:13, 19<br><b>tunnel</b> [2] 50:10; 54:18<br><b>tunneled</b> [2] 14:22; 52:21<br><b>tunnels</b> [1] 107:20<br><b>turns</b> [1] 324:8<br><b>Twelve</b> [1] 226:23<br><b>Twenty</b> [1] 162:3<br><b>Twenty-five</b> [1] 216:13<br><b>twice</b> [3] 175:13; 207:17;<br>226:15<br><b>two-thirds</b> [1] 178:4<br><b>twofold</b> [3] 211:25; 226:1;<br>227:8<br><b>type</b> [16] 20:11; 24:3; 34:20;<br>54:20; 72:9; 93:3; 126:23;<br>152:20; 260:3; 298: 16; 299:10,<br>11; 300:12; 306:2; 331:9;<br>332:13<br><b>types</b> [2] 292:16; 299:6<br><b>typically</b> [3] 225:4; 235:19;<br>283:18<br><b>typing</b> [1] 63:10<br><b>tyrosine</b> [1] 210:19 | — U — |
|--|--|--|-------|

**uncertain** [1] 126:14  
**unclear** [2] 30:13; 295:11  
**uncomfortable** [1] 65:4  
**uncommon** [1] 243:19  
**Undergirding** [1] 174:1  
**undergo** [2] 175:17; 281:8  
**undergoing** [2] 20:3; 226:14  
**undergone** [1] 56:17  
**underlinement** [1] 38: 14  
**underlying** [5] 172:7; 183:5;  
 191:21; 192:1; 312:1  
**underpins** [1] 196:19  
**understand** [6] 31:2, 22;  
 224:1; 308:3; 317:10; 332:5  
**understanding** [5] 31:8; 75:3;  
 151:18; 173:13; 334:9  
**understood** [1] 221:7  
**underway** [1] 306:9  
**uneasy** [2] 112:8; 158:22  
**unfortunate** [1] 169:25  
**Unfortunately** [2] 73:11;  
 223:2  
**unfortunately** [1] 263:17  
**unhappy** [1] 142:8  
**uniform** [1] 237:1  
**uniformly** [3] 19:19; 20:3;  
 34:9  
**unique** [3] 7:17; 137:1; 263:5  
**unit** [1] 73:16  
**United** [16] 7:19; 111:7;  
 164:24; 165:15; 170:17;  
 174:19; 178:13; 197:7; 198:17;  
 213:11; 221:17; 231:1; 235:6;  
 243:8, 16; 308:24  
**u n i t[3]** 29:13; 31:11; 114:3  
**universal** [2] 157:18, 22  
**universe** [1] 331:4  
**University** [20] 5:16, 18, 22;  
 23; 6:3, 6, 9, 13, 18, 23; 56:3;  
 157:20; 164:4; 167:4, 7, 10,  
 16, 18, 21; 200:24  
**unknown** [3] 63:1; 237:7;  
 283: 10  
**unreasonable** [1] 114:25  
**unrelated** [7] 165:11; 202:24;  
 204:3; 206:9; 220:5; 242:15;  
 263:3  
**unscientific** [1] 329:5  
**unscrupulous** [1] 329:6  
**untoward** [1] 247:24  
**untreated** [2] 182:17; 218:8  
**unusual** [1] 191:11  
**update** [1] 174:5  
**upper** [1] 44:11  
**upward** [2] 176:14, 18  
**urge** [1] 35:11  
**urged** [1] 60:10  
**urinary** [4] 142:17; 143:21;  
 197:10; 327:14  
**urine** [1] 142:18  
**USA** [1] 181:4  
**usage** [3] 288:21; 293:21;  
 318:23  
**useful** [13] 47:23, 25; 48:10;  
 51:1; 88:22; 91:21; 92:16;  
 134:5; 169:1; 171:3; 173:24;  
 262:13; 321:13  
**usefulness** [6] 49:1; 52:15;  
 130:9; 289:7; 300:7; 335:21  
**uselessness** [1] 115:6  
**uses** [4] 29: 14; 49:20; 174:24;

202: 1  
**usual** [1] 292:14  
**UTI** [1] 42:15  
**utility** [1] 321:5  
**utilize** [1] 63:18  
**utilized** [1] 63:17

**- V -**

**vaccine** [1 ] 189:7  
**vagaries** [1] 31:13  
**vaginitis** [1] 241:18  
**vague** [1] 327:1  
**valid** [2] 23:19; 143:15  
**validity** [1] 62:21  
**valuable** [2] 171:3; 327:17  
**alue** [13] 40:8; 43:18; 51:17;  
 2:5, 6; 57:15; 80:25; 99:6;  
 07:2; 1 72: 14; 205: 14; 289:6;  
 35:20  
**alue** [2] 51:24; 205:9  
**alve** [2] 18:12; 100:18  
**alves** [2] 15:4; 60:4  
**ancomycin** [14] 90:19;  
 33:8, 10, 17; 134:2, 3;  
 57:19; 176:11; 188:22;  
 05:24; 213:8; 222:5; 246:3,  
 1  
**anishingly** [1] 239:3  
**ariability** [2] 41:20, 21  
**variable** [2] 128:15; 194:5  
**variables** [1] 234:15  
**variation** [3] 178: 10; 190:23,  
 24  
**variations** [1] 279:21  
**raries** [1] 178:18  
**rarity** [7] 72:4; 80: 76; 95:1;  
 177:22; 179:22; 197: 12;  
 332: 14  
**rary** [3] 57:23; 178:17; 298:4  
**varying** [1] 45:15  
**vascular** [6] 14:18; 15:4;  
 18:12, 14; 87:12; 223:4  
**vast** [3] 61:10; 80:18; 114:21  
**vein** [4] 34:24; 50:20; 63:12;  
 140:13  
**venous** [4] 14:21, 23; 15:3;  
 109:11  
**ventilated** [2] 233:20; 250: 17  
**ventricular** [1] 15:5  
**ventriculoatrial** [1] 34:21  
**Venus** [1] 240:11  
**versus** [25] 24:2; 25:23;  
 26:18; 27:1; 31:11; 43:13;  
 48:8; 50:19; 52:22; 56:12;  
 63:12; 71:15; 90:8, 20; 91:7;  
 104:1; 105:12; 126:25; 131:26;  
 133:8, 10, 11; 137:11; 281:4;  
 315:12  
**Vesga** [2] 218:10, 21  
**viable** [1] 228:10  
**Vice** [2] 167:20; 196:10  
**view** [7] 54:12; 168:18; 265:3  
 307:3; 312:5; 321:14; 323:14  
**viewing** [1] 50:16  
**Virginia** [3] 5:21; 6:23  
**virtually** [1] 31:7  
**visit** [13] 21:1, 4, 19; 237:13;  
 274:18; 275:8; 279:17, 18;  
 280:9, 10, 13, 15; 285:4  
**visits** [4] 51:6; 279:19;

280:14; 281:9  
**vital** [2] 20:9; 147:25  
**vitro** [13] 19:1; 199:21; 203:6;  
 207: 10; 208:4; 209:22; 210: 16;  
 220:10; 247: 12; 257:4; 264:12,  
 21; 265:1  
**voiced** [1] 268:23  
**volunteers** [3] 224:22;  
 225: 13; 226: 13  
**vote** [13] 162:24; 164:23;  
 292:24; 294:5; 313:4; 316:21,  
 23; 317:11; 318:18; 321:2, 6;  
 333:15  
**voted** [/] 333:12  
**voting** [5] 294:6, 9; 309:6;  
 311:3; 318:17  
**VRE** [2] 120:5, 7

**- W -**

**waffle** [1] 127:10  
**wrait** [3] 108:15; 109:25;  
 187:24  
**wraiver** [1] 165:3  
**wraivers** [2] 7:20; 164:25  
**walks** [1] 201:1  
**wall**[1] 204:5  
**waned** [1] 254:15  
**wanted** [18] 28:17; 34:16;  
 37:5; 72:25; 75: 13; 111:23;  
 119:3; 125:21; 126:18; 157:10;  
 212:5; 254:3; 262:5; 270:18;  
 288:6; 293:23; 300:24; 327:8  
**wwanting** [1] 325:11  
**wants** [4] 134:10; 153:15;  
 163:10; 260:16  
**wards** [5] 188:13, 14; 189:8;  
 190:8, 9  
**warrant** [1] 294:1  
**waxed** [1] 254:15  
**ways** [12] 76:3; 113:13;  
 115:16; 126:4, 24; 127:7;  
 131:2; 254:7; 255:7; 309:20;  
 311:1, 24  
**We'd** [3] 248:2, 10; 258:14  
**we'd** [8] 29:4; 30:13, 25; 74:5;  
 96:15; 122:19; 127:20; 135:23  
**We'll** [/] 5:15; 10:24; 67:21;  
 69:10; 195:24; 269:10; 272:18  
 318:25; 335:23; 338:7  
**we'll** [25] 7:6; 9:11, 15; 31:3;  
 38:25; 64: 11; 67:22; 68: 14;  
 81:14; 129:6; 163:7, 17;  
 187:24; 196:4; 199:10; 271:21;  
 272: 18; 276:22; 286: 10; 288:4  
 7; 32 1:2; 323: 10  
**We're** [6] 55:6; 106:19;  
 141:15; 151:14; 263:19;  
 265:21  
**We've** [8] 94:22; 198:7, 21;  
 224:4; 257:4; 259:7; 316:7, 10  
**we've** [43] 49:21; 63:17;  
 74:20; 76:22; 82:21; 84:7, 18;  
 88:9, 10; 101:11; 126:20, 22;  
 129:16; 136:23; 151:10; 173:2;  
 176:17; 178:25; 186:20;  
 190:16, 17; 191:12; 197:24;  
 198:5, 7, 18; 234:1; 243:10;  
 244:7; 247:10, 11, 22; 250:20  
 258:23; 270: 14,  
 19; 286:12; 292:13; 294:22;

, 329:14; 333:4, 6; 337:25  
**weakness** [2] 70:14; 106:9  
**wealth**[1] 201:20  
**week** [5] 37:18, 19; 133:18;  
 189:16, 25  
**weeks** [13] 21:10; 37:12;  
 132:18; 139:9; 141:18; 142:6;  
 146:25; 147:1; 149:14; 162:10;  
 189:17, 18  
**weight** [lo] 30:6, 23; 68:18;  
 69:11, 24; 70:15; 71:13; 74:5;  
 97:11; 102:1  
**weighting** [1] 31:4  
**WEINSTEIN** [7] 6:20; 33:9;  
 95:10, 21; 111:4, 6; 133:13  
**Weinstein** [3] 6:20; 95:9;  
 111:5  
**welcome** [6] 5:3; 33:4;  
 171:23; 290:18; 323:13;  
 326: 19  
**weren't** [5] 61:5; 121:13;  
 190:9; 192:1; 238:21  
**West** [2] 6:7; 167:8  
**whatsoever** [1] 300:11  
**wheel** [1] 105:25  
**whereas** [6] 43:23; 85:8;  
 204:6, 10; 207:25; 21 1:25  
**Whereupon** [4] 67:23;  
 163: 1 7; 269: 18; 338:9  
**whichever** [1] 291:7  
**white** [9] 16:19; 36:6, 9, 11,  
 12; 142:20; 180:8; 270:24  
**WHITNEY** [/] 167:23; 174:8;  
 191:25; 192:6, 19; 193:8, 21;  
 194:9, 15, 18; 195:4  
**Whitney** [13] 167:23; 174:6;  
 195:21; 212:7, 19; 213:9;  
 215:22; 216:17; 245:14;  
 267:12; 268:6; 295:8; 303:2  
**wholesale** [1] 258:4  
**wide** [8] 68:6; 179:22; 192:21;  
 195: 14; 197:12; 220:25; 238:8;  
 335:13  
**widely** [2] 45:20; 295:15  
**wider** [5] 40:13; 45:13, 16;  
 46:8, 12  
**widespread** [4] 7:18; 72:6;  
 169:6; 190:16  
**wild** [/] 199:21  
**William** [1] 164:21  
**willing** [2] 85:12, 79  
**wind** [1] 33:13  
**window** [2] 289:21, 23  
**winter** [2] 188:7; 190:6  
**Wisconsin** [1] 6:14  
**wish** [6] 8:7; 166:18; 168:10;  
 170:9; 315:5; 316:14  
**women** [1] 233: 13  
**won't** [8] 80:1; 83:5; 158:18;  
 173:21; 260:8; 266:4; 269:7;  
 305:10  
**wonder** [3] 77:5; 147:13;  
 325:5  
**wondered** [6] 34:20; 36:2, 5;  
 77:3; 290:11; 328:10  
**wondering** [2] 26:16; 223:17  
**Wood** [/] 6:20  
**word** [3] 17:6; 53:2; 329:6  
**wording** [2] 323:4; 328:12  
**words** [10] 83:11; 191:8;  
 201:25; 248:3; 249:13; 265:10;

301:23; 311:7; 312:9; 331:17  
**work**[13] 8:11; 24:8; 65:1;  
 74:10; 104:13; 113:15; 253:4;  
 - 254:10, 12, 23; 315:11;  
 321:20; 326:19  
**workable**[1] 109:19  
**workbooks** [1] 76:14  
**worked** [2] 198:1; 302:21  
**working** [7] 11:2; 13:12, 17;  
 24:7; 26:2; 74:9; 173: 1  
**works** [14] 151:6; 175:7;  
 252:23; 254:23, 25; 264:23;  
 265:4; 313:1; 314:9; 315:13;  
 321:18; 324:6; 328:4; 336:16  
**world** [11] 108:5, 14; 198:12,  
 15; 199:17; 203:2; 216:23;  
 217:1, 8; 220:10; 223:25  
**worldwide** [3] 197:6; 243:7;  
 308:25  
**worried** [4] 255:18; 263:19,  
 21; 314:10  
**worry** [s] 245:21; 246:6;  
 265:8; 314:5; 316:1; 326:15;  
 327:3  
**worrying** [1] 327:9  
**worse** [ 1] 255:24  
**worthwhile** [2] 150:2; 294:4  
**Wouldn't** [1] 60:3  
**wouldn't** [15] 38:5; 59:13;  
 63:25; 66:9; 81:4; 83:21;  
 104:12; 106:11; 108:22; 113:8;  
 129:10; 141:10; 264:25;  
 266: 11; 335:8  
**write** [2] 8:18; 13:13  
**written**[1 1] 24:15; 59:2;  
 75:17; 77:5; 81:5; 96:12;  
 135:16; 165:4; 243:6; 254:22;  
 294: 11  
**wrong** [3] 80:23; 224:4;  
 261:17  
**wrote** [2] 294:14; 315:21

**- X -****X-rays** [1] 240:9**- Y -**

**Yeah**[31] 26:3; 38:12; 56:14;  
 57:2; 68: 13; 69:20; 75: 13;  
 78:24; 85: 10; 92:22; 94:3;  
 95:24; 111:1; 114:7; 123:22;  
 130:21, 22; 131:22; 132:10;  
 136:22; 141:13; 145:5; 155:16;  
 160:10, 19; 193:21; 290:6;  
 302:6, 15; 314:19; 333:20  
**yeah** [6] 130:22; 139:9; 155:2;  
 193:21; 301:22; 303:8  
**year** [26] 8:22, 25; 9:22;  
 12:25; 58:6; 87:15; 113:3;  
 172:4; 173:4, 11; 175: 14;  
 198:6, 20; 204:24; 207:12;  
 208:6; 210:25; 215:10; 245:16;  
 254:5; 290: 13; 291: 16; 292: 18;  
 295:20; 311:20; 315:21  
**years** [28] 25:9; 29:19; 41:8;  
 43:10; 47:10; 57:16; 58:18;  
 70: 1; 115:25; 176: 12; 185:4;  
 186:14, 24; 188:6; 213:24;  
 214:5; 215:20; 221:25; 231:7;  
 235:2; 258:12, 22, 23; 301:24;  
 305:7; 316:7, 11

**yellow** [3] 212:15; 225:24;  
 271:5  
**yield** [5] 61:14; 62:3; 130:1;  
 131:5; 159:10  
**York** [2] 188:6, 25  
**You'd** [1] 143:22  
**you'd** [12] 75:19, 27; 102:4;  
 125:15; 134:6, 142:10; 145:1;  
 156:8; 239:22; 301:19; 325:13  
**You'll** [1] 158:10  
**you'll** [5] 30:24; 145:19;  
 179:9, 279:3; 298:12  
**You've** [3] 178:1; 270:17;  
 328: 17  
**you've** [36] 33:13, 18; 63:22;  
 65:7, 20; 85:11; 89:15; 93:12;  
 106:21; 114:15; 132:18, 19;  
 137:12, 13; 139:23; 141:20;  
 142:25; 143:3; 177:21, 24;  
 199:15; 221:15, 23; 228:4;  
 243:5; 246:25; 250:7; 256:16;  
 264:8; 279:13; 312:22; 315:9;  
 325: 17,  
 22; 337:5, 18  
**young** [2] 180:3; 240:9  
**younger** [1] 249:5  
**yourself** [1] 72:14  
**yourselves** [1] 198:9

**- Z -**

**Zeller** [1] 211:16  
**zero** [2] 725: 73; 242:24  
**ZHU** [1] 39:13  
**Zhu** [2] 39:11, 14